ML
Uploaded byMike Lauer
1,171 views

CV 5 17 15

This document is a curriculum vitae for Dr. Michael S. Lauer that provides biographical information over 10 pages. It includes his education history, postdoctoral training, licensure and certifications, appointments, awards and honors, memberships, research interests, teaching experience, and publications. He is currently the Director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute at the NIH in Bethesda, Maryland. The CV demonstrates an accomplished career in cardiology, epidemiology, and biomedical research leadership.

Embed presentation

Download to read offline
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 1 Michael S. Lauer, MD, FACC, FAHA CURRICULUM VITAE NAME: Michael Solon Lauer, MD, FACC, FAHA ADDRESS: Home: 12101 Ravenwood Court Silver Spring, MD 20902 Business: 6701 Rockledge Drive, Room 8128 Bethesda, MD 20892 Phone: 301 435 0422 (business) Email: lauermichael@yahoo.com (personal) lauerm@nhlbi.nih.gov (business) PLACE OF BIRTH: Wynnewood, Pennsylvania (July 11, 1961) FAMILY: Married (1989) to Dr. Robin Avery Nathan Max (born November 7, 1991) Daniel Akiva (born May 31, 1994) EDUCATION: 1983 BS Rensselaer Polytechnic Institute (summa cum laude), Troy, New York 1985 MD Albany Medical College (magna cum laude), Albany, New York 1989-1990 Program in Clinical Effectiveness, Harvard School of Public Health, Boston, MA 2004 Josiah Macy Scholar in Physician Education, Program for Physician Educators, Harvard Medical School and Harvard Graduate School of Education, Boston and Cambridge, MA 2010 NIH Senior Leadership Program (University of Maryland) POSTDOCTORAL TRAINING: 1985-1986 Intern in Medicine, Massachusetts General Hospital and Harvard Medical School, Boston 1986-1988 Resident in Medicine, Massachusetts General Hospital and Harvard Medical School, Boston 1988-1991 Clinical Fellow in Medicine (Cardiology), Harvard Medical
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 2 School and Beth Israel Hospital, Boston 1990-1991 Research Fellow, Framingham Heart Study and Boston University Medical School, Framingham, MA LICENSURE AND CERTIFICATION: 1987 Massachusetts License Registration 1988 Specialty Certification (ABIM) in Internal Medicine 1991 Subspecialty Certification (ABIM) in Cardiovascular Disease 1993 Ohio License Registration 2001 Subspecialty Recertification (ABIM) in Cardiovascular Disease 2011 Subspecialty Recertification (ABIM) in Cardiovascular Disease (top decile on April 11, 2011, secure examination) HOSPITAL, INSTITUTIONAL, AND EXECUTIVE LEADERSHIP APPOINTMENTS: 1991-1993 Physician, Lahey Clinic Medical Center and Harvard Medical School, Burlington, MA 1993-2007 Staff, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2004 Co-director, Coronary Intensive Care Unit, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2007 Vice Chair, Cleveland Clinic Foundation Institutional Review Board 1999-2007 Director, Exercise Laboratory, Cleveland Clinic Foundation, Cleveland, Ohio 2007-2009 Director, Division of Prevention and Population Science (DPPS), National Heart, Lung, and Blood Institute (NHLBI/NIH), Bethesda, Maryland Oversight of 50 FTEs, research portfolio of ~$300 million
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 3 2009- Director, Division of Cardiovascular Sciences (DCVS), National Heart, Lung, and Blood Institute (NHLBI/NIH), Bethesda, Maryland Oversight of 123 FTEs, research portfolio of ~$1.5 billion AWARDS AND HONORS: 1979 Salutatorian, Shenendehowa Central School, Clifton Park, NY 1982 Dean's Outstanding Research Award, Albany Medical College Daggett Prize in Anatomy, Albany Medical College 1982 Knudson Prize in Biochemistry, Albany Medical College Townsend Prize in Physiology, Albany Medical College 1983 Glen H. Leak Memorial Fellowship, American Cancer Society Research Award, Association of Medical Schools of NY Elected Sigma Xi Alpha Omega Alpha BS, summa cum laude, Rensselaer Polytechnic Institute 1984 Henry Schaeffer Prize in Pathology, Albany Medical College 1985 MD magna cum laude, Albany Medical College 1989 Kellogg Foundation Fellowship for study at the Harvard School of Public Health 1993 Elected Fellow, American College of Cardiology 1996 Merck American College of Cardiology/European Society of Cardiology International Exchange Fellowship Distinguished Teacher Award, Cleveland Clinic Foundation 1997 Named First Vice Chair – CCF Institutional Review Board 2000 Paper of Dr. Christopher Cole, a fellow under my direct supervision, selected as Finalist in the American College of Cardiology Young Investigator Award Competition; paper received honorable mention 2000 Named as Contributing Editor, JAMA (ongoing) 2000-2001 Awarded two-year Established Investigator Grant, American Heart
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 4 Association (0040244N), $140,000 over two years. 2001 Named Vice-Chair of the Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council of Clinical Cardiology, American Heart Association. 2001-2004 NIH R01 HL-66004 grant on Heart Rate Recovery and Mortality for $660,000. 2003 Named Chairman of the Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council of Clinical Cardiology, American Heart Association. 2003 Invited Guest Lecturer, 50th Annual Meeting of the Israel Heart Society, Tel Aviv, Israel. 2004 Michael Pollock State-of-the-Art Lecturer, American Heart Association. 2004-2007 NIH R01 HL072771-01Al grant on Logical Analysis Data for $1,032,000. 2004 Paper of Hitinder S. Gurm MD – Honorable Mention – William E. Lower Award. Clinical First Prize under my direct supervision. 2005 Paper of Rohit Bhatheja, MD – Honorary Award Winner (Echo- nuclear paper) – William E. Lower Award under my direct supervision. 2005 Elected member of American Society for Clinical Investigation Award (ASCI) 2005 Reappointment as Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University for academic year. 2005 The Marie and Sam Miller Professional Excellence Award, Scientific Achievement Award in Clinical Research 2005 Appointed Professor of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine 2006 Center for Clinical Investigation, Office of Faculty Affairs, Secondary Appointment, Case Western Reserve University School of Medicine
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 5 2006 Candidate for Cardiovascular Medicine Chair, Cleveland Clinic 2006 Visiting Professorships, University of Alberta and Indiana University 2006 Torgny Sjoenstrand Honorary Lecture in Clinical Physiology Annual Meeting of the Swedish Society of Medicine 2006 Scholarship in Teaching Award, Case Western Reserve University School of Medicine (for Clinical Research Skills Block) 2007 Fellow (Dr. Esther Kim) wins first place, Young Investigator Award for Clinical Research American College of Cardiology, March, 2007 2008 Ancel Keys Lecture, American Heart Association 2009 National Institutes of Health Awards of Merit (2) for work on NHLBI Short Detail Program NHLBI Critical Reading Website (Today’s News blog) 2010 National Institutes of Health Award of Merit for work on NHLBI Grand Opportunities Exome Sequencing Project National Institutes of Health Director’s Awards for work on: Office of the Director Team on Comparative Effectiveness Research Through ARRA and Beyond National Institutes of Health Equal Employment Opportunity (EEO) 2010 Award of the Year: “For building a diverse professional staff and promoting the Spirit of Fairness, Equality, and Inclusion” 2012 NHBLI Merit Award “For Activities in Comparative Effectiveness Research” Arthur S. Flemming Award for exceptional service in Federal Government “For [playing] a key role in setting the national cardiovascular research agenda and [being] example in empowering his staff through creation of an active learning environment.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 6 2013 NIH Director’s Group Award: “NINDS Stroke Research Priorities Planning Team, for extraordinary leadership, perseverance, and creativity in coordinating and implementing the NINDS Stroke Research Priorities planning effort.”   NIH Director’s Group Award: “The Health Care Systems Research Collaboratory, for planning, developing innovative solicitations, review and launch of the Health Care Systems (HCS) Research Collaboratory.” NHLBI Director’s Individual Award: “In recognition of the extraordinary work to promote individual and collective learning at the NHLBI.” 2014 NHLBI Director’s Group Award: “InCites Working Group – for the dedication and collaboration exhibited by the trans-NHLBI InCites Working Group in building a model learning environment for portfolio analysis at the Institute.” MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS (selected examples): 1989- American College of Physicians 1999-2007 American Medical Association 1993-1997 Cleveland Clinic Committee on Medical Records and Statistics 1994-2007 Cleveland Clinic Institutional Review Board 1995-2000 Cleveland Clinic Electronic Medical Records Committee 1997-2007 Vice-Chairman, Cleveland Clinic Institutional Review Board 2000-2007 Contributing Editor, JAMA 1998-2002 American College of Cardiology, Coding and Nomenclature Committee 2003-2007 Professor of Medicine CCLCM of CWRU 2003-2005 Admissions Committee of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 7 2004-2007 “MAC” Multidisciplinary Advisory Committee – Director, Richard A. Rudick, M.D. – Cleveland Clinic Foundation, K12 Program of the National Institutes of Health 2004-2007 Cleveland Clinic Lerner College of Medicine Research Curriculum Committee 2005-2007 Cleveland Clinic Lerner College of Medicine Physicians Advisors Committee 2005-2007 Program Oversight Committee for the MD/MS Biomedical Investigation Program at CWRU 2005-2007 Annual Scientific Sessions Program Committee of the American College of Cardiology 2005-2007 Lower & Peskind Awards Committee 2005-2007 Selected ad hoc member of NIH Study Section on Human Services Research 2005-2007 ACCF/AHA Writing Committee to Update the 2000 Clinical Expert Consensus Document on EBCT for the Diagnosis and Prognosis of Coronary Artery Disease 2005- American Association for the Advancement of Science (AAAS) 2005-2007 Professor, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine 2006 NIH Study Section Member, (ZHL1 CSR-H (M1). Bethesda MD 2006 Acute Cardiac Care Abstract Grader for Prague, Czech Republic 2006 ACCF/AHA Writing Committee to Develop a Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients with Chest Pain 2006-2007 Research Education Committee, CCLCM of CWRU 2006-2007 PhD Molecular Curriculum Committee for CCLCM of CWRU 2006-2007 Tarazi Award Selection Committee
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 8 2006 Cardiovascular Medicine Outcomes Book Committee for 2006 2006 Selected ad hoc member of NIH Study Section on Heart Failure Clinic Research Network 2007 ACC/Duke University Think Tank on Cardiovascular Imaging 2007- NHLBI and NIH search committees Director, NHLBI Office of Communications Director, NHLBI Office of Global Health (Chair) Director, NHLBI Division for the Application of Research Discoveries Deputy Director, NHLBI Division of Blood Disease and Resources Deputy Director, NHLBI Division of Extramural Activities Director, NIMH Division of Services and Interventions Research Director, NCI Division of Cancer Prevention 2008- American Heart Association Research Committee 2008-2010 ACC/AHA Committee on Cardiovascular Risk Assessment 2008-2010 ACC/AHA Writing Committee on CT coronary angiography 2009- Editorial Board, Annals of Internal Medicine 2009- NIH Coordinating Committee for Comparative Effectiveness Research (Co-Chair since December, 2009) 2008- American Heart Association Quality of Care and Outcomes Research (QCOR) Planning Committee 2010-2011 NIH CTSA IC Directors Advisory Committee 2010 US Department of Health and Human Services Comparative Effectiveness Research Coordination and Implementation Committee (CER-CIT)
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 9 2011- Patient Centered Outcomes Research Institute (PCORI) Methodology Committee; Scientific Publications Working Group; Program Evaluation Group; Scientific Oversight Committte FDA Advisory Panels on Vytorin, Qnexa and CV Toxicity of GI drugs 2012- Clinical Trials Transformation Initiative Executive Committee 2013- NIH Scientific Data Council 2014- NIH Co-Chair for President’s Precision Medicine Initiative 2015- NIH Committee on Efficient and Sustainable Funding Policies MAJOR RESEARCH AND ACADEMIC INTERESTS: 1. Molecular biology and pharmacology, Rensselaer Polytechnic Institute 1979-1983 2. Cardiovascular epidemiology, Framingham Heart Study, 1990 - 1999 3. Exercise epidemiology, Cleveland Clinic Foundation, 1993 - 2007 4. Computerized medical record, Cleveland Clinic, 1994 - 2000 5. Clinical trials, 1997 – ongoing 6. Clinical cardiovascular epidemiology, 1993 – ongoing 7. Biostatistics, 2004-ongoing 8. Medical Editing (JAMA), 2000-2007 9. Comparative Effectiveness Research, 1990 – 10. Economics of Publicly Funded Biomedical Research, 2010 -- PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES: 1991-1993 Staff Cardiologist, Lahey Clinic Medical Center, Burlington, MA 1993-2007 Staff Cardiologist, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2003 Co-Director, Cleveland Clinic Foundation Coronary Intensive Care Unit 1997-2007 Vice Chair, Cleveland Clinic Foundation Institution Review Board 1999-2007 Medical Director, Cleveland Clinic Foundation Exercise Stress Laboratory
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 10 TEACHING AND LECTURE EXPERIENCE (selected examples): 1988 Lecturer in electrocardiography, Massachusetts General Hospital, Boston Lecturer in "Introduction to Clinical Medicine," Harvard Medical School and Massachusetts General Hospital, Boston 1993 Cardiology Grand Rounds, Cleveland Clinic Foundation, "Hypertension and Left Ventricular Hypertrophy" 1994 Medical Grand Rounds, Cleveland Clinic Foundation, "Medicine in Nazi Germany" 1994 Cleveland Clinic Health Talks, "Prevention and Regression of Heart Disease" Rainbow and Babies' Hospital Grand Rounds, "Medicine in Nazi Germany" 1995 Cleveland Clinic Coronary Club, "The Epidemiology of Coronary Artery Disease" 1993- Ernstene, Shirey, Consult and CCU Teaching Services, Cleveland Clinic 1995 Cleveland Clinic CME Course in Cardiovascular Risk Factors, "Left Ventricular Hypertrophy as a Risk Factor" 1996 MetroHealth Systems, Chronotropic Incompetence Cleveland Clinic Cardiology Grand Rounds, Chronotropic Incompetence John Carroll University, Medicine in Nazi Germany CNR, Pisa, Italy Exercise Hypertension University of Heidelberg, Heidelberg, Germany and Katholic University, Leuven, Belgium, Left Ventricular Hypertrophy 1997 Cleveland Clinic Ethics Committee Lessons from Nuremberg
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 11 Cleveland Clinic Internal Medicine Review Course, The Electrocardiogram American College of Cardiology Annual Scientific Sessions: Info@ACC Enhancing Your Productivity: Evaluating Electronic Medical Records for Clinical Practice Cleveland Clinic Foundation Section of Heart Failure: Left Ventricular Hypertrophy as a Cardiovascular Risk Factor: an epidemiologic perspective Walt Disney World and Cleveland Clinic Foundation Cholesterol Summit, Directed Workshop on Early Detection of Coronary Artery Disease. Cleveland Clinic Division of Medicine, Course on Foundations of Clinical Medicine, Dealing with Data. Cardiology Grand Rounds, Cleveland Clinic Foundation, The Electronic Medical Record. 1998 Cleveland Clinic Foundation Executive Health: Prevention of Coronary Heart Disease. American College of Cardiology, GUSTO IV Scientific Investigators Committee John Carol University, University Heights, OH AMedicine in Nazi Germany. Cleveland Clinic Department of Pulmonary Medicine, Management of Acute Coronary Syndromes in the Intensive Care Unit. Cleveland Clinic Department of Pulmonary Medicine, Management of Pericardial Disease in the Intensive Care Unit. Marquette Annual ECG Analysis Seminar; Rehabilitating the Exercise Electrocardiogram: Asking the Right Questions and Getting the Right Answers. Duke Clinical Research Institute, GUSTO IV Mini-symposium; “Role of Glycoprotein IIb/IIIa Inhibitors in the Management of Acute Coronary Syndromes.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 12 Cleveland Clinic Department of Cardiology: Introduction to Biostatistics Series of lectures to Cardiology Fellows Cleveland Clinic Division of Medicine, Journal Club Staff Supervisor 1999 Cleveland Clinic Division of Medicine Grand Rounds: Rehabilitating the Exercise Electrocardiogram. Sid Peterson Hospital, Kerville, Texas Long Term Management Strategies in Acute Coronary Syndromes: Risk Stratification of the Patient Who has had Coronary Artery Bypass Grafting. Cleveland Clinic Nursing Cardiac Care Symposium; Invited Speaker – Strategies for the Prevention and Treatment of Sudden Cardiac Death. Mt. Sinai Hospital, Cleveland, Medical Grand Rounds; Rehabilitating the Exercise Electrocardiogram. Duluth Clinic Annual Cardiovascular Conference, Keynote Speaker AUpdate in Heart Failure. New York Hospital Cornell Medical Center Cardiology Grand Rounds Chronotropic Incompetence: New Insights into an Old Sign. GUSTO IV Investigators Meeting: Introduction to the GUSTO IV Acute Myocardial Infarction Trial: 2 hour lecture on the background, rationale, and design of the trial as well as taking of questions from regional investigators. American Society of Echocardiography, Invited Speaker; Is Nuclear Ever Better. American Heart Association, Invited to Moderate How-to Session “Timing of Post-MI Risk Stratification.” Cleveland Clinic Foundation, Department of Rheumatology, Cardiac Imaging in Chronic Disease. Cleveland Clinic Foundation, Division of Surgery, Grand Rounds, “Preoperative Cardiac Evaluation of the Patient Undergoing Noncardiac Surgery: a Cardiologists Perspective.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 13 General Electric-Marquette Corporation, Milwaukee, Wisconsin: New Developments in Exercise Testing. 2000 Cleveland Clinic Department of Hospital-Based Internal Medicine: New Developments in Exercise Testing. General Electric-Marquette Corporation Annual Meeting in Fort Lauderdale, Florida: The Future of Exercise Testing. American College of Cardiology Annual Meeting, Invited Speaker at Symposium on Clinical Evaluation of the Patient Undergoing Noncardiac Surgery. Invited Speaker at Symposium: Exercise Testing in the New Millennium, Featuring Who’s Who in Exercise Testing, organized by Dr. Myrvin H. Ellestad and Dr. Ronald Startt-Selvester, on Use of Chronotropic Response and Heart Rate Recovery in Exercise Testing. Cleveland Clinic Foundation Fellowship Lectures on Statistical Review of Journal Articles. Cleveland Clinic Foundation Symposium on Dimensions in Cardiac Care, lecture on Beyond the ST Segment: New Developments in Exercise Testing. Cleveland Clinic Foundation Cardiovascular Board Review Course; Clinical Epidemiology and Biostatistics: How to Interpret a Clinical Research Study and Exercise ECG Stress Testing: Diagnostic Utility and Prognostic Implications. American Heart Association Cardiovascular Seminar on Novel New Markers in the ECG Stress Test, invited lectures on Chronotropic and Blood Pressure Responses. 2001 American College of Cardiology Symposium, invited lecture on Post-MI Risk Stratification: The Role of Exercise Electrocardiography. American College of Cardiology Oral Presentation; Prognosis in Patients with an Excellent Exercise Capacity. American College of Cardiology Oral Presentation; Logical Data Analysis for Assessment of Prognosis Among Patient Undergoing
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 14 Exercise Electrocardiography. Cleveland Clinic Foundation Symposium on Preventing Heart Disease; Resuscitating the Exercise Test. American College of Sports Medicine, invited clinical lecture: “Exercise Testing: A New Look at an Old Technology.” American College of Sports Medicine invited lecturer at Clinical Symposium on Detection of Silent Coronary Disease, “Use of Chronotropic Response and Heart Rate Recovery.” Cleveland Clinic Foundation Cardiology Review Course, “Clinical Trials and Population Studies: Things You Must Know” Cleveland Clinic Foundation Cardiology Review Course, “ECG Stress Testing—Outdated or Up-to-date?” Cleveland Clinic Foundation House Staff, “Introduction to Journal Reading (2 lectures)” 2002 American College of Cardiology, Invited Symposium Lecture, March, 2002: “Role of the Exercise ECG” American College of Cardiology, Invited Lecture, March 2002: “Maximizing the Use of Exercise Testing” American College of Cardiology, Oral Presentation, March 2002: “Ventricular Ectopic Activity Predicts Mortality When It Occurs During Recovery, but Not Just During Exercise.” Metro Health Center, Cleveland, Invited Lecture and Cardiology Grand Rounds, April 2002: “The Exercise Test: Looking Beyond the ST-Segment” Office of Human Research Protection and Cleveland Clinic Foundation Department of Bioethics Symposium on Research Protection, Invited Lecture, May 2002: “Issues Involving Authorship and Publication of Clinical Research” Brigham and Women’s Hospital, Harvard Medical School, Cardiology Grand Rounds, May 2002: “The Exercise Test: Looking Beyond the ST-segment”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 15 Maine Medical Center of Portland, Maine, Invited Lecture, Visiting Professor, Cardiology Grand Rounds, May 2002: “The Exercise Test: Looking Beyond the ST-Segment” Maine Medical Center of Portland, Maine, Invited Lecture, Visiting Professor, Fellows Noon Conference, May 2002: “Ethical Issues Regarding Authorship” Bikur Cholim Hospital, Jerusalem, Israel, June 2002: “The Exercise Test: Looking Beyond the ST-Segment” Hartford Hospital Department of Cardiovascular Medicine, Visiting Professor and Invited Speaker, July 2002: “The Exercise Test: Looking Beyond the ST-Segment” American College of Cardiology, Yellowstone Summit, West Yellowstone, Montana, August 2002, invited speaker: “Stress Testing: Which Modality to Choose” Cleveland Clinic Foundation Medical House Staff Journal Club, September 2002: “Introduction to Clinical Journal Reading” Cleveland Clinic Foundation Division of Medicine, September 2002: “Clinic Research Methods, Part I” (This was given twice, under the auspices of Dr. James Stoller) Cleveland Clinic Foundation Division of Medicine, September 2002: “Clinical Research Methods, Part II” (This lecture was given twice, under the auspices of Dr. James Stoller) Cleveland Clinic Foundation Cardiovascular Medicine Board Review Course, September 2002: “Statistics for the Clinical Cardiologist” Cleveland Clinic Foundation Cardiovascular Medicine Board Review Course, September 2002: “ECG Stress Testing---New Approaches to an Old Modality” Israeli Women’s Health Fellowship of the Jewish Community
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 16 Federation of Cleveland, October 2002: Seminar in “Topics on Cardiovascular Disease in Women” American College of Rheumatology, New Orleans, October 2002, invited speaker: “Aspirin for Primary Prevention of Cardiovascular Disease” American Heart Association, November 2002: Moderator and Invited Speaker “Using the Heart Rate to Improve Stress Test Interpretation” Tel HaShomer Medical Center and Tel Aviv University, December 2002: Visiting Professor and lecture on “Exercise Testing” Looking Beyond the ST-Segment” John Carroll University Freshman Program Speaker, December 2002: “Ethical Issues in Research” 2003 Cleveland Clinic Foundation Imaging Fellows Conference, January Invited Speaker “Clinical Trials and Observational Studies: Things You Must Know” January 2003 Biostats Seminar – Two fellowship lectures on “Clinical Research Design” January 2003. University of North Carolina at Chapel Hill, invited speaker, UNC Heart Center Grand Rounds. Cleveland Clinic Foundation Imaging Fellows Conference, Core Fellows Lecture Series (Part I) Invited Speaker “Clinical Trials and Observational Studies: Things You Must Know.” Cleveland Clinic Foundation CTS Research Team Grand Rounds Speaker, “Exercise Testing: Looking Beyond the ST Segment February 2003. Lakewood Hospital, Cleveland, Ohio Grand Rounds Speaker, “Exercise Testing: Looking Beyond the ST Segment February 2003.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 17 Case Western Reserve University School of Medicine Grand Rounds, Invited Speaker, March 2003. “The Exercise Test: Beyond the ST Segment.” ACC Poster Session – “Heart Rate Recovery After Exercise and Mortality with Exercise Testing” ACC Meet the Experts – “Customizing the Image to the Patients: AKA What Test is for Whom?” ACC Oral Contributions – “Exercise Testing: Predicting Mortality,” and “Association of Abnormal Heart Rate Recovery and Chronotropic Incompetence with Obesity in a Healthy Cohort.” ACC Oral Contributions – “Stress Echocardiography: Ploughing New Ground” and Survival Benefits of Early Myocardial Revascularization after Stress Echocardiography: A Propensity Analysis.” ACC Oral Contribution – “The Old and the New” The ECT and Novel Biomarkers in Acute Coronary Syndromes” and Does the Presence of Electrocardiographic Left Ventricular Hypertrophy Predict One-Year Mortality in Non-ST Elevation Acute Coronary Syndromes.” Cleveland Clinic Foundation Heart Failure Invited Speaker – “Recent Innovations in Exercise Testing.” Annual Meeting of the Israel Heart Society, Tel Aviv, Israel, Invited Guest Lecturer, “Assessment of Prognostic Ambulatory Patients with Congestive Heart Failure,” April 2003. Cleveland Clinic Foundation Heart Failure Research Invited Speaker, April 2003. “Exercise Testing: Beyond ST Segment” Indiana University School of Medicine/Krannert Institute of Cardiology, Cardiovascular Research Conference, Invited Speaker, “Exercise Testing—Beyond the ST-Segment,” May 2003. 30th International Congress on Electrocardiology, Helsinki,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 18 Finland, Invited Speaker, “Recovery after Graded Exercise Testing: An Under-appreciated Time of Great Prognostic Value,” June 2003. Invited Speaker “Internal Medicine Noon Conference” Cleveland Clinic Foundation – “Introduction to Journal Club Part Deux.” Residents Conference – “Clinical Epidemiology and Biostatistics for the Clinical Practitioner.” Invited Speaker – Cardiovascular Board Review Course – “An Intensive Review of Cardiology” and “Statistics for the Clinical Cardiologists” and “ECG Stress Testing – New Approach to Old Modality,” InterContinental Hotel Amphitheater, CCF. Residency Conference – “Clinical Epidemiology and Biostatistics for the Clinical Practitioner.” Invited Speaker – “Women’s Health Seminar on Cardiovascular Disease” with visiting scholars and Israeli physicians, Jewish Community Federation of Cleveland Women’s Health Program. Cleveland Clinic Foundation Symposium on Men’s Health, Invited Lecture on Screening for Coronary Artery Disease.” Invited State-of-the-Art Speaker for the Annual Michael Pollock Lecture on “Exercise Testing---Still the First Choice” at the American Heart Association meeting on November 8, 2003, Orlando, Florida. 2004 Visiting Professor and Invited Speaker – Tufts University, Boston, Massachusetts – two lectures, one on “Methods in Clinical Epidemiology” and one on “New Insights into Exercise Testing.” Invited Speaker – Cardiovascular Board Review Coarse – “An Intensive Review of Cardiology” and “Statistics for the Clinical Cardiologists” and “ECG Stress Testing—New Approach to an Old Modality,” InterContinental Hotel Amphitheater, Cleveland Clinic Foundation.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 19 ACC Scientific Sessions 2004 Program Presenter, “Gender Differences in Diagnosis of Coronary Artery Disease” ACC Scientific Sessions 2004 Program Presenter “Stress Testing: Does It Have Any Role?” 5Th Scientific Forum on Quality of Care and Outcomes Research in Cardiology, Invited Lecturer, May 16, 2004, “How to Get Your Outcomes Research Published.” ACP (American College of Physicians) Two “Meet the Professor” Sessions as an Invited Speaker – “Stress Testing: “When” “Which One” “How Often” Heart Failure Therapeutics Meeting, Guest Speaker, July 21, 2004, “Metabolic Stress Testing.” Journal Club Part I and Part II, Invited Speaker, August 9 and September 15, 2004. Mayo Clinic, Rochester Minnesota, Grand Rounds Speaker, August 11, 2004, Two Lectures – Exercise Testing—Beyond the ST-Segment.” Symposium at AHA Physicians Outcomes Meeting and Invited Speaker – “Publishing Outcomes Research” Omni Shoreham Hotel, Washington, DC. Cardiovascular Board Review Course, Cleveland Clinic Foundation –Invited Speaker, “Statistics for the Clinical Cardiologist” and “ECG Stress Testing—New Approach to an Old Modality.” Human in Medicine Series – Cleveland Clinic Foundation Noon Conference – Invited Speaker, October 6, 2004, “Nazi Medicine.” Men’s Health Summit, Cleveland Clinic Foundation Symposium, October 14, 2004, Invited Speaker – “Treadmills and Scans: Screening for Coronary Artery Disease.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 20 European Society of Cardiology Conference, Rome, Italy, October 17, 2004, Invited Speaker – “Roll of Exercise Testing After Acute Coronary Syndrome.” American Heart Association, Scientific Sessions 2004, November 8, 2004, Invited Speaker – “How to Interpret a Stress Test.” Department of Internal Medicine Residency Program, Invited Lecturer, December 1, 2004, - “Stress Testing.” NIH Workshop – NHLBI Working Group on “Subclinical Coronary Artery Disease: Functional Capacity as a Risk Marker,” Bethesda, MD, July 13-14, 2004 Fellows’ Noon Conference, Invited Speaker, “Exercise Stress Testing Part I,” July 29, 2004 Heart Failure Therapeutic Meeting – Invited Speaker – “Metabolic Stress Testing,” July 21, 2004 Introduction to Journal Club Part I Noon Conference, Medical House Staff, “Introduction to Journal Club.” August 8, 2004 Mayo Clinic Internal Medicine Grand Rounds, Rochester, Minnesota, Invited Speaker, Two talks, “Exercise Testing: Beyond the ST Segment, and “Ethical Issues in Medical Authorship,” August 11, 2004 Nephrology Grand Rounds, Cleveland Clinic Foundation, “Exercise Testing: Beyond the ST Segment,” August 27, 2004 Introduction to Journal Clubs Part II Noon Conference, Cleveland Clinic Foundation, “Introduction to Journal Club,” September 14, 2004 5th Annual Intensive Review in Cardiology, Cardiovascular Board Review Course, Invited Speaker, two talks – “Statistics for the Clinical Cardiologist” and “ECG Stress Testing –New Approach to an Old Modality,” September 22, 2004 Cleveland Clinic Foundation Division of Medicine – Invited Speaker, Cleveland Clinic Foundation, Humanities in Medicines Series Noon Conference, “Nazi Medicine,” October 5, 2004
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 21 Men’s Health Summit, Cleveland Clinic Foundation, Invited Speaker, “Treadmills and Scans” and “Screening for Coronary Artery Disease, “October 14, 2004 European Society of Cardiology Working Group on Acute Cardiac Care, Rome, Italy, Invited Speaker, “Risk Stratification and Secondary Prevention in Post-Infarct Survivors in the Reperfusion Era,” October 17, 2004 Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Invited Speaker – Medical School Dean’s Dinner, “Heart Rate Recovery,” November 18, 2004 Internal Medicine Noon Conference, Internal Medicine Residency Program, Cleveland Clinic Foundation, Invited Speaker, “Cardiac Stress Testing.” December 1, 2004 2005 Cleveland Clinic Foundation, Department of Interventional Cardiology, Invited Speaker, “Pre-Operative Cardiac Evaluation with Special Emphasis on Ramifications of Recently Published CARP Trial,” January 19, 2005 Boston Medical Center Cardiology Grand Rounds, Boston, Massachusetts, Invited Speaker, “Risk Stratifying the Cardiac Patient with Exercise Testing” February 9, 2005 American College of Cardiology Annual Scientific Session 2005, Orlando, Florida, Co-Chair – “Meet the Experts:” – Medical Manuscripts: Editors’ Perceptive,” March 08, 2005 Cleveland Clinic Foundation Internal Medicine Noon Conference, Invited Speaker, “Pharmaceutical Industry and Medical Education: A Free Lunch?” March 22, 2005 Cleveland Clinic Foundation, Department of Infectious Disease, Retreat Presentation/Invited Speaker, “NIH Grants/External Research Funding.” March 22, 2005 American College of Physicians Annual Session (Faculty Member) and Invited Speaker, “Noninvasive Cardiac Imaging: Which Test for Which Patient?” San Francisco, California, April 14-16, 2005 Cleveland Clinic Foundation, Department of Cardiac Surgery,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 22 (CVIR) Invited Speaker, “Quantitative Electrocardiography and Prognosis after Cardiac Surgery,” May 10, 2005. Research Day 2005, Cleveland Clinic Foundation, Department of Thoracic and Cardiovascular Surgery, Visiting Professor Lecture – “Short- and Long-Term Outcomes of Cardiac Surgery for Observant Jehovah’s Witnesses” – Sponsor for Dr. Mariano Brizzio. June 10, 2005. Solon Family Health Center/CCF Chagrin Falls Physician Staff, Invited Speaker, “Non-invasive Cardiac Testing: Which Test for Which Patient?” August 31, 2005 Course Director, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Clinical Epidemiology (45 hour contact course for second year medical students), July-September, 2005 2005 Cardiovascular Board Review Course, invited speaker, “Cardiac Testing” – “ETT” Series of Cardiology Fellow Presentations in Epidemiology and Biostatistics (2005 – ongoing) Invited Speaker – CCF - An Intensive Review of Cardiology, (2 talks) “Exercise ECG Stress Testing: New Approach to an Old Modality” and “Statistics for the Cardiologist.” September 21, 2005. 4th International Meeting on Intensive Cardiac Care, Invited Speaker, “The Significance of Troponin Elevation in Patients with and without Renal Failure.” Tel Aviv, Israel September 27-29, 2005. Acute Care Nurse Practitioner Students, Invited Speaker, Cleveland Clinic, “Stress Testing.” November 1, 2005 Grand Round for Clinical Research at Cleveland Clinic – Invited Speaker, “Investigator Responsibilities and Academic Freedom in Clinical Research” Bunts Auditorium November 22, 2005. Numerous television and radio interviews (Fox, Metro-News, Men’s Health Magazine). Gill Heart Institute, University of Kentucky, Grand Rounds
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 23 speaker at Fellow’s Conference. “Gill Seminar Series – IM and Associated Stress Testing.” December 2, 2005. 2006 Invited guest lecturer on Cardiovascular Chronic Disease for Seminar Course Lecture/Foundations in Research and Scholarship in Class 483. February 1, 2006. Invited Speaker – Clinical Ethics Symposium for First Year Medical Student, Fire Restaurant, Shaker Heights, OH “Ethics in Research,” March 5, 2006 Co-Chair (with Dr. Martha Gulati). “Meet the Experts Session, Modern Exercise Test Interpretations.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 13, 2006 Co-Chair. “Writing for Publication While in Training, Cardiac Care Associates and Young Academic Cardiologists.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA March 14, 2006. Invited Speaker for Symposium - “How Editors Approach Industry-Related Conflicts of Interest.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA March 14, 2006 Invited Speaker for Symposium – “Cardiologists on Trial: Reflection on Credible Evidence.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 14, 2006. “Asymptomatic diabetics and metabolic syndrome: role of imaging: - “Is there a role for the stress electrocardiogram?” Invited Speaker, American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 13, 2006. “Tuesday Morning Vascular Medicine Conference” Lecturer- Invited Speaker, “Pre-Operative Cardiovascular Risk Assessment and Management for Vascular Surgery.” Cleveland Clinic, March 21, 2006 CME Symposium “Updates on Cardiovascular Medicine” New Milford Hospital/New York Presbyterian Columbia and Cornell University Medical Center, Invited Speaker, “Exercise and
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 24 Exercise Testing: not Enough Respect,” New Milford, CT, March 28, 2006. Invited Speaker – Cleveland Clinic Cardiovascular Medicine Athero-Thrombosis Group Meeting, “Autonomic Nervous System Research in the Stress Lab,” March 2006. Invited guest lecturer, Cleveland Clinic/Case Western Reserve Acute Care Nurse Practitioner Class – Stress talk, “Specialty Assessment and Diagnostics.” April 4, 2006 Baystate Medical Center, Plotkin Conference, Invited Speaker at the “Log Cabin Conference Center,” “Noninvasive Cardiac Testing: Which Test for Each Patient?” Holyoke, MA. April 7, 2006 Invited Speaker – Clinical Trials Course for the Department of Quantitative Health Sciences, “Clinical Trials from Viewpoint of Journal Editor,” Cleveland Clinic, May 4, 2006. 7th American Heart Association Forum on Quality of Care and Outcomes in CVD and Stroke, Washington, DC, Invited Speaker, “Writing for Medical Journals: A Session with the Editors,” “Publication in JAMA: An Editor’s Perspective.” May 8, 2006. Krannert Institute of Cardiology of Indiana University, Invited Speaker, Indianapolis, IN, Grand Rounds. “Ethical Issues in Biomedical Authorship” and “Author Responsibilities and Academic Freedom: an Editor’s Perspective.” May 9, 2006. University of Alberta, Edmonton Canada, Invited Distinguished Speaker/Grand Rounds, “Contemporary Ethical Issues in Biomedical Authorship” May 17, 2006. Spring Ohio College of Clinical Pharmacy Meeting, Cleveland, OH, Invited Speaker – Keynote Address, “Conflict of Interest: Perspectives of a Physician and a Medical Editor,” May, 24, 2006. Invited Speaker – Cleveland Clinic Intensive Review in Internal Medicine, “Board Simulation in Biostatistics” Intercontinental Hotel, Cleveland Clinic. June 13, 2006. Invited Speaker – 2006 Clinical Research Grand Rounds, “Designing Clinical Trials.” Center for Clinical Trials, Cleveland Clinic, June 27, 2006.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 25 Conflict of Interest Concerns in Biostatistical Work, invited as “Special Contributed Panel” member, Montreal Canada, July 20, 2006. IBC Meeting, invited speaker, “Editors’ Approach to Industry Related Conflict of Interest: JAMA, July 26, 2006, Montreal Canada. The American College of Cardiology Foundation, Cardiovascular Board Review, invited speaker/faculty. “Exercise Treadmill Testing.” September 7, 2006, Dallas, TX Case Western Reserve EPBI 510 Class Health Disparities Graduate Course, invited speaker, “SES and Cardiac Parameters.” September 11, 2006. Inventors’ Forum on Managing Innovation/COI 2006-2007, invited speaker, “Do’s and Don’ts of IRB.” September 14, 2006. Beterson 16-Year Long-Term Followup Study - Mortality in MS Workshop, invited speaker for meeting on Survival in MS. “Exercise Treadmill Testing.” September 17, 2006, New York, NY Annual Intensive Review of Cardiology, Cleveland Clinic, invited speaker, 2 talks, “Electrocardiogram Stress Testing – A New Approach to an Old Modality” and “Statistics for the Cardiologist.” September 20, 2006. CCLCM invited speaker for medical student class. “Authorship,” September 22, 2006. American Association for Thoracic Surgery and Directors of the Cleveland Clinic Kaufman Center for Heart Failure 21st Century 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical therapies for Better Outcomes, Invited Speaker. “Predicting outcomes in patients with heart failure: Clinical characteristics, peptides perfusion and function. October 20, 2006 “A New Dimension in Leadership: Emotional Intelligence” Workshop, Cleveland Clinic Center for Leadership and Learning, Cleveland OH, October 23, 2006 American Association for Thoracic Surgery – 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 26 Therapies for Better Outcomes - Invited Speaker - Predicting Outcomes in Patients with Heart Failure: clinical Characteristics, peptides, perfusion and Function.” MBNA Conference Center, Cleveland Clinic InterContinental Hotel, Cleveland Ohio Acute Cardiac Care Congress 2006, European Cardiac Society and Israel Heart Association, Czech Republic, October 21-24, 2006, Scientific Committee and Invited Speaker. Swedish Society of Clinical Physiology – Invited Speaker – “Torgny Sjostrand Honorary Lecture in Clinical Physiology, Annual Meeting of the Swedish Society of Medicine, Goteborg, Sweden. “Exercise Testing—An Integrated Physiological Approach of High Prognostic Value in Clinical Medicine” and “Exercise Testing and Autonomic Function in Cardiovascular Disease.” November 30, 2006. The Department of Bioethics, invited guest lecturer, “Contemporary Ethical Issues in Biomedical Authorship: An Editor’s Perspective.” Cleveland Clinic. December 5, 2006. Cerebrovascular Research invited speaker. “Introduction to Diagnostic Tests.” December 14, 2006. 2007 Cleveland Clinic, Division of Medicine Grand Rounds Speaker. “Cardiovascular Medicine Department Update.” January 4, 2007. MetroHealth Heart & Vascular Center Grand Rounds, invited speaker, “Ethical Issues in Biomedical Authorship, January 10, 2007. Invited Clinical Trials Course Speaker (with Drs. Gerald Beck and A. Michael Lincoff) – Cleveland Clinic. “Authorship and Clinical Trials.” January 11, 2007. Framingham Heart Study, Invited speaker, “Advances in Exercise Testing,” Framingham, MA. February 8, 2007. Planning and Implementation of Performance Management Systems in Healthcare Organizations, Weatherhead Executive Education, Weatherhead School of Management, Case Western Reserve University. March 9, 2007.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 27 Keynote Speaker, Cleveland Clinic Lerner College of Medicine, March 22, 2007. Invited Speaker and Faculty Member – American College of Physicians, “Meet the Professor Courses,” and “Noninvasive Testing for Coronary Artery Disease.” San Diego, CA April 19, 2007. ACC 56th Annual Scientific Session – invited speaker and faculty. Four talks: “How to Get Your Paper Published,” “Screening for Coronary Artery Disease in High-risk Asymptomatic Patients,” “Modern Exercise Testing Interpretation: An Oxymoron,” and “Meet Your Medical Editors.” March 24-27, 2007 Invited “Noon Conference” Speaker – Internal Medicine, Cleveland Clinic. “Update on Stress Testing – Exercise Treadmill Testing.” April 23, 2007. Various radio and television interviews, HealthNews, Heart Advisor, BBC. Fox, The Heart.Org., Cleveland Clinic ACC Think Tank on Cardiovascular Imaging, presentation on new research paradigms, Tyson’s Corner, VA, October, 2007 Invited plenary session comment on CORE-64 Trial, American Heart Association Scientific Sessions, November 4, 2007, Orlando, FL 2008 (selected) “Data Primarily Collected for New Insights.” February 28, 2008 Institute of Medicine Roundtable on Evidence-Based Medicine Washington, DC Washington Business & Health CEO Summit in conjunction with the University of Washington, Seattle, WA, March 26, 2008. “Prevention of Coronary Artery Disease.” Visiting Professor, Duke University and Duke Clinical Research Institute, Durham, NC, April 13-15, 2008. Three lectures: “Evidence-Based Overview of Noninvasive Cardiac Testing,” “Novel Statistical Approaches for Analyzing Large Databases,” and “Ethics of Biomedical Authorship” Visiting Professor, Boston University, Boston, MA, May 21-22,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 28 2008. “Evidence-Based Overview of Noninvasive Cardiac Testing.” Baaken Heart-Brain Summit, Cleveland Clinic, Cleveland, OH, June 3, 2008. “Vagal Tone and Outcomes in Patients with Cardiovascular Disease.” NIH OBSSR Summer Course in Clinical Trials, Airlie, VA. July 16, 2008. Featured lecture: “Ethical Issues in Biomedical Authorship and Peer Review.” Ancel Keys Memorial Lecture of the American Heart Association, New Orlean, LA, November 10, 2008. “Discarding Logic.” 2009 (selected) Visiting Professor, Indiana University, Indianapolis, Indianna. February 3, 2009. “A Research Agenda for Cardiovascular Disease: Crossroads of Evidence and Public Policy.” Cleveland Clinic Cardiovascular Summit, Cleveland, Ohio. June 3, 2009. Two lectures: “Does Non-invasive Imaging Prevent Death,” and “Does Exercise Help Patients with Heart Failure?” NIH OBSSR Summer Course in Clinical Trials, Airlie, VA. July 16, 2008. Featured lecture: “Ethical Issues in Biomedical Authorship and Peer Review.” American Heart Association Basic Science Conference, July 21, 2009, Las Vegas, NV. “NHLBI Research Funding and Update on Priorities.” Visiting Professor, Christiana Medical Center, July 22, 2009, Newark, DE. “Reflections on Comparative Effectiveness.” World Hemophilia Federation, September 24, 2009, Montreal, Quebec, Canada. “Economics and Comparative Effectiveness: Threats to Care?” Invited Lecturer, Institute of Medicine Forum on Drug Discovery, Development, and Translation, Transforming Clinical Trials in the United States, October 7, 2009, Washington, DC. “Clinical Research in Acute and Chronic Life-threatening Conditions: A Government Perspective.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 29 Visiting Professor, Henry Ford Hospital, October 13, 2009, Detroit, MI. “Reflections on Comparative Effectiveness.” Invited Lecturer, Personalized Medicine Coalition and the National Pharmaceutical Council, October 28, 2009, Arlington, VA. “Thoughts about Personalized Medicine and Comparative Effectiveness Research.” American Association of Medical Colleges Convention, November 9, 2009, Boston, MA. “Comparative Effectiveness: Views from the National Institutes of Health.” Moderator, Plenary Session, American Heart Association Annual Scientific Sessions, November 16, 2009, Orlando, FLA. “The Challenges of Imaging Wisely and Responsibly.” Sixth Annual Global Cardiovascular Clinical Trialists’ Forum, December 2-5, 2009, Paris, France, and Luxembourg City, Luxembourg. Two talks: “Comparative Effectiveness Research and Pragmatic Trials,” and “Nonindustry Sponsored Trials and the Role of NHLBI and EU Public Institutions.” US Critical Illness and Clinical Trials Group, December 9, 2009, Bethesda, MD. “Comparative Effectiveness Research: NIH Perspectives.” 2010 (selected) NCI ARRA Comparative Effectiveness Symposium, January 5, 2010, Bethesda, MD. “The 2010 NIH Vision for Comparative Effectiveness Research.” Invited Guest Lecturer, Centers for Medicare and Medicaid Services, January 13, 2010, Baltimore, MD. “Evidence- Development: Perspectives from the NIH” Visiting Professor, Massachusetts General Hospital, March 3, 2010, Boston, MA. “Comparative Effectiveness Research One Year Later.” Keynote Speaker, 3rd Annual NIH Conference on Dissemination and Implementation Research, March 15, 2010, Bethesda, MD. “Where Does Comparative Effectiveness Research Fit in the Domains of Dissemination and Implementation.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 30 Invited Speaker, American College of Cardiology Annual Sessions, March 16, 2010, Atlanta, GA. “Cardiovascular Risk in Asymptomatic Adults, Use of Noninvasive Tests, ECG, IMT, CAC.” Invited Meet-the-Expert Speaker, American College of Physicians Annual Meeting, April 23, 2010, Toronto, Ontario, Canada. “Noninvasive Cardiac Imaging, Which Test for Which Patient?” Invited Panelist, University of Pennsylvania R13 Special Conference, April 27, 2010, Philadelphia, PA. “Statistical Issues in Comparative Effectiveness Research.” Keynote Speaker, Delaware Health Alliance Annual Meeting, May 4, 2010, Newark, DE. “Comparative Effectiveness Research: One Year Later.” Invited Symposium Speaker, American Thoracic Society Annual Scientific Meeting, May 17, 2010, New Orleans, LA. “Comparative Effectiveness Research at NHLBI: Opportunities and Challenges.” Sharma Visiting Professor, Mt Sinai Medical Center Cardiovascular Institute, May 24, 2010, New York City, NY. Invited Speaker, NHLBI Public Interest Organizations Annual Meeting, May 25, 2010, Bethesda, MD. “Cardiovascular Highlights from the American Recovery and Reinvestment Act.” Invited Speaker for Highlighted Symposium, American College of Sports Medicine Annual Scientific Meeting, June 3, 2010, Baltimore, MD. “Autonomic Function and Outcomes in Patients with Cardiovascular Disease.” Invited Speaker for Symposium, American Health Insurance Plans Institute Annual Meeting, June 10, 2010, Las Vegas, NV. “Using Science to Improve the Nation’s Health System: The Case of Comparative Effectiveness Research.” Invited Speaker for Lewin Group Symposium on Responding to the National Comparative Effectiveness Research Agenda: Evolving Data Sources and Analytics, June 15, 2010, Washington, DC. “What are the Limits of Randomized Clinical Trials: Then What?”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 31 Invited Speaker and Panelist for National Pharmaceutical Council on Shaping Convergent Strategies for Comparative Effectiveness Research, June 24, 2010, Washington, DC. “The Patient-Centered Outcomes Research Institute (PCORI).” Invited Speaker for NHLBI Workshop on Comparative Effectiveness, July 13, 2010, Bethesda, MD. “Comparative Effectiveness Research at NHLBI: Opportunities and Challenges.” Invited Speaker, Market Access World, October 6, 2010, Washington DC. “How is the stimulus being invested by NIH – Timelines, Implemention, Pathway, Structure?” Invited Keynote Speaker, American Geriatric Society CER conference, November 2, 2010, Bethesda, MD. Invited Speaker, CBI 4th Annual CER Summit, Thursday, November 18, 2010, Philadephia, PA. Invited Keynote Speaker, NIH CTSA Consortium CER Symposium, December 1, 2010, Bethesda, MD. “How Can CTSAs and External Partners Collaborate to Support a National CER Agenda?” Invited Visiting Professor and Grand Rounds Speaker, Cleveland Clinic Heart and Vascular Institute, December 3, 2010, Cleveland, OH. “Cardiovascular Comparative Effectiveness Research in the Era of Health Care Reform.” Invited Speaker, Heart Rhythm Society Research Meeting, December 15, 2010, Washington, DC. Grand Rounds Speaker and Visiting Professor, George Washington University Department of Cardiology, December 16, 2010, Washington, DC. “A Philosophy of Non-Invasive Diagnostic Testing” Grand Rounds Speaker, George Washington University Department of Medicine, December 17, 2010, Washington, DC. “Comparative Effectiveness Research: Two Years Later.” 2011 (selected) Invited Plenary Speaker, International Society for Cardiac Magnetic Resonance, February 4, 2011, Nice, France.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 32 “Cardiovascular Imaging: Why Randomized Trials are Needed.” Invited Grand Rounds Speaker and Visiting Professor, Oregon Health Sciences University, February 8, 2011, Portland Oregon. Two lectures, one on “Ethics in Authorship and Peer Review” and one on “The Case for Comparative Effectiveness Research.” Invited Speaker and Visiting Professor, Rockefeller University, February 16, 2011, New York, NY. “The Case for Comparative Effectiveness Research.” Invited Speaker, Late Phase Drug Development Symposium, March 23, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Speaker, American Occupational Health Conference, March 29, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Speaker, American College of Cardiology, April 3, 2011, New Orleans, LA. “What Parameters Should be Used to Assess Improved Patient Outcomes of Cardiovascular Imaging?” Invited Speaker, NHLBI WHI Investigators Meeting, May 5, 2011, Seattle, WA. “The Case for Comparative Effectiveness Research.” Invited Speaker, Harvard Medical School Post-Approval Summit, May 11, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Grand Rounds Speaker, Indiana University Krannert Institute, May 31, 2011, Indianapolis, IN. “The Economics of Cardiovascular Research.” Invited Speaker, NCCAM Advisory Council Meeting, June 3, 2011, Bethesda, MD. “The Case for Comparative Effectiveness Research.” Invited Speaker, Drug Information Association (DIA) Meeting, June 20, 2011, Chicago, IL. “Comparative Effectiveness and Health Technology Assessment: How NIH is Addressing the Challenge.” Invited Speaker, National Health Leadership Council Forum and National Business Coalition on Health, June 22, 2011,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 33 Minneapolis, MN. “Science for the Benefit of the Nation’s Health Care: The Case for Comparative Effectiveness Research.” Invited Speaker, North American Conference of Epidemiology, June 23, 2011, Montreal, Quebec, CA. “NIH Perspective: Observations (on Observations) and Experiments.” Invited Speaker, National Institute on Minority and Health Disparities, Special Course on Integrating Principles of Science, Practice, and Policy in Health Disparities Research, June 29, 2011, Bethesda, MD. “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited speaker, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, July 6, 2011, White Oak, MD. “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited speaker, NHLBI Workshop on Heart Failure Prevention, July 14, 2011, Bethesda, MD. “NHLBI Perspective: Thoughts about Inputs and Outputs.” Invited speaker, Center for Medical Technology and Policy (CMTP) CER Institute, July 25, 2011, Santa Fe, NM. “Comparative Effectiveness Research: Federal NIH Perspectives on Science, Practice, and Policy.” Invited speaker, NHLBI Office of Administrate Management Seminar Series presentation, August 17, 2011, Bethesda, MD. “What’s the Story Behind the Explosion of Diagnostic Tests and Imaging?” Invited Keynote speaker, American Heart Association Pharmaceutical Roundtable Outcomes Center Steering Committee Annual Meeting, September 12, 2011, Palo Alto, CA. “Cardiovascular Outcomes Research: Going Forward.” Invited speaker, CBI 14th Registries and Post-Approval Studies Congress, September 21, 2011, Philadelphia, PA. “NIH Address: Advancing Comparative Effectiveness Research through the Patient-Centered Outcomes Research Institute (PCORI).” Visiting Professor and invited speaker for Medical Grand Rounds, University of Wisconsin, September 23, 2011, Madison, WI.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 34 “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited guest speaker, National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) Advisory Council Meeting, September 27, 2011, Bethesda, MD. “Science to Improve the Nation’s Health Care: The Case for Comparative Effectiveness Research.” Invited Keynote speaker, Market Access World USA 2011, October 5, 2011, Washington DC. “Comparative Effectiveness Research: Updates from the NIH.” Invited speaker, Duke University Think Tank on Rescuing Clinical Trials, October 6, 2011, Tysons Corner, VA. “Patient and Physician Perceptions on Clinical Research and Trials,” and “NIH and VA investment in funding trials and funding research networks: is it helping, and is it paying off?” Invited Keynote speaker, 3rd Annual CER Summit, October 12, 2011, Washington DC. “The Role of the NIH in Comparative Effectiveness Research.” Invited speaker, Institute of Medicine Forum on Drug Discovery, November 7, 2011, Washington DC. “Developing a Robust Clinical Trials Workforce.” Invited speaker and Distinguished Visiting Professor, Cedars-Sinai Heart Institute (UCLA), November 8, 2011, Los Angeles, CA. “The Case for Comparative Effectiveness Research.” Invited speaker, American College of Cardiology Cardiovascular Symposium, November 13, 2011, Orlando, Fla. “Comparative Effectiveness in Heart Failure: Are Randomized Trials Necessary?” Invited guest speaker, FAES Public Health, November 16, 2011, Bethesda, MD. “The Case for Comparative Effectiveness Research.” Invited speaker, NIH Centers for Population Health and Health Disparities, November 29, 2011, Bethesda, MD. “Biomedical Research: How Do We Know We are on Track?” Invited speaker, Global Cardiovascular Clinical Trialists Forum,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 35 December 5, 2011, Paris, France. “New Designs and Paradigms for Large Simple Trials.” Invited speaker, Gilbert Beebe Symposium on Tracking Radiation Exposure from Medical Diagnostic Procedures, National Academies of Science, December 8, 2011, Washington, DC. “The Physician’s Perspective on What to Report.” 2012 (selected) Invited speaker, Health Sector Management Program of the Fuqua School of Business and Duke University, January 11, 2012, Bethesda, MD. “Biomedical Research: How Do We Know we are on Track?” Invited speaker and Visiting Professor, Cleveland MetroHealth Cardiology Grand Rounds, February 1, 2012, Cleveland, OH. “National Policy Issues Surrounding Comparative Effectiveness Research.” Invited speaker, Cleveland MetroHealth Medical Grand Rounds, February 2, 2012, Cleveland, OH. “Evaluation and Screening of Asymptomatic People.” Invited speaker and Visiting Professor, Yale University School of Medicine Cardiology Grand Rounds, February 7, 2012, New Haven, CT. “Cardiovascular Outcomes Research Going Forward.” Invited speaker, Cleveland Clinic Medical Grand Rounds, February 23, 2012, Cleveland, OH. “A National Agenda for Comparative Effectiveness Research: PCORI and Beyond.” Keynote speaker, Washington University Symposium on Comparative Effectiveness and Shared Decision Making, March 13, 2012, St. Louis, MO. “Challenges and Successes in CER Implementation: Examples from Pragmatic Trials.” Invited speaker for cardiovascular symposium, American College of Cardiology, March 25, 2012, Chicago, IL. “The Year in Review: Diagnostic Testing.” Invited speaker, American College of Cardiology, March 25, 2012, Chicago, IL. “Risk Stratification: Looking Beyond the ECG During Stress Testing.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 36 Invited speaker, ExL Pharma Symposium, April 2, 2012, Washington, DC. “NIH’s Expectations for Using CER Evidence for Commercialization.” Invited speaker, University of Missouri at Kansas City, April 17, 2012, Kansas City, MO. “A National Agenda for Comparative Effectiveness Research: PCORI and Beyond.” Keynote Speaker, Cardiovascular Molecular Imaging Symposium, Society of Nuclear Medicine, April 19, 2012, Bethesda, MD. “Comparative Effectiveness: Where Does Molecular Imaging Fit in Relation to Biomarkers?” Invited speaker, Inova Summit, April 27, 2012, Tysons Corner, VA. “Appropriateness of Imaging: The Use and Abuse of Noninvasive Imaging.” Invited speaker, Christiana Care’s Value Symposium, April 30, 2012, Newark, DE. “Creating Value Through Science.” Invited speaker, Institute of Medicine Clinical Effectiveness Research Innovation Collaborative of the IOM Roundtable on Value and Science-Driven Health Care, May 8, 2012, Washington, DC. “Implications of the Digital Infrastructure for Clinical Research: Simplified Trial Design.” Invited Plenary Speaker, International Research Congress on Integrative Medicine and Health, May 17, 2012, Portland, OR. “Comparative Effectiveness Research: Implications for Practice and Policy.” Keynote Speaker, Cardiovascular Research Roadmap Symposium, Ohio State University, June 1, 2012, Columbus, OH. “Biomedical Research: How Do We Know We are on Track?” Invited speaker, Cardiac Safety Research Consortium Thinktank, FDA, June 4, 2012, White Oak, MD. “Efficient Electronic Infrastructure: an NIH View.” Invited speaker, NHLBI Advisory Council, June 13, 2012, Bethesda, MD. “Biomedical Research: How Do We Know We are on Track?” Keynote speaker, Center for Business Intelligence Forum on Investigator-initiated Research Studies and Grants, June 14, 2012,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 37 Philadelphia, PA. “NIH Perspectives on Investigator-Initiated Clinical Research.” Invited speaker, American Society for Echocardiography, July 3, 2012, National Harbor, Maryland. “Comparative Effectiveness Trials for Imaging in Coronary Artery Disease: Is there Evidence?” Invited speaker, NHLBI Division of Intramural Research Grand Rounds, July 2012, Bethesda, MD. “Two Case Studies of Exercise Testing with NIH Patients” Invited Keynote Speaker, 12th Annual NIH OBSSR Summer Institute on Randomized Behavioral Clinical Trials, July 2012, Airlie Conference Center, Warrenton, VA. “Biomedical Research: How Do We Know We Are On Track?” Invited Speaker, New York University School of Medicine Cardiology Grand Rounds, September 7, 2012, New York City, NY. “Biomedical Research: How Do We Know We are on Track?” Invited Speaker, Northwestern University Conference on Path to Improved Risk Stratification in Sudden Cardiac Death, September 2012, Chicago, IL. “Funding Risk Stratification Research – Addressing the Challenges - NIH perspective” Invited speaker, NHLBI Board of External Experts Semi-Annual Meeting, October 10, 2012, Rockville, MD. “Transformative Change in Epidemiology.” Invited Speaker, Cleveland Clinic Foundation Heart Failure Summit, October 17, 2012, Cleveland OH. “Comparative Effectiveness Research in Heart Failure.” Invited Speaker, US Conference on Rare Diseases and Orphan Products, October 22, 2012, Washington, DC. “Comparative Effectiveness Research in Rare Diseases.” Invited Opening Address, NIH Common Fund Health Care Systems Collaboratory Steering Committee Inaugural Meeting, October 26, 2012, Bethesda, MD. “Pragmatic Trials: Back into a Future Disruptive Technology.” Invited Speaker, Summit on Eliminating Health Disparities, November 1, 2012, National Harbor, MD. “NIH Patient Centered Outcomes and Effectiveness Research.”
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 38 Invited Keynote Speaker, National Comparative Effectiveness Research Summit, November 5, 2012, Washington, DC. “Current CER Landscape and NIH Activities” Invited Speaker, CBI Conference November 16, 2012, Philadelphia, PA. “Government-Funded Research on Patient- Reported Outcomes.” Invited Opening Speaker, Institute of Medicine Workshop, November 26, 2012, Washington, DC. “A Vision of Large Simple Trials in a Learning Health Care System.” Invited Speaker, Cardiovascular Clinical Trialists Forum, December 3, 2012, Paris, France. “Registries and Post-Market Surveillance as Complements to Randomized Trials.” Invited Speaker, FDA Symposium on Cardiac Safety, December 10, 2012, White Oak, MD. “Current Heuristic Approaches.” Invited Speaker, NHLBI Centers for Cardiovascular Outcomes Research Steering Committee Meeting, December 11, 2012, Arlington, VA. “Large Simple Trials in Learning Health Care Systems.” 2013 (selected) January 28, 2013: Columbia University Dean’s Symposium Keynote-equivalent Presentation on Funding Research in Dynamic and Disruptive Fiscal Times, New York, NY January 29, 2013: DHHS ASPE Invited Presentation on NIH Role in Comparative Effectiveness Research, Humphrey Building, Washington, DC February 7, 2013: DCVS Clinical Trials Group on Our Innovator’s Dilemma, Rockville, MD April 13, 2013: American College of Physicians Annual Scientific Meeting Meet The Professor Symposium sole presenter on Screening for Coronary Artery Disease, San Francisco, CA
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 39 April 17, 2013: NHLBI BEE Presentation on Transforming Epidemiology, Rockville, MD May 2, 2013: NIDDK Presentation on Transforming Clinical Trials, Bethesda, MD May 9, 2013: Virtual Symposium on Radiation Safety in Computed Tomography Presentation on Evidence Gap Problem, San Francisco, CA May 9, 2013: Virtual Symposium on Radiation Safety in Computed Tomography Presentation on Problems due to Downstream Procedures, San Francisco, CA May 13, 2013: Clinical Trials Transformation Initiative Presentation on Perspectives on Large, Simple Trials, Rockville, MD July 21, 2013: OBSSR Course on Randomized Trials, Keynote address on “Our Innovator’s Dilemma,” Airlie Conference Center, Warrenton, VA May 15, 2013 (in absentia, talk given by Larry Fine): NHLBI Leadership Retreat Presentation on Map of Implementation Research at NHLBI, Bethesda, MD May 28, 2013: DCVS Journal Club presentation on angioedema, mini-Sentinel June 5, 2013: NCI Brain Tumor Epidemiology Consortium, Keynote address on Transforming Epidemiology, Chicago, IL June 19, 2013: NHLBAC Presentation on Transforming Epidemiology, Bethesda, MD June 19, 2013: NHLBAC Presentation on Guidelines, Bethesda, MD
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 40 June 23, 2013: Academy Health Presentation on NHLBI Support of Health Services Research, Baltimore, MD June 27, 2013: National Pharmaceutical Council ISPOR Roundtable on Observational Studies and Guidelines, Washington, DC July 17, 2013: NIH Office of Science Policy Program and Evalaution Committee Presentation on Patient-Centered Outcomes Research Institute (PCORI) activities July 21, 2013: OBSSR Course on Randomized Trials, Keynote address on “Our Innovator’s Dilemma,” Airlie Conference Center, Warrenton, VA July 22, 2013: NHLBI Annual K-awardees Meeting, invited talk on “NHLBI Research: A Vision of the Future,” Natcher Conference Center, Bethesda, MD August 2, 2013: NHLBI Heart Failure Network Strategy Planning Meeting, invited opening talk on “NHLBI Perspectivies: Turn the Curve,” Bethesda, MD August 20, 2013: Stanford University School of Medicine Cardiovascular Grand Rounds on “Economic Perspectives on Government-Sponsored Research,” Palo Alto, CA August 21, 2013: Stanford University School of Medicine Department of Medicine Grand Rounds on “Transforming Clinical Trials in an Era of Big Data and Small Budgets,” Palo Alto, CA November 5, 2013: Invited Faculty, NIH PBHL 571-NIH Graduate School of Public Health, “The Case for Comparative Effectiveness Research,” Bethesda, MD November 17, 2013: Invited Special Lecture, American Heart Association Annual Scientific Sessions, “A Tribute to Dr. Sonia Skarlatos,” Dallas, TX
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 41 November 19, 2013: Invited Speaker, American Heart Association Annual Scientific Sessions, Cardiovascular Seminar CVS.809ic, “Cardiorespiratory Fitness as a Therapeutic Target,” Dallas, TX November 18, 2013: Invited Speaker, American Heart Association Annual Scientific Sessions, Cardiovascular Seminar CVS.213, “Practical Trials in Outcome Science,” Dallas, TX November 21, 2013: Invited Speaker, GenTAC Steering Committee Meeting, “Let Me Tell You Two Stories: Perspectives in a Time of Big Data and Small Budgets,” Bethesda, MD December 6, 2013: Invited Webinar Presentation, NHLBI BEE Council Working Group on Epidemiology and Population Sciences, “Thoughts about NHLBI and Epidemiology: ‘Big Picture’ Fiscal Challenges,” Bethesda, MD 2014 (Selected): February 6, 2014: Invited Speaker and Visiting Professor, University of Pennsylvania Perelman School of Medicine, “Cardiology Grand Rounds: Supporting Biomedical Research – An Economic Perspective,” Philadelphia, PA February 7, 2014: Invited Speaker, NHLBI MESA Steering Committee, “Thoughts about NHLBI and 21st Century Epidemiology – ‘Big Picture’ Challenges,” Washington, DC February 20, 2014: Invited Speaker, ISCTM 10th Annual Meeting, “The Necessity for Clinical Trials Innovation: Making it Work at the National Heart, Lung, and Blood Institute,” Washington, DC March 13, 2014: Invited Speaker, NIH IC Directors’ Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD March 26, 2014: Invited Speaker, White House OMB Roundtable on Exploring the the Use of Low-Cost Randomized Experiments to
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 42 Advance Evidence-Based Government, “Rediscovering Low-Cost Randomized Trials in an Era of Big Data and Small Budgets,” Washington, DC March 31, 2014: Invited Speaker, American College of Cardiology session on the Impact of the Evolving Health Landscape on the Academic Mission, “Perspective of the NHLBI,” Washington, DC April 2, 2014: Invited Speaker, Workshop on Innovative Study Designs and Methods for Developing, Testing, and Implementing Behavioral Interventions to Improve Health, “The Need for Creative New Methods in Clinical Research,” Washington, DC April 9, 2014: Invited Speaker, American Society of Hematology Government Affairs Committee, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Washington, DC April 29, 2014: Invited Speaker, Workshop on Pathways to Improved Risk Stratification, “Supporting Biomedical Research in Tough Fiscal Times – Throughts from the NHLBI,” Crystal City, VA May 16, 2014: Invited Speaker for the 4th Shiu Kwong Ho Memorial Lecture at the Beth Israel Deaconess Hospital, “Supporting Biomedical Research in Tough Fiscal Times … Thoughts from the NHLBI,” Boston, MA May 29, 2014: Invited Speaker, NHLBI Workshop on Salt in Human Health and Sickness, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD June 20, 2014: Invited Speaker, NIH Scientific Program and Review Interest Group (SPRIG), “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD June 22, 2014: Invited Plenary Speaker, American Society of Echocardiography, “The Cost of Innovation: NHLBI Perspectives,” Portland, OR
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 43 July 11, 2014: Invited Grand Rounds Speaker, NIH Common Fund HCS Collaboratory, “Portfolio Evaluation from the Field – Perspective of the NHLBI,” Bethesda, MD July 28, 2014: Invited presentation at the White House, White House Office of Science and Technology Policy (OSTP) Conference on Low-Cost Randomized Controlled Trials, “Rediscovering Low-Cost Randomized Trials in an Era of Big Data and Small Budgets,” Washington, DC July 29, 2014: Invited Speaker, MCRN Scientific Lead and Investigator Retreat, “Barriers of Clinical Trials in the US to Meet Public Health Needs,” Washington, DC August 19, 2014: Invited Speaker, NIH Common Fund HCS Collaboratory Steering Committee, “The Collaboratory at Age 2: Back to the Future,” Bethesda, MD September 15, 2014: Invited Speaker, American College of Cardiology Legislative Conference, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Washington, DC September 19, 2014: Invited Speaker, Building Industry Government Academic Partnerships Workshop, National Academy of Sciences, “Welcome and Thoughts from the NHLBI,” Washington, DC September 22, 2014: Invited Keynote Address, Southeastern Conference Symposium on Prevention of Obesity, Overcoming a 21st Century Public Health Challenge, “Setting an Agenda for Obesity Prevention – Asking the Right Questions,” Atlanta, GA September 29, 2014: Invited Speaker, NHLBI K Award Investigators’ Meeting, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Bethesda, MD
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 44 September 30, 2014: Invited Speaker, NHLBI Arterial Stiffness Grantees Meeting, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Bethesda, MD October 1, 2014: Invited Speaker and Visting Professor, University of Maryland School of Medicine, Medical Grand Rounds, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Baltimore, MD October 7, 2014: Invited Speaker, National Cancer Institute (NCI) Community Oncology Research Program, “Practical Trials in Outcomes Science – Thoughts from the NHLBI,” Rockville, MD October 9, 2014: Invited Speaker, NIH National Children’s Study Review Committee, “Preliminary Test Analyses of Birth Weight in the National Children’s Vanguard Study,” Bethesda, MD October 15, 2014: Invited Speaker, NHLBI Office of Biostatistics Research Seminar, “Perspectives on Portfolio Prediction and Performance,” Bethesda, MD October 20, 2014: Invited Speaker, CSR Advisory Council Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD October 28, 2014: Invited Speaker, NIGMS Seminar, “Portfolio Productivity, Field Stories from NHLBI,” Bethesda, MD October 28, 2014: Invited (Remote) Speaker, Framingham Heart Study Research Conference, “Funding Epidemiology and Population Science in Times of Bigger Data and Smaller Budgets,” Framingham, MA November 4, 2014: Invited Seminar Speaker, NIH FAES Graduate School of Public Health, “The Case for Comparative Effectiveness Research,” Bethesda, MD
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 45 November 17, 2014: Invited Plenary Speaker, American Heart Association, “Risk Assessment in Primary Prevention – Future Directions,” Chicago, IL November 17, 2014: Invited Cardiovascular Symposium Speaker, American Heart Association, “NHLBI and Its Role [in the AHA CV GPS Project],” Chicago, IL 2015 (Selected): January 23, 2015: Invited Speaker, NIBIB Advisory Council Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD February 3, 2015: Invited Speaker, NHLBI Pragmatic Trials Grantee Meeting, “A Tale of Two Books (and Some Journal Articles, and a Poem),” Rockville, MD February 11, 2015: Invited Speaker, NIH Workshop on Precision Medicine, “Building a Large US Cohort,” Bethesda, MD March 2, 2015: Keynote Speaker, 25th Anniversay Celebration of the Welch Center, Johns Hopkins University Bloomberg School of Public Health, “The Future of Observational Studies and Clinical Trials,” Baltimore, MD March 4, 2015: Invited Plenary Speaker, American Heart Assocation Epi/Lifestyle Meeting, “eData Sciences and Epidemiology,” Baltimore, MD March 10, 2015: Invited Speaker, Institute of Medicine Roundtable on Translating Genomic-Based Research for Health, “Precision Medicine: NIH Perspectives,” Washington, DC March 19, 2015: Invited Speaker, NHLBI Office of Management Senior Leadership Team, “Developing an Evidence-Based, Data- Driven Culture – Field Stories from DCVS,” Bethesda, MD
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 46 March 30, 2015: Invited Speaker, MRCT Conference on Promoting Clinical Trial Data Transparency at the Harvard Faculty Club, “NHLBI Data Repository (BioLINCC),” Cambridge, MA April 1, 2015: Invited Speaker, NIDDK Meeting on Urinary Stone Disease, “Pragmatic Clinical Trials: Databases, Registries, and Electronic Health Records,” Bethesda, MD April 16, 2015: Invited Grand Rounds Speaker, Johns Hopkins University Department of Anesthesiology and Critical Care Medicine, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from NHLBI,” Baltimore, MD April 27, 2015: Invited Speaker, American Heart Association Data Summit, “NHLBI and NIH Data Repositories – BioLINCC and dbGaP,” Baltimore, MD May 7, 2015: Invited Speaker, Women’s Health Initiative Annual Meeting, “Supporting Clinical Research in Tough Fiscal Times,” Bethesda, MD May 13, 2015: Invited Speaker, NIH Committee on Efficient and Sustainable Funding Policies, “Developing Efficient and Sustainable Funding Policies: An Analysis of the Productivity of NHLBI Cardiovascular Scientists,” Bethesda, MD May 14, 2015: Invited Speaker, NIA Extramural Seminar, “Efficient and Sustainable Funding – Analyses of the Productivity of NHLBI Cardiovascular Scientists,” Bethesda, MD May 20,2015: Invited Keynote Speaker (Founders Lecture), Society for Clinical Trials, “Is There a Future for Clinical Trials?,” Arlington, VA
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 47 EDITORIAL WORK: 1994-2000 Associate Editor, Journal Watch in Cardiology, Massachusetts Medical Society 1994- Abstract Grader, American College of Cardiology 1995- Peer Review: New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Lancet, Annals of Internal Medicine, Preventive Medicine, Hypertension, American Journal of Physiology, Journal of General Internal Medicine, Circulation, American Journal of Cardiology, American Heart Journal, American Journal of Medicine, Journal of the American College of Cardiology, Journal of Thoracic and Cardiovascular Surgery, Coronary Artery Disease, American Journal of Gastroenterology, Kidney International 1998 Reviewer for American Medical Informatics Society Annual Symposium 2000- Abstract Grader, American Heart Association 2000-2007 Contributing Editor, Journal of the American Medical Association (JAMA) 2003-2007 Clinical Reviews Editor, Journal of the American Medical Association (JAMA) 2009- Editorial Board, Annals of Internal Medicine 2012- Consulting Editor, Journal of the American College of Cardiology 2013- Consulting Editor, Circulation Research 2015- Consulting Editor, Scientific Data (Nature Publishing Group) ACADEMIC APPOINTMENTS: 1992-1993 Clinical Instructor in Medicine, Harvard Medical School 1995-1998 Clinical Assistant Professor of Medicine in the College of Medicine, Pennsylvania State University 1998-2007 Clinical Associate Professor Medicine in the College of Medicine,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 48 Pennsylvania State University 2000-2007 Director of Clinical Research, Department of Cardiology, Cleveland Clinic Foundation 2003-2007 Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University 2005-2007 Professor of Epidemiology and Biostatistics in the School of Medicine of Case Western Reserve University CLINICAL TRIALS: 1996 Clinical Events and ECG Committee, EPILOG Trial 1996-1999 Clinical Endpoints Committee, ACUTE Trial 1997-1999 Cleveland Clinic Foundation PI, ASSENT II Trial National Steering Committee, GUSTO IV Trial 1997-2002 Associate Chairman, Cleveland Clinic Cardiovascular Coordinating, Center, Electrocardiogram Core Laboratory 2003-2005 Member, DSMB of TAXUS V and TAXUS V ISR Trials GRANT SUPPORT: 1998-2001 Screening for left ventricular dysfunction in asymptomatic, high risk subjects with abbreviated echocardiography: American Heart Association National Grant, David Baker, MD, Principal Investigator, Michael S. Lauer, MD, Consultant. Cleveland Clinic Foundation is receiving $25,000 for core laboratory echocardiography interpretation. 1999-2002 Association of myocardial ischemia as assessed by dobutamine echocardiography with plasma ANP and BNP levels obtained before and after stress: grant from Promotion and Mutual Aid Corporation for Private Schools of Japan and the Kansai Medical University, 2nd Department of Internal Medicine, Osaka, Japan, Hisako Tsuji, MD, and Michael S. Lauer, MD, Principal Investigators. Cleveland Clinic Foundation is receiving $23,000 for recruiting patients and coordinating the project.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 49 2000-2002 Computerized, heart rate adjusted exercise ST-segment analyses and prediction of all-cause mortality. Established Investigator Grant, American Heart Association, Michael S. Lauer, MD, Principal Investigator, approximately $140,000 over three years. 2001-2004 Heart rate recovery and mortality. National Institutes of Health R01HL66004-01, initiating March 1, 2001, $660,000 over three years. 2003-2004 The Association of the Mediwave Ischemic Index with Myocardial Perfusion Abnormalities: A Prospective Pilot Study. $35,000 over one year. 2004-2008 Logical Analysis of Data and Cardiac Surgical Risk. National Institutes of Health R01HL-072771, $1,032,000 over 3-4 years. 2005-2010 PI of Core E (Clinical Research Skills and Development Core) of National Institutes of Health SCCOR grant P50 HL77107 (Eric J. Topol, MD, PI), $500,000 over 5 years for this Core. 2005-2007 American Arthritis Foundation Grant, “Mortality Outcomes in Pediatric Rheumatology” – PI – Philip Hashkes, Consultant. OUTSIDE/COMMUNITY ACTIVITIES: I am actively involved in the Kemp Mill Synagogue, a Modern Orthodox Jewish congregation attending daily minyanim, leading services, and on an occasional basis reading Torah (“leining”) and giving Torah-oriented talks. I completed a 4-year term as a Member of the Beachwood Kehilla Board of Trustees, serving as Recording Secretary. I regularly participate in Torah study, including the daily Daf Yomi program. I enjoy reading books about economics, history, science, and cognitive/organizational psychology.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 50 Bibliography1–305 1. Danthi NS, Wu CO, DiMichele DM, Hoots WK, Lauer MS. Citation Impact of NHLBI R01 Grants Funded Through the American Recovery and Reinvestment Act as Compared to R01 Grants Funded Through a Standard Payline. Circ Res. 2015;116:784–8. 2. Harrington RA, Barac A, Brush JE, Hill JA, Krumholz HM, Lauer MS, Sivaram CA, Taubman MB, Williams JL. COCATS 4 Task Force 15: Training in Cardiovascular Research and Scholarly Activity. J Am Coll Cardiol. 2015;65:1899–906. 3. Lauer MS, Gordon D, Olive M. Matching Taxpayer Funding to Population Health Needs: Not so Simple. Circ Res. 2015;116:1301–3. 4. Lauer MS, Kiley JP, Mockrin SC, Mensah GA, Hoots WK, Patel Y, Cook NL, Patterson AP, Gibbons GH. National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning: Setting an Agenda Together for the NHLBI of 2025. Circulation. 2015;131:1106–9. 5. Sorlie PD, Sholinsky P, Lauer MS. Reinvestment in Government-Funded Research: A Great Way to Share. Circulation. 2015;131:17–8. 6. Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J Am Med Inf Assoc. 2014;21:576–577. 7. Danthi N, Wu CO, Shi P, Lauer M. Percentile ranking and citation impact of a large cohort of national heart, lung, and blood institute-funded cardiovascular R01 grants. Circ Res. 2014;114:600–606. 8. Eapen ZJ, Lauer MS, Temple RJ. The imperative of overcoming barriers to the conduct of large, simple trials. JAMA. 2014;311:1397–1398. 9. Kaltman JR, Evans FJ, Danthi NS, Wu CO, DiMichele DM, Lauer MS. Prior publication productivity, grant percentile ranking, and topic-normalized citation impact of NHLBI cardiovascular R01 grants. Circ Res. 2014;115:617–24. 10. Lauer MS. Personal reflections on big science, small science, or the right mix. Circ Res. 2014;114:1080–1082. 11. Lauer MS. Investing in clinical science: make way for (not-so-uncommon) outliers. Ann Intern Med. 2014;160:651–652. 12. Lauer MS, Bonds D. Eliminating the “expensive” adjective for clinical trials. Am Hear J. 2014;167:419–420. 13. Lauer MS. Commentary on Vickers. Clin Trials. 2014;11:622–623.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 51 14. Lauer MS. Time to bring the “electrocardio-ome” into modern cardiovascular epidemiology? J Am Coll Cardiol. 2014;64:907–909. 15. Gordon DJ, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2014;370:782. 16. Lauer MS. The basic science that is epidemiology. JACC Cardiovasc Imaging. 2014;7:879–881. 17. Witt CM, Rafferty Withers S, Grant S, Lauer MS, Tunis S, Berman BM. What can comparative effectiveness research contribute to integrative health in international perspective? J Altern Complement Med. 2014;20:874–880. 18. Dubois RW, Lauer M, Perfetto E. When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. J Compar Eff Res. 2013;2:383–391. 19. Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2013;62:1396–8. 20. Gordon D, Taddei-Peters W, Mascette A, Antman M, Kaufmann PG, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2013;369:1926–1934. 21. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013;22:508–516. 22. Lauer MS. Rigorous science as the road to better public health. Popul Heal Metr. 2013;11:10. 23. Lauer MS, D’Agostino Sr. RB. The randomized registry trial--the next disruptive technology in clinical research? N Engl J Med. 2013;369:1579–1581. 24. Pearson GD, Kaltman JR, Lauer MS. Evidence-based medicine comes of age in pediatric cardiology. J Am Coll Cardiol. 2013;61:2565–7. 25. Sorlie PD, Bild DE, Lauer MS. Cardiovascular Epidemiology in a Changing World- Challenges to Investigators and the National Heart, Lung, and Blood Institute. Am J Epidemiol. 2012;175:597–601.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 52 26. Blajchman MA, Carson JL, Eikelboom JW, Heddle NM, Lacroix J, Lauer MS, Platt R, Tilley B, Triulzi D, Vickers AJ, Yusuf S, Glynn S, Mondoro TH, Wagner E. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 2012;52:1363–1378. 27. Galis ZS, Hoots WK, Kiley JP, Lauer MS. On the value of portfolio diversity in heart, lung, and blood research. Am J Respir Crit Care Med. 2012;186:575–578. 28. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby J V, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2012;60:569–580. 29. Lauer MS. Lemons for Obesity. Ann Intern Med. 2012; 30. Lauer MS. Responses to commentaries. Stat Med. 2012; 31. Lauer MS. A policy for science. J Am Coll Cardiol. 2012;59:2154–2156. 32. Lauer MS. Advancing Cardiovascular Research. Chest. 2012;141:500–505. 33. Lauer MS. From hot hands to declining effects: the risks of small numbers. J Am Coll Cardiol. 2012;60:72–74. 34. Lauer MS. And what about exercise? Fitness and risk of death in “low-risk” adults. J Am Hear Assoc. 2012;1:e003228. 35. Lauer MS. Time for a creative transformation of epidemiology in the United States. JAMA. 2012;308:1804–1805. 36. Lauer MS. Commentary: How the debate about comparative effectiveness research should impact the future of clinical trials. Stat Med. 2012;31:3051–3053. 37. Pattakos G, Koch CG, Brizzio ME, Batizy LH, Sabik JF, Blackstone EH, Lauer MS. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med. 2012;172:1154–1160. 38. Schwartz S, Lauer M, McNeil B, Tunis S, Diamond G, Silber J, Herzig A, Temple B, Lee J, Rhodes K, Morton S, Rotelli M. Panel discussion 1. Clin Trials. 2012;9:13–21. 39. Lauer MS. Advancing the paradigm for cardiovascular imaging research. J Nucl Cardiol. 2012;19:5–8.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 53 40. Cook NL, Lauer MS. The socio-geography of heart failure: why it matters. Circ Hear Fail. 2011;4:244–245. 41. Gorodeski EZ, Ishwaran H, Kogalur UB, Blackstone EH, Hsich E, Zhang ZM, Vitolins MZ, Manson JE, Curb JD, Martin LW, Prineas RJ, Lauer MS. Use of Hundreds of Electrocardiographic Biomarkers for Prediction of Mortality in Postmenopausal Women The Women’s Health Initiative. Circ Qual Outcomes. 2011;4:521–532. 42. Hattori N, Carrino DA, Lauer ME, Vasanji A, Wylie JD, Nelson CM, Apte SS. Pericellular versican regulates the fibroblast-myofibroblast transition: a role for ADAMTS5 protease-mediated proteolysis. J Biol Chem. 2011;286:34298–34310. 43. Hsich E, Gorodeski EZ, Blackstone EH, Ishwaran H, Lauer MS. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes. 2011;4:39–45. 44. Lauer MS. Cardiovascular Science in the Service of National Strength. Jama-Journal Am Med Assoc. 2011;306:2145–2146. 45. Lauer MS. Advancing the paradigm for cardiovascular imaging research. J Nucl Cardiol. 2011; 46. Lauer MS. What Now With Screening Electrocardiography? Ann Intern Med. 2011;155:395–397. 47. Lauer MS. How will exercise capacity gain enough respect? Circulation. 2011;123:1364– 1366. 48. Lauer MS. Thought exercises on accountability and performance measures at the National Heart, Lung, and Blood Institute (NHLBI): an invited commentary for circulation research. Circ Res. 2011;108:405–409. 49. Lauer MS. Commentary: Will academia embrace comparative effectiveness research? Acad Med. 2011;86:671–673. 50. Lauer MS. Heart rate recovery: what now? J Intern Med. 2011;270:597–599. 51. Lauer MS. Pseudodisease, the Next Great Epidemic in Coronary Atherosclerosis? Arch Intern Med. 2011;171:1268–1269. 52. Lauer MS. Pseudodisease, the next great epidemic in coronary atherosclerosis?: comment on “Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.” Arch Intern Med. 2011;171:1268–1269.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 54 53. Lauer MS, Hodes R. Epidemiology, Comparative Effectiveness Research, and the National Institutes of Health Forces for Health. Epidemiology. 2011;22:625–628. 54. Rader F, Costantini O, Jarrett C, Gorodeski EZ, Lauer MS, Blackstone EH. Quantitative electrocardiography for predicting postoperative atrial fibrillation after cardiac surgery. J Electrocardiol. 2011;44:761–767. 55. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL. Survival Rates of Children With Acute Lymphoblastic Leukemia Presenting to a Pediatric Rheumatologist in the United States. J Pediatr Hematol Oncol. 2011;33:424–428. 56. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr. SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748–2764. 57. Ishwaran H, Kogalur UB, Gorodeski EZ, Minn AJ, Lauer MS. High-dimensional variable selection for survival data. J Am Stat Assoc. 2010;105:205–217. 58. Lauer MS. The historical and moral imperatives of comparative effectiveness research. Stat Med. 2010;29:1982–1987. 59. Lauer MS. National Heart, Lung, and Blood Institute and the American Recovery and Reinvestment Act of 2009: 1 year later. J Am Coll Cardiol. 2010;56:234–236. 60. Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol. 2010;56:106–108. 61. Lauer MS, Collins FS. Using science to improve the nation’s health system: NIH's commitment to comparative effectiveness research. JAMA. 2010;303:2182–2183. 62. Lauer MS, Skarlatos S. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community. Circulation. 2010;121:929–933. 63. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond. Circulation. 2010;
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 55 64. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Jacobs AK, Kaul S, Moliterno DJ, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121:2509–2543. 65. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr. SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584–636. 66. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62:599– 608. 67. Lauer MS. Risk stratification for sudden cardiac death: a puzzle beyond p values. J Am Coll Cardiol. 2010;56:1484–1485. 68. Bild DE, Lauer MS. How one program at the National Heart, Lung, and Blood Institute establishes its scientific priorities. J Am Coll Cardiol. 2009;53:2259–2261. 69. Douglas PS, Taylor A, Bild D, Bonow R, Greenland P, Lauer M, Peacock F, Udelson J. Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. Circ Cardiovasc Imaging. 2009;2:339–348. 70. Gorodeski EZ, Cantillon DJ, Goel SS, Kaufman ES, Martin DO, Hsich EM, Blackstone EH, Lauer MS. Microvolt T-wave alternans, peak oxygen consumption, and outcome in patients with severely impaired left ventricular systolic function. J Hear Lung Transpl. 2009;28:689–696. 71. Gorodeski EZ, Ishwaran H, Blackstone EH, Lauer MS. Quantitative electrocardiographic measures and long-term mortality in exercise test patients with clinically normal resting electrocardiograms. Am Hear J. 2009;158:61–70 e1. 72. Hsich E, Gorodeski EZ, Starling RC, Blackstone EH, Ishwaran H, Lauer MS. Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction. Circulation. 2009;119:3189–3197. 73. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ,
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 56 Collins FS, Croyle RT, Davis BR, Downing GJ, Duross A, Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH, Greenland P, Gulcher JR, Hsu A, Hudson KL, Kardia SL, Kimmel PL, Lauer MS, Miller AM, Offit K, Ransohoff DF, Roberts JS, Rasooly RS, Stefansson K, Terry SF, Teutsch SM, Trepanier A, Wanke KL, Witte JS, Xu J. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med. 2009;11:559–567. 74. Lauer MS. CT angiography: first things first. Circ Cardiovasc Imaging. 2009;2:1–3. 75. Lauer MS. Elements of danger--the case of medical imaging. N Engl J Med. 2009;361:841–843. 76. Lauer MS. Discarding logic: 2008 Ancel Keys Memorial Lecture. Circulation. 2009;119:1533–1537. 77. Lauer MS. Autonomic function and prognosis. Cleve Clin J Med. 2009;76 Suppl 2:S18– 22. 78. Lauer MS. Comparative effectiveness research: the view from the NHLBI. J Am Coll Cardiol. 2009;53:1084–1086. 79. Lauer MS, Skarlatos SI, Bild DE. The Extramural Division of Cardiovascular Sciences of the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2009;54:265–268. 80. Lauer MS, Sorlie P. Alcohol, cardiovascular disease, and cancer: treat with caution. J Natl Cancer Inst. 2009;101:282–283. 81. Nabel EG, Lauer MS. The cardiovascular programs of the National Heart, Lung, and Blood Institute: from vision to action to impact. J Am Coll Cardiol. 2009;53:1082–1083. 82. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, Kapadia SR, Lauer MS, Topol EJ. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2009;2:46– 53. 83. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP. American Heart Association/american College of Cardiology Foundation/heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the America. Hear Rhythm. 2008;5:e1– 21.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 57 84. Adams BJ, Carr JG, Ozonoff A, Lauer MS, Balady GJ. Effect of exercise training in supervised cardiac rehabilitation programs on prognostic variables from the exercise tolerance test. Am J Cardiol. 2008;101:1403–1407. 85. Aronow HD, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, Houghtaling PL, Granger CB, Harrington RA, Van de Werf F, Topol EJ, Lauer MS. Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008;102:1119–1124. 86. Lauer MS. Review: 64-slice computed tomography coronary angiography accurately diagnoses coronary artery disease. ACP J Club. 2008;149:13. 87. Myerburg RJ, Chaitman BR, Ewy GA, Lauer MS. Task force 2: training in electrocardiography, ambulatory electrocardiography, and exercise testing. J Am Coll Cardiol. 2008;51:348–354. 88. Peterson PN, Magid DJ, Ross C, Ho PM, Rumsfeld JS, Lauer MS, Lyons EE, Smith SS, Masoudi FA. Association of exercise capacity on treadmill with future cardiac events in patients referred for exercise testing. Arch Intern Med. 2008;168:174–179. 89. Shishehbor MH, Oliveira LP, Lauer MS, Sprecher DL, Wolski K, Cho L, Hoogwerf BJ, Hazen SL. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol. 2008;101:1741–1746. 90. Ho PM, Rumsfeld JS, Peterson PN, Masoudi FA, Strunk A, Ross C, Lyons EE, Smith SS, Lauer MS, Magid DJ. Chest pain on exercise treadmill test predicts future cardiac hospitalizations. Clin Cardiol. 2007;30:505–510. 91. Hsich E, Chadalavada S, Krishnaswamy G, Starling RC, Pothier CE, Blackstone EH, Lauer MS. Long-term prognostic value of peak oxygen consumption in women versus men with heart failure and severely impaired left ventricular systolic function. Am J Cardiol. 2007;100:291–295. 92. Kim ES, Ishwaran H, Blackstone E, Lauer MS. External prognostic validations and comparisons of age- and gender-adjusted exercise capacity predictions. J Am Coll Cardiol. 2007;50:1867–1875. 93. Koch CG, Li L, Lauer M, Sabik J, Starr NJ, Blackstone EH. Effect of functional health- related quality of life on long-term survival after cardiac surgery. Circulation. 2007;115:692–699. 94. Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297:1376–1378. 95. Lauer MS. Choosing the right coronary test. Cleve Clin J Med. 2007;74:122.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 58 96. Lauer MS. What is the best test for a patient with classic angina? Cleve Clin J Med. 2007;74:123–126. 97. Lauer MS. Cardiovascular medicine update 2007: perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins. Cleve Clin J Med. 2007;74:505–511. 98. Lauer MS. Screening for coronary heart disease: has the time for universal imaging arrived? Cleve Clin J Med. 2007;74:645–650,653–654,656. 99. Lauer MS, Blackstone EH. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine, 3rd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2007. p. 756(e). 100. Lauer MS, Martino D, Ishwaran H, Blackstone EH. Quantitative measures of electrocardiographic left ventricular mass, conduction, and repolarization, and long-term survival after coronary artery bypass grafting. Circulation. 2007;116:888–893. 101. Lauer MS, Murthy SC, Blackstone EH, Okereke IC, Rice TW. [18F]Fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: impact of verification bias. Arch Intern Med. 2007;167:161–165. 102. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med. 2007;147:821– 828. 103. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM, Blackstone EH, Lytle BW. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. 2007;49:2191– 2201. 104. Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, Moliterno DJ, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit- only stenting? J Am Coll Cardiol. 2007;49:849–854. 105. Thambidorai SK, Jaffer SJ, Shah TK, Stewart WJ, Klein AL, Lauer MS. Association of atheroma as assessed by intraoperative transoesophageal echocardiography with long-term mortality in patients undergoing cardiac surgery. Eur Hear J. 2007;28:1454–1461. 106. Westerhout CM, Lauer MS, James S, Fu Y, Wallentin L, Armstrong PW. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. Eur Hear J. 2007;28:2064–2069.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 59 107. Yamada H, Tabata T, Jaffer SJ, Drinko JK, Jasper SE, Lauer MS, Thomas JD, Klein AL. Clinical features of mixed physiology of constriction and restriction: echocardiographic characteristics and clinical outcome. Eur J Echocardiogr. 2007;8:185–194. 108. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Cl. J Am Coll Cardiol. 2007;49:378–402. 109. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Harrington RA, Abrams J, Anderson JL, Bates ER, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks Jr. SJ, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Cl. Circulation. 2007;115:402–426. 110. Bis KG, Shetty AN, Brewington S, Arpasi P, Kosuri R, Stein W, Lauer M, O’Neill W. Coronary 64-slice computed tomographic angiography models employing aortic root and selective catheter directed contrast enhancement in swine: technical feasibility and preliminary results using 3D and 4D reconstructions. Int J Cardiovasc Imaging. 2006;22:517–531. 111. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Hear J. 2006;27:413–418. 112. Heerey A, Lauer M, Alsolaiman F, Czerr J, James K. Cost effectiveness of biventricular pacemakers in heart failure patients. Am J Cardiovasc Drugs. 2006;6:129–137. 113. Kligfield P, Lauer MS. Exercise electrocardiogram testing: beyond the ST segment. Circulation. 2006;114:2070–2082. 114. Latif AA, Almahameed A, Lauer MS. Should we screen for abdominal aortic aneurysms? Cleve Clin J Med. 2006;73:9–10, 13, 16–7 passim. 115. Lauer MS. Believability of clinical trials: a diagnostic testing perspective. J Thorac Cardiovasc Surg. 2006;132:249–251. 116. Lauer MS, Ellis S. Is routine functional testing after coronary bypass surgery worthwhile? J Invasive Cardiol. 2006;18:153–154.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 60 117. Lauer MS, Pothier CE, Chernyak YB, Brunken R, Lieber M, Apperson-Hansen C, Starobin JM. Exercise-induced QT/R-R-interval hysteresis as a predictor of myocardial ischemia. J Electrocardiol. 2006;39:315–323. 118. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch KP. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry. 2006;11:514–522. 119. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA. 2006;295:784–792. 120. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, Blackstone EH, Lauer MS. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation. 2006;113:230– 237. 121. Westerhout CM, Fu Y, Lauer MS, James S, Armstrong PW, Al-Hattab E, Califf RM, Simoons ML, Wallentin L, Boersma E. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol. 2006;48:939–947. 122. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, Thompson PD, Williams MA, Lauer MS. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nut. Circulation. 2005;111:369–376. 123. Bhatheja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol. 2005;95:1159–1164. 124. Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138–145. 125. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Thisted RA. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005;353:468–475. 126. Hesse B, Morise A, Pothier CE, Blackstone EH, Lauer MS. Can we reliably predict long- term mortality after exercise testing? An external validation. Am Hear J. 2005;150:307– 314.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 61 127. Khan MN, Pothier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol). Am J Cardiol. 2005;96:1328–1333. 128. Lauer MS. Can the ST segment be saved? J Nucl Cardiol. 2005;12:622–624. 129. Lauer MS. Coronary artery disease in diabetes: which (if any) test is best? Cleve Clin J Med. 2005;72:6,8–9. 130. Lauer MS. Cardiac troponins and renal failure: the evolution of a clinical test. Circulation. 2005;112:3036–3037. 131. Lauer M, Froelicher ES, Williams M, Kligfield P. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2005;112:771–776. 132. O’Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation. 2005;111:2313– 2318. 133. Pereira JJ, Balaban K, Lauer MS, Lytle B, Thomas JD, Garcia MJ. Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery. Am J Med. 2005;118:735–742. 134. Rajagopal V, Gurm HS, Brunken RC, Pothier CE, Bhatt DL, Lauer MS. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting. Am Hear J. 2005;149:534–540. 135. Troughton RW, Prior DL, Frampton CM, Nash PJ, Pereira JJ, Martin M, Fogarty A, Morehead AJ, Starling RC, Young JB, Thomas JD, Lauer MS, Klein AL. Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). Am J Cardiol. 2005;96:257–262. 136. Ziada KM, Yadav JS, Mukherjee D, Lauer MS, Bhatt DL, Kapadia S, Roffi M, Vora N, Tiong I, Bajzer C. Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). Am J Cardiol. 2005;96:519–523. 137. Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA. 2004;292:1462–1468.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 62 138. Asada J, Tsuji H, Iwasaka T, Thomas JD, Lauer MS. Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia. Am J Cardiol. 2004;93:702–704. 139. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, Lytle BW, Blackstone EH, Lauer MS, Klein AL. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol. 2004;43:1445–1452. 140. Blackstone EH, Lauer MS. Caveat emptor: the treachery of work-up bias. J Thorac Cardiovasc Surg. 2004;128:341–344. 141. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109:2290– 2295. 142. Chen MS, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery and impact of myocardial revascularization on long-term mortality. Circulation. 2004;110:2851–2857. 143. Christopher Jones R, Pothier CE, Blackstone EH, Lauer MS. Prognostic importance of presenting symptoms in patients undergoing exercise testing for evaluation of known or suspected coronary disease. Am J Med. 2004;117:380–389. 144. Cura FA, Roffi M, Pasca N, Wolski KE, Lincoff AM, Topol EJ, Lauer MS. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST- segment after reperfusion therapy substudy). Am J Cardiol. 2004;94:859–863. 145. Ellis K, Pothier CE, Blackstone EH, Lauer MS. Is systolic blood pressure recovery after exercise a predictor of mortality? Am Hear J. 2004;147:287–292. 146. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 2004;292:2396–2398. 147. Ishwaran H, Blackstone EH, Pothier CE, Lauer MS. Relative risk forests for exercise heart rate recovery as a predictor of mortality. J Am Stat Assoc. 2004;99:591–600. 148. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol. 2004;44:1025–1029. 149. Lauer MS. Clinical epidemiology, clinical care, and the public’s health. Mayo Clin Proc. 2004;79:975–976.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 63 150. Lauer MS. Chronotropic incompetence: ready for prime time. J Am Coll Cardiol. 2004;44:431–432. 151. Mills RM, Lauer MS. Endomyocardial biopsy: a procedure in search of an indication. Am Hear J. 2004;147:759–760. 152. O’Neill JO, Young JB, Pothier CE, Lauer MS. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol. 2004;44:820–826. 153. Pothier CE, Lauer MS. Functional capacity and activities of daily living in women. In: Shaw LJ, Redberg RD, editors. Coronary disease in women: evidence-based diagnosis and treatment. Totowa, NJ: Humana Press; 2004. p. 103–118. 154. Seshadri N, Gildea TR, McCarthy K, Pothier C, Kavuru MS, Lauer MS. Association of an abnormal exercise heart rate recovery with pulmonary function abnormalities. Chest. 2004;125:1286–1291. 155. Shishehbor MH, Hoogwerf BJ, Lauer MS. Association of triglyceride-to-HDL cholesterol ratio with heart rate recovery. Diabetes Care. 2004;27:936–941. 156. Yamani MH, Lauer MS, Starling RC, Pothier CE, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, McNeil A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. Am J Transpl. 2004;4:257–261. 157. Mark DB, Shaw LJ, Lauer MS, O’Malley PG, Heidenreich P. 34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective? J Am Coll Cardiol. 2003;41:1906–1917. 158. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med. 2003;163:2576– 2582. 159. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–3010. 160. Baker DW, Bahler RC, Finkelhor RS, Lauer MS. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Hear J. 2003;146:736– 740. 161. Beyer DR, Lauer MS, Davis S. Readability of informed-consent forms. N Engl J Med. 2003;348:2262–2263.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 64 162. Cheng YJ, Lauer MS, Earnest CP, Church TS, Kampert JB, Gibbons LW, Blair SN. Heart rate recovery following maximal exercise testing as a predictor of cardiovascular disease and all-cause mortality in men with diabetes. Diabetes Care. 2003;26:2052–2057. 163. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med. 2003;348:781–790. 164. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Hear J. 2003;146:692– 698. 165. Gurm HS, Lauer MS. Predicting incidence of some critical events by sun signs -- The PISCES study. ACC Curr J Rev. 2003;12:22–24. 166. Lauer MS. Is heart rate recovery a modifiable risk factor? J Cardiopulm Rehabil. 2003;23:88–89. 167. Lauer MS. Recovery after graded exercise testing: an under-appreciated time of great prognostic value. Int J Bioelectromagn. 2003;5:90. 168. Lauer MS. Who should be taking aspirin to prevent coronary events? Cleve Clin J Med. 2003;70:1076–1080. 169. Mark DB, Lauer MS. Exercise capacity: the prognostic variable that doesn’t get enough respect. Circulation. 2003;108:1534–1536. 170. Messinger-Rapport B, Pothier Snader CE, Blackstone EH, Yu D, Lauer MS. Value of exercise capacity and heart rate recovery in older people. J Am Geriatr Soc. 2003;51:63– 68. 171. Seshadri N, Acharya N, Lauer MS. Association of diabetes mellitus with abnormal heart rate recovery in patients without known coronary artery disease. Am J Cardiol. 2003;91:108–111. 172. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, Krawczynska E, Cerqueira M, Maddahi J. Prognostic value of normal exercise and adenosine (99m)Tc- tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med. 2003;44:134–139. 173. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol. 2003;42:831–838. 174. Lauer MS, Topol EJ. Clinical trials--multiple treatments, multiple end points, and multiple lessons. JAMA. 2003;289:2575–2577.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 65 175. Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: coronary risk scores. Lancet. 2003;362:1776–1777. 176. Lauer MS, Blackstone EH. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine, 2nd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p. 981–1004. 177. Acevedo M, Sprecher DL, Lauer MS, Francis G. Routine statin treatment after acute coronary syndromes? Am Hear J. 2002;143:940–942. 178. Aronow HD, Lauer MS. Reducing early mortality after acute coronary syndromes. Cardiol Rev. 2002;19:11–16. 179. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346:2047–2052. 180. Aviles RJ, Wright RS, Aviles JM, McDonald F, Ballman K, Harker-Murray A, Scott C, Lauer MS, Kopecky SL, Jaffe AS. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. Am J Cardiol. 2002;90:875–878. 181. Cole CR, Lauer MS, Bigger JT. Clinical assessment of the autonomic nervous system. In: Topol EJ, editor. Textbook of cardiovascular medicine, 2nd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p. 1615–1655. 182. Lauer MS. Cardiologist on trial: reflections on credible evidence. J Am Coll Cardiol. 2002;40:563–564. 183. Lauer MS. Exercise testing for assessment of autonomic function. Am Hear J. 2002;144:580–582. 184. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468–1474. 185. Lauer MS. Health toll of the Middle East crisis. Lancet. 2002;359:1860–1861. 186. Lauer MS. Chronotropic incompetence and heart rate recovery. In: Ellestad M, editor. Exercise testing: new concepts for the new century. Norwell, MA: Kluwer Academic; 2002. p. 38–48. 187. Lauer MS. The “exercise” part of exercise echocardiography. J Am Coll Cardiol. 2002;39:1353–1355.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 66 188. Lauer MS, Alexe S, Pothier Snader CE, Blackstone EH, Ishwaran H, Hammer PL. Use of the logical analysis of data method for assessing long-term mortality risk after exercise electrocardiography. Circulation. 2002;106:685–690. 189. Lauer MS, Froelicher V. Abnormal heart-rate recovery after exercise. Lancet. 2002;360:1176–1177. 190. Lauer MS, Pothier CE. Exercise training in heart failure patients: a brief review. Am J Med Sport. 2002;4:302–308. 191. Mahon NG, Blackstone EH, Francis GS, Starling 3rd RC, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;40:1106–1113. 192. Marwick TH, Case C, Sawada S, Vasey C, Short L, Lauer M. Use of stress echocardiography to predict mortality in patients with diabetes and known or suspected coronary artery disease. Diabetes Care. 2002;25:1042–1048. 193. Morise AP, Lauer MS, Froelicher VF. Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease. Am Hear J. 2002;144:818–825. 194. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes. 2002;51:803–807. 195. Pereira JJ, Lauer MS, Bashir M, Afridi I, Blackstone EH, Stewart WJ, McCarthy PM, Thomas JD, Asher CR. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356–1363. 196. Shishehbor MH, Baker DW, Blackstone EH, Lauer MS. Association of educational status with heart rate recovery: a population-based propensity analysis. Am J Med. 2002;113:643–649. 197. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all- cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA. 2001;286:1187–1194. 198. Anderson ST, Pahlm O, Bacharova L, Barbagelata A, Chaitman BR, Clemmensen P, Goodman S, Heden B, Klootwijk PJ, Lauer M, MacFarlane PW, Rautaharju P, Reddy S, Selvester RH, Sgarbossa EB, Underwood D, Warner RA, Wagner GS. Standards for the function of an academic 12-lead electrocardiographic core laboratory. J Electrocardiol. 2001;34:41–47.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 67 199. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063–1068. 200. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992–997. 201. Cole CR, Lauer MS. Exercise testing and risk assessment. In: Foody JM, editor. Preventive cardiology: strategies for the prevention and treatment of coronary artery disease. Totowa, NJ: Humana Press; 2001. p. 238–301. 202. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol. 2001;37:1558–1564. 203. Foody JM, Cole CR, Blackstone EH, Lauer MS. A propensity analysis of cigarette smoking and mortality with consideration of the effects of alcohol. Am J Cardiol. 2001;87:706–711. 204. Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med. 2001;110:253–259. 205. Lauer MS. Exercise electrocardiogram testing and prognosis. Novel markers and predictive instruments. Cardiol Clin. 2001;19:401–414. 206. Lauer MS. Lipid-lowering drugs in acute coronary syndromes. Biomed Pharmacother. 2001;55:413. 207. Lauer MS. Uses of error: more chefs. Lancet. 2001;358:1641. 208. Lauer MS. Focused review: heart rate responses in stress testing, clinical implications. ACC Curr J Rev. 2001;10:16–19. 209. Lauer MS. Medical therapy for coronary artery disease works, even (especially) in the real world. Am J Med. 2001;110:497–498. 210. Lauer MS, Fontanarosa PB. Updated guidelines for cholesterol management. JAMA. 2001;285:2508–2509.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 68 211. Lauer MS, Snader CE. Using exercise testing to prognosticate patients with heart failure. Which parameter should we measure? Cardiol Clin. 2001;19:573–581. 212. Lin SS, Lauer MS, Asher CR, Cosgrove DM, Blackstone E, Thomas JD, Garcia MJ. Prediction of coronary artery disease in patients undergoing operations for mitral valve degeneration. J Thorac Cardiovasc Surg. 2001;121:894–901. 213. Marwick TH, Case C, Sawada S, Rimmerman C, Brenneman P, Kovacs R, Short L, Lauer M. Prediction of mortality using dobutamine echocardiography. J Am Coll Cardiol. 2001;37:754–760. 214. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–2209. 215. Pashkow F, Lauer MS, Harvey SA. Diagnosis of coronary artery disease. In: Roitman JL, herridge M, editors. American College of Sports Medicine resource manual for guidelines for exercise testing and prescription. New York: Lippincott, Williams and Wilkins; 2001. p. 246–253. 216. Peterson JG, Lauer MS. Using aspirin and ACE inhibitors in combination: why the hullabaloo? Cleve Clin J Med. 2001;68:569–574. 217. Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, Blackstone EH, Harrington RA, Califf RM, Lauer MS. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 2001;87:532–536. 218. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation. 2001;104:1911–1916. 219. Campbell L, Snader CE, Lauer MS. Relationship between exercise hypertension and perfusion defects. Cardiol Rev. 2000;17:24–27. 220. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med. 2000;132:552–555. 221. Dresing TJ, Blackstone EH, Pashkow FJ, Snader CE, Marwick TH, Lauer MS. Usefulness of impaired chronotropic response to exercise as a predictor of mortality, independent of the severity of coronary artery disease. Am J Cardiol. 2000;86:602–609.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 69 222. Lauer MS. Commentary on use of daclizumab for preventing acute rejection in non- sensitized patients receiving first transplants. Evidence-based Cardiovasc Med. 2000;4. 223. Lauer MS. Role of stress testing and cardiac imaging in patients who have undergone previous coronary revascularization. Cardiol Rev. 2000;8:158–165. 224. Lauer MS. Primary angioplasty--time is of the essence. JAMA. 2000;283:2988–2989. 225. Lauer MS. Role of stress testing and cardiac imaging after myocardial revascularization. Cardiol Rev. 2000;8:158–165. 226. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA. 2000;284:1392–1398. 227. Pasquet A, Lauer MS, Williams MJ, Secknus MA, Lytle B, Marwick TH. Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction. Impact of pre-operative myocardial function, perfusion, and metabolism. Eur Hear J. 2000;21:125–136. 228. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000;109:371–377. 229. Shaw LJ, Hachamovitch R, Heller G V, Marwick TH, Travin MI, Iskandrian AE, Kesler K, Lauer MS, Hendel R, Borges-Neto S, Lewin HC, Berman DS, Miller D. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group. Am J Cardiol. 2000;86:1–7. 230. Srivastava R, Blackstone EH, Lauer MS. Association of smoking with abnormal exercise heart rate responses and long-term prognosis in a healthy, population-based cohort. Am J Med. 2000;109:20–26. 231. Campbell L, Marwick TH, Pashkow FJ, Snader CE, Lauer MS. Usefulness of an exaggerated systolic blood pressure response to exercise in predicting myocardial perfusion defects in known or suspected coronary artery disease. Am J Cardiol. 1999;84:1304–1310. 232. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351– 1357. 233. Lauer M. Making sense of blood pressure medication. Health News (Rochester). 1999;5:3. 234. Lauer MS. Resuscitating the exercise stress test. Cleve Clin J Med. 1999;66:278–282.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 70 235. Lauer MS. Chronotropic incompetence: new insights. In: Pashkow F, Defoe WA, editors. Clinical cardiac rehabilitation: a cardiologist’s guide, 2nd edition. Baltimore: Williams and Wilkins; 1999. 236. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol. 1999;34:618–620. 237. Lauer MS, Cole C, Krumholz HM. Exercise electrocardiography with right precordial leads. N Engl J Med. 1999;341:208; author reply 209. 238. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. 1999;281:524–529. 239. Lauer MS, Larson MG, Evans JC, Levy D. Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. Am Hear J. 1999;137:903–909. 240. Marwick TH, Shaw LJ, Lauer MS, Kesler K, Hachamovitch R, Heller G V, Travin MI, Borges-Neto S, Berman DS, Miller DD. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med. 1999;106:172–178. 241. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33:750–758. 242. McHam SA, Marwick TH, Pashkow FJ, Lauer MS. Delayed systolic blood pressure recovery after graded exercise: an independent correlate of angiographic coronary disease. J Am Coll Cardiol. 1999;34:754–759. 243. Pasquet A, Armstrong G, Beachler L, Lauer MS, Marwick TH. Use of segmental tissue Doppler velocity to quantitate exercise echocardiography. J Am Soc Echocardiogr. 1999;12:901–912. 244. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K, Young JB, Lauer MS. Ventilatory and heart rate responses to exercise  : better predictors of heart failure mortality than peak oxygen consumption. Circulation. 1999;100:2411–2417. 245. Schweikert RA, Pashkow FJ, Snader CE, Marwick TH, Lauer MS. Association of exercise-induced ventricular ectopic activity with thallium myocardial perfusion and angiographic coronary artery disease in stable, low-risk populations. Am J Cardiol. 1999;83:530–534.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 71 246. Shaw LJ, Heller G V, Travin MI, Lauer M, Marwick T, Hachamovitch R, Berman DS, Miller DD. Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. Economics of Noninvasive Diagnosis (END) Study Group. J Nucl Cardiol. 1999;6:559–569. 247. Singh JP, Larson MG, Manolio TA, O’Donnell CJ, Lauer M, Evans JC, Levy D. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Circulation. 1999;99:1831–1836. 248. Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller G V, Iskandrian AE, Kesler KL, Travin MI, Lewin HC, Hendel RC, Borges-Neto S, Miller DD. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study G. J Am Coll Cardiol. 1999;33:661–669. 249. Lauer MS. Noninvasive risk stratification after myocardial infarction: which test is best? Am Hear J. 1998;136:565–569. 250. Folz-Murphy N, Partin M, Williams L, Harris CM, Lauer MS. Physician use of an ambulatory medical record system: matching form and function. Proc AMIA Symp. 1998;260–264. 251. Grady TA, Chiu AC, Snader CE, Marwick TH, Thomas JD, Pashkow FJ, Lauer MS. Prognostic significance of exercise-induced left bundle-branch block. JAMA. 1998;279:153–156. 252. James KB, Rodkey S, McCarthy PM, Thomas JD, Blackburn G, Sapp S, Vargo R, Lauer MS, Young JB. Exercise performance and chronotropic response in heart failure patients with implantable left ventricular assist devices. Am J Cardiol. 1998;81:1230–1232. 253. Lauer MS, Fortin D. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998. p. 1083–1106. 254. Lauer MS, Lytle B, Pashkow F, Snader CE, Marwick TH. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery- bypass grafting. Lancet. 1998;351:615–622. 255. Lauer MS, Mehta R, Pashkow FJ, Okin PM, Lee K, Marwick TH. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol. 1998;32:1280–1286. 256. Lin SS, Lauer MS, Marwick TH. Risk stratification of patients with medically treated unstable angina using exercise echocardiography. Am J Cardiol. 1998;82:720–724.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 72 257. Marwick TH, Lauer MS, Lobo A, Nally J, Braun W. Use of dobutamine echocardiography for cardiac risk stratification of patients with chronic renal failure. J Intern Med. 1998;244:155–161. 258. Pilote L, Pashkow F, Thomas JD, Snader CE, Harvey SA, Marwick TH, Lauer MS. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol. 1998;81:219–224. 259. Secknus MA, Niedermaier ON, Lauer MS, Marwick TH. Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography. Am J Cardiol. 1998;81:1318–1322. 260. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, Topol EJ. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366– 1370. 261. Taragin MI, Lauer M, Savir M, Sivan E, Siesel D, Aufgang B. HCFA documentation guidelines and the need for discrete data: a golden opportunity for applied health informatics. Proc AMIA Symp. 1998;653–656. 262. Asher CR, Chung MK, Eagle KA, Lauer MS. Atrial fibrillation following cardiac surgery. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. Philadelphia: Lippincott-Raven; 1997. p. 183–204. 263. Ballal RS, Secknus MA, Mehta R, Kapadia S, Lauer MS, Marwick TH. Cardiac outcomes in coronary patients with submaximum dobutamine stress echocardiography. Am J Cardiol. 1997;80:725–729. 264. Heupler S, Lauer M, Williams MJ, Shan K, Marwick TH. Increased left ventricular cavity size, not wall thickness, potentiates myocardial ischemia. Am Hear J. 1997;133:691–697. 265. Lauer MS, Pashkow FJ, Larson MG, Levy D. Association of cigarette smoking with chronotropic incompetence and prognosis in the Framingham Heart Study. Circulation. 1997;96:897–903. 266. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Age and referral to coronary angiography after an abnormal treadmill thallium test. Am Hear J. 1997;133:139–146. 267. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Sex and diagnostic evaluation of possible coronary artery disease after exercise treadmill testing at one academic teaching center. Am Hear J. 1997;134:807–813.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 73 268. Marwick TH, Mehta R, Arheart K, Lauer MS. Use of exercise echocardiography for prognostic evaluation of patients with known or suspected coronary artery disease. J Am Coll Cardiol. 1997;30:83–90. 269. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol. 1997;80:865–870. 270. Popovic AD, Thomas JD, Neskovic AN, Cosgrove 3rd DM, Stewart WJ, Lauer MS. Time-related trends in the preoperative evaluation of patients with valvular stenosis. Am J Cardiol. 1997;80:1464–1468. 271. Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. J Am Coll Cardiol. 1997;30:641–648. 272. Eagle KA, Lauer MS. Preoperative evaluation before noncardiac vascular surgery. Cleve Clin J Med. 1996;63:325–330. 273. Lauer MS. The diagnosis of coronary artery disease in the setting of left ventricular hypertrophy. In: Marwick TH, editor. Cardiac stress testing and imaging. New York: Churchill Livingston; 1996. p. 189–202. 274. Lauer MS. The enlarged heart: risk factor with a paradox. Heartline. 1996;26:4–5. 275. Lauer MS. Implications of exercise hypertension. Cardiol Rev. 1996;13:35–39. 276. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation. 1996;93:1520–1526. 277. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Gender and referral for coronary angiography after treadmill thallium testing. Am J Cardiol. 1996;78:278–283. 278. Levy D, Lauer MS. Left ventricular hypertrophy: echocardiographic assessment and prognostic ijmplications. In: Sutton MSJ, Oldershaw PJ, Kotler MN, editors. Textbook of echocardiography and doppler in adults and children. Cambridge: Blackwell Science; 1996. p. 342–352. 279. Okin PM, Lauer MS, Kligfield P. Chronotropic response to exercise. Improved performance of ST-segment depression criteria after adjustment for heart rate reserve. Circulation. 1996;94:3226–3231.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 74 280. Smedira NG, Zikri M, Thomas JD, Lauer MS, Kelleman JJ, McCarthy PM. Blunt traumatic rupture of a mitral papillary muscle head. Ann Thorac Surg. 1996;61:1526– 1528. 281. Williams B, Isaacson JH, Lauer MS. An 81-year-old woman with dyspnea on exertion. Cleve Clin J Med. 1996;63:209–212. 282. Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;27:132–139. 283. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995;25:1155–1160. 284. Lauer MS, Eagle KA. Atrial fibrillation following cardiac surgery. In: Podrid PJ, Kowey P, editors. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams and Wilkins; 1995. 285. Brener SJ, Pashkow FJ, Harvey SA, Marwick TH, Thomas JD, Lauer MS. Chronotropic response to exercise predicts angiographic severity in patients with suspected or stable coronary artery disease. Am J Cardiol. 1995;76:1228–1232. 286. Lauer MS. The epidemiology of heart disease: what we have learned from 40 years of research. Heartline. 1995;25:4–5. 287. Lauer MS. Left ventricular hypertrophy and cardiovascular prognosis. Cleve Clin J Med. 1995;62:169–175. 288. Lauer MS, Larson MG, Levy D. Gender-specific reference M-mode values in adults: population-derived values with consideration of the impact of height. J Am Coll Cardiol. 1995;26:1039–1046. 289. Lauer MS, Okin PM, Anderson KM, Levy D. Impact of echocardiographic left ventricular mass on mechanistic implications of exercise testing parameters. Am J Cardiol. 1995;76:952–956. 290. Lauer MS, Pashkow FJ, Harvey SA, Marwick TH, Thomas JD. Angiographic and prognostic implications of an exaggerated exercise systolic blood pressure response and rest systolic blood pressure in adults undergoing evaluation for suspected coronary artery disease. J Am Coll Cardiol. 1995;26:1630–1636. 291. Marwick TH, Shan K, Go RT, MacIntyre WJ, Lauer MS. Use of positron emission tomography for prediction of perioperative and late cardiac events before vascular surgery. Am Hear J. 1995;130:1196–1202.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 75 292. Lauer MS, Anderson KM, Larson MG, Levy D. A new method for indexing left ventricular mass for differences in body size. Am J Cardiol. 1994;74:487–491. 293. Coles NA, Lauer MS, Field TS, Connolly M, Eagle KA. Cardiac emergencies at a major international airport: a prospective observational study. Am Hear J. 1992;124:257–260. 294. Galderisi M, Lauer MS, Levy D. Echocardiographic determinants of clinical outcome in subjects with coronary artery disease (the Framingham Heart Study). Am J Cardiol. 1992;70:971–976. 295. Krumholz HM, Douglas PS, Lauer MS, Pasternak RC. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med. 1992;116:785–790. 296. Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992;19:130–134. 297. Lauer MS, Eagle KA. Atrial fibrillation following cardiac surgery. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. New York: Raven Press; 1992. p. 127–144. 298. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180–1184. 299. Lauer MS, Levy D. Left ventricular hypertrophy: risk, clinical correlates, and therapeutic implications. Focus Hypertens. 1992;3:5–10. 300. Lauer MS, Levy D, Anderson KM, Plehn JF. Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. Ann Intern Med. 1992;116:203–210. 301. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA. 1991;266:231–236. 302. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1991;18:1287–1294. 303. Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis. 1989;31:367–378.
Michael S. Lauer, MD, FACC, FAHA Curriculum Vitae Page 76 304. Miller KJ, Lauer MS, Caloccia W. Interactions of molecules with nucleic acids. XII. A theoretical model for the interaction of a fragment of bleomycin with DNA. Biopolymers. 1985;24:913–934. 305. Miller KJ, Lauer MS, Archer S. Interaction of molecules with nucleic acids. V. Thioxanthenones into DNA. Int J Quantum Chem. 1980;18:11–34.

More Related Content

PDF
6 septimoreporte
byGloriana Pichardo
 
DOCX
CURRICULUM VITAE 2015
byJohn C. Ruckdeschel, M.D.
 
PDF
JNC7
bySantiago Silva
 
DOCX
Trivedi CV-updated-April2015-LinkedIn
byRudra Trivedi
 
PPTX
Amusa atanda ajisegiri
byOyintola Isiaka Amusa
 
DOCX
ckwillie_resume_2015_v5
byChris Willie
 
DOCX
Resume_Informatica_4.3yrs_CSC_MCA_from_NIT_Venkat_CV.v1.0
byVenkat Bathem
 
PDF
Jerry Vigil CV - Software Engineer - San Francisco, CA, USA
byMktNeutral
 
6 septimoreporte
byGloriana Pichardo
 
CURRICULUM VITAE 2015
byJohn C. Ruckdeschel, M.D.
 
JNC7
bySantiago Silva
 
Trivedi CV-updated-April2015-LinkedIn
byRudra Trivedi
 
Amusa atanda ajisegiri
byOyintola Isiaka Amusa
 
ckwillie_resume_2015_v5
byChris Willie
 
Resume_Informatica_4.3yrs_CSC_MCA_from_NIT_Venkat_CV.v1.0
byVenkat Bathem
 
Jerry Vigil CV - Software Engineer - San Francisco, CA, USA
byMktNeutral
 

Viewers also liked

PDF
CV_OR(EN)
byoreyesc
 
PDF
Yury's CV as of 2013.03.31
byYury Velikanov
 
DOCX
2016 UK CV MRagge
byMichael Ragge
 
PDF
Ines Mergel CV December 2012
byInes Mergel
 
PDF
CHINOY CV-May 2016
byMala Chinoy
 
PDF
Heidi Kraay CV
byHeidi Kraay
 
PDF
CV Stephen G. Barr
bySGB Media Group
 
DOC
CV-Anglais
byJoseph Bejjani
 
PDF
CV-Abdullah Aziz
byAbdullah Aziz
 
PDF
Dan Wang - CV
bydw4085
 
PDF
Ibrahim-CV-2016-Updated
byIbrahim Abdel-Rahman
 
RTF
Laura Boley Sales Leadership Resume
byLaura Boley
 
PDF
Robin resume pub works
byRobin Paul Roderick
 
DOCX
James Henry Robinson
byJames Henry Robinson
 
PDF
Fahim M Jamal Resume 1
byFahim Jamal
 
CV_OR(EN)
byoreyesc
 
Yury's CV as of 2013.03.31
byYury Velikanov
 
2016 UK CV MRagge
byMichael Ragge
 
Ines Mergel CV December 2012
byInes Mergel
 
CHINOY CV-May 2016
byMala Chinoy
 
Heidi Kraay CV
byHeidi Kraay
 
CV Stephen G. Barr
bySGB Media Group
 
CV-Anglais
byJoseph Bejjani
 
CV-Abdullah Aziz
byAbdullah Aziz
 
Dan Wang - CV
bydw4085
 
Ibrahim-CV-2016-Updated
byIbrahim Abdel-Rahman
 
Laura Boley Sales Leadership Resume
byLaura Boley
 
Robin resume pub works
byRobin Paul Roderick
 
James Henry Robinson
byJames Henry Robinson
 
Fahim M Jamal Resume 1
byFahim Jamal
 

Similar to CV 5 17 15

DOCX
CURRICULUM VITAEaecom5.2.2015
byEdgar Lichstein
 
PDF
Dsoffercv
bycambridgeWD
 
PDF
Curriculum Vitae 1 27 15
byDr Jim Patel
 
DOC
Curriculum Vitae BFW Updated 04_11_2016
byBarry Walter
 
PPT
Peter libby, md
bySociety for Heart Attack Prevention and Eradication
 
PPT
208 peter libby
bySociety for Heart Attack Prevention and Eradication
 
PPT
208 peter libby
bySHAPE Society
 
PPT
Libby
bySociety for Heart Attack Prevention and Eradication
 
DOCX
Curriculum vitae
byDr. Theodore Shively
 
DOC
Kenneth W. Rundell resume
byKenneth Rundell
 
DOC
DKCassavarCV.8-23-15
byDan Cassavar MD MBA FACC FACP FSCAI
 
PDF
Dr Harb Research
byWalid Harb MD, FACP
 
DOC
JPH CV update January 2015
byJoseph Hanna
 
DOC
Jialal-CV-6-2016
bykenny jialal
 
PPT
Lf speaker profiles version 1
bynvehrenhelm
 
PPTX
Dr ravi r kasliwal cardiologist medanta medicity
byDr R R Kasliwal
 
PDF
Cv+stolzfus+daniel+paul+revised+july+2020
byElia Ahadi
 
DOCX
vinay.docx
byShardaBharti1
 
DOCX
David S. Baskin CV Dec 2015
bypnsdsb
 
PDF
Curriculum vitae (LaTeX PDF)
byTomas J. Aragon
 
CURRICULUM VITAEaecom5.2.2015
byEdgar Lichstein
 
Dsoffercv
bycambridgeWD
 
Curriculum Vitae 1 27 15
byDr Jim Patel
 
Curriculum Vitae BFW Updated 04_11_2016
byBarry Walter
 
Peter libby, md
bySociety for Heart Attack Prevention and Eradication
 
208 peter libby
bySociety for Heart Attack Prevention and Eradication
 
208 peter libby
bySHAPE Society
 
Libby
bySociety for Heart Attack Prevention and Eradication
 
Curriculum vitae
byDr. Theodore Shively
 
Kenneth W. Rundell resume
byKenneth Rundell
 
DKCassavarCV.8-23-15
byDan Cassavar MD MBA FACC FACP FSCAI
 
Dr Harb Research
byWalid Harb MD, FACP
 
JPH CV update January 2015
byJoseph Hanna
 
Jialal-CV-6-2016
bykenny jialal
 
Lf speaker profiles version 1
bynvehrenhelm
 
Dr ravi r kasliwal cardiologist medanta medicity
byDr R R Kasliwal
 
Cv+stolzfus+daniel+paul+revised+july+2020
byElia Ahadi
 
vinay.docx
byShardaBharti1
 
David S. Baskin CV Dec 2015
bypnsdsb
 
Curriculum vitae (LaTeX PDF)
byTomas J. Aragon
 

CV 5 17 15

  • 1.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 1 Michael S. Lauer, MD, FACC, FAHA CURRICULUM VITAE NAME: Michael Solon Lauer, MD, FACC, FAHA ADDRESS: Home: 12101 Ravenwood Court Silver Spring, MD 20902 Business: 6701 Rockledge Drive, Room 8128 Bethesda, MD 20892 Phone: 301 435 0422 (business) Email: lauermichael@yahoo.com (personal) lauerm@nhlbi.nih.gov (business) PLACE OF BIRTH: Wynnewood, Pennsylvania (July 11, 1961) FAMILY: Married (1989) to Dr. Robin Avery Nathan Max (born November 7, 1991) Daniel Akiva (born May 31, 1994) EDUCATION: 1983 BS Rensselaer Polytechnic Institute (summa cum laude), Troy, New York 1985 MD Albany Medical College (magna cum laude), Albany, New York 1989-1990 Program in Clinical Effectiveness, Harvard School of Public Health, Boston, MA 2004 Josiah Macy Scholar in Physician Education, Program for Physician Educators, Harvard Medical School and Harvard Graduate School of Education, Boston and Cambridge, MA 2010 NIH Senior Leadership Program (University of Maryland) POSTDOCTORAL TRAINING: 1985-1986 Intern in Medicine, Massachusetts General Hospital and Harvard Medical School, Boston 1986-1988 Resident in Medicine, Massachusetts General Hospital and Harvard Medical School, Boston 1988-1991 Clinical Fellow in Medicine (Cardiology), Harvard Medical
  • 2.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 2 School and Beth Israel Hospital, Boston 1990-1991 Research Fellow, Framingham Heart Study and Boston University Medical School, Framingham, MA LICENSURE AND CERTIFICATION: 1987 Massachusetts License Registration 1988 Specialty Certification (ABIM) in Internal Medicine 1991 Subspecialty Certification (ABIM) in Cardiovascular Disease 1993 Ohio License Registration 2001 Subspecialty Recertification (ABIM) in Cardiovascular Disease 2011 Subspecialty Recertification (ABIM) in Cardiovascular Disease (top decile on April 11, 2011, secure examination) HOSPITAL, INSTITUTIONAL, AND EXECUTIVE LEADERSHIP APPOINTMENTS: 1991-1993 Physician, Lahey Clinic Medical Center and Harvard Medical School, Burlington, MA 1993-2007 Staff, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2004 Co-director, Coronary Intensive Care Unit, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2007 Vice Chair, Cleveland Clinic Foundation Institutional Review Board 1999-2007 Director, Exercise Laboratory, Cleveland Clinic Foundation, Cleveland, Ohio 2007-2009 Director, Division of Prevention and Population Science (DPPS), National Heart, Lung, and Blood Institute (NHLBI/NIH), Bethesda, Maryland Oversight of 50 FTEs, research portfolio of ~$300 million
  • 3.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 3 2009- Director, Division of Cardiovascular Sciences (DCVS), National Heart, Lung, and Blood Institute (NHLBI/NIH), Bethesda, Maryland Oversight of 123 FTEs, research portfolio of ~$1.5 billion AWARDS AND HONORS: 1979 Salutatorian, Shenendehowa Central School, Clifton Park, NY 1982 Dean's Outstanding Research Award, Albany Medical College Daggett Prize in Anatomy, Albany Medical College 1982 Knudson Prize in Biochemistry, Albany Medical College Townsend Prize in Physiology, Albany Medical College 1983 Glen H. Leak Memorial Fellowship, American Cancer Society Research Award, Association of Medical Schools of NY Elected Sigma Xi Alpha Omega Alpha BS, summa cum laude, Rensselaer Polytechnic Institute 1984 Henry Schaeffer Prize in Pathology, Albany Medical College 1985 MD magna cum laude, Albany Medical College 1989 Kellogg Foundation Fellowship for study at the Harvard School of Public Health 1993 Elected Fellow, American College of Cardiology 1996 Merck American College of Cardiology/European Society of Cardiology International Exchange Fellowship Distinguished Teacher Award, Cleveland Clinic Foundation 1997 Named First Vice Chair – CCF Institutional Review Board 2000 Paper of Dr. Christopher Cole, a fellow under my direct supervision, selected as Finalist in the American College of Cardiology Young Investigator Award Competition; paper received honorable mention 2000 Named as Contributing Editor, JAMA (ongoing) 2000-2001 Awarded two-year Established Investigator Grant, American Heart
  • 4.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 4 Association (0040244N), $140,000 over two years. 2001 Named Vice-Chair of the Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council of Clinical Cardiology, American Heart Association. 2001-2004 NIH R01 HL-66004 grant on Heart Rate Recovery and Mortality for $660,000. 2003 Named Chairman of the Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council of Clinical Cardiology, American Heart Association. 2003 Invited Guest Lecturer, 50th Annual Meeting of the Israel Heart Society, Tel Aviv, Israel. 2004 Michael Pollock State-of-the-Art Lecturer, American Heart Association. 2004-2007 NIH R01 HL072771-01Al grant on Logical Analysis Data for $1,032,000. 2004 Paper of Hitinder S. Gurm MD – Honorable Mention – William E. Lower Award. Clinical First Prize under my direct supervision. 2005 Paper of Rohit Bhatheja, MD – Honorary Award Winner (Echo- nuclear paper) – William E. Lower Award under my direct supervision. 2005 Elected member of American Society for Clinical Investigation Award (ASCI) 2005 Reappointment as Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University for academic year. 2005 The Marie and Sam Miller Professional Excellence Award, Scientific Achievement Award in Clinical Research 2005 Appointed Professor of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine 2006 Center for Clinical Investigation, Office of Faculty Affairs, Secondary Appointment, Case Western Reserve University School of Medicine
  • 5.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 5 2006 Candidate for Cardiovascular Medicine Chair, Cleveland Clinic 2006 Visiting Professorships, University of Alberta and Indiana University 2006 Torgny Sjoenstrand Honorary Lecture in Clinical Physiology Annual Meeting of the Swedish Society of Medicine 2006 Scholarship in Teaching Award, Case Western Reserve University School of Medicine (for Clinical Research Skills Block) 2007 Fellow (Dr. Esther Kim) wins first place, Young Investigator Award for Clinical Research American College of Cardiology, March, 2007 2008 Ancel Keys Lecture, American Heart Association 2009 National Institutes of Health Awards of Merit (2) for work on NHLBI Short Detail Program NHLBI Critical Reading Website (Today’s News blog) 2010 National Institutes of Health Award of Merit for work on NHLBI Grand Opportunities Exome Sequencing Project National Institutes of Health Director’s Awards for work on: Office of the Director Team on Comparative Effectiveness Research Through ARRA and Beyond National Institutes of Health Equal Employment Opportunity (EEO) 2010 Award of the Year: “For building a diverse professional staff and promoting the Spirit of Fairness, Equality, and Inclusion” 2012 NHBLI Merit Award “For Activities in Comparative Effectiveness Research” Arthur S. Flemming Award for exceptional service in Federal Government “For [playing] a key role in setting the national cardiovascular research agenda and [being] example in empowering his staff through creation of an active learning environment.”
  • 6.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 6 2013 NIH Director’s Group Award: “NINDS Stroke Research Priorities Planning Team, for extraordinary leadership, perseverance, and creativity in coordinating and implementing the NINDS Stroke Research Priorities planning effort.”   NIH Director’s Group Award: “The Health Care Systems Research Collaboratory, for planning, developing innovative solicitations, review and launch of the Health Care Systems (HCS) Research Collaboratory.” NHLBI Director’s Individual Award: “In recognition of the extraordinary work to promote individual and collective learning at the NHLBI.” 2014 NHLBI Director’s Group Award: “InCites Working Group – for the dedication and collaboration exhibited by the trans-NHLBI InCites Working Group in building a model learning environment for portfolio analysis at the Institute.” MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS (selected examples): 1989- American College of Physicians 1999-2007 American Medical Association 1993-1997 Cleveland Clinic Committee on Medical Records and Statistics 1994-2007 Cleveland Clinic Institutional Review Board 1995-2000 Cleveland Clinic Electronic Medical Records Committee 1997-2007 Vice-Chairman, Cleveland Clinic Institutional Review Board 2000-2007 Contributing Editor, JAMA 1998-2002 American College of Cardiology, Coding and Nomenclature Committee 2003-2007 Professor of Medicine CCLCM of CWRU 2003-2005 Admissions Committee of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  • 7.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 7 2004-2007 “MAC” Multidisciplinary Advisory Committee – Director, Richard A. Rudick, M.D. – Cleveland Clinic Foundation, K12 Program of the National Institutes of Health 2004-2007 Cleveland Clinic Lerner College of Medicine Research Curriculum Committee 2005-2007 Cleveland Clinic Lerner College of Medicine Physicians Advisors Committee 2005-2007 Program Oversight Committee for the MD/MS Biomedical Investigation Program at CWRU 2005-2007 Annual Scientific Sessions Program Committee of the American College of Cardiology 2005-2007 Lower & Peskind Awards Committee 2005-2007 Selected ad hoc member of NIH Study Section on Human Services Research 2005-2007 ACCF/AHA Writing Committee to Update the 2000 Clinical Expert Consensus Document on EBCT for the Diagnosis and Prognosis of Coronary Artery Disease 2005- American Association for the Advancement of Science (AAAS) 2005-2007 Professor, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine 2006 NIH Study Section Member, (ZHL1 CSR-H (M1). Bethesda MD 2006 Acute Cardiac Care Abstract Grader for Prague, Czech Republic 2006 ACCF/AHA Writing Committee to Develop a Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients with Chest Pain 2006-2007 Research Education Committee, CCLCM of CWRU 2006-2007 PhD Molecular Curriculum Committee for CCLCM of CWRU 2006-2007 Tarazi Award Selection Committee
  • 8.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 8 2006 Cardiovascular Medicine Outcomes Book Committee for 2006 2006 Selected ad hoc member of NIH Study Section on Heart Failure Clinic Research Network 2007 ACC/Duke University Think Tank on Cardiovascular Imaging 2007- NHLBI and NIH search committees Director, NHLBI Office of Communications Director, NHLBI Office of Global Health (Chair) Director, NHLBI Division for the Application of Research Discoveries Deputy Director, NHLBI Division of Blood Disease and Resources Deputy Director, NHLBI Division of Extramural Activities Director, NIMH Division of Services and Interventions Research Director, NCI Division of Cancer Prevention 2008- American Heart Association Research Committee 2008-2010 ACC/AHA Committee on Cardiovascular Risk Assessment 2008-2010 ACC/AHA Writing Committee on CT coronary angiography 2009- Editorial Board, Annals of Internal Medicine 2009- NIH Coordinating Committee for Comparative Effectiveness Research (Co-Chair since December, 2009) 2008- American Heart Association Quality of Care and Outcomes Research (QCOR) Planning Committee 2010-2011 NIH CTSA IC Directors Advisory Committee 2010 US Department of Health and Human Services Comparative Effectiveness Research Coordination and Implementation Committee (CER-CIT)
  • 9.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 9 2011- Patient Centered Outcomes Research Institute (PCORI) Methodology Committee; Scientific Publications Working Group; Program Evaluation Group; Scientific Oversight Committte FDA Advisory Panels on Vytorin, Qnexa and CV Toxicity of GI drugs 2012- Clinical Trials Transformation Initiative Executive Committee 2013- NIH Scientific Data Council 2014- NIH Co-Chair for President’s Precision Medicine Initiative 2015- NIH Committee on Efficient and Sustainable Funding Policies MAJOR RESEARCH AND ACADEMIC INTERESTS: 1. Molecular biology and pharmacology, Rensselaer Polytechnic Institute 1979-1983 2. Cardiovascular epidemiology, Framingham Heart Study, 1990 - 1999 3. Exercise epidemiology, Cleveland Clinic Foundation, 1993 - 2007 4. Computerized medical record, Cleveland Clinic, 1994 - 2000 5. Clinical trials, 1997 – ongoing 6. Clinical cardiovascular epidemiology, 1993 – ongoing 7. Biostatistics, 2004-ongoing 8. Medical Editing (JAMA), 2000-2007 9. Comparative Effectiveness Research, 1990 – 10. Economics of Publicly Funded Biomedical Research, 2010 -- PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES: 1991-1993 Staff Cardiologist, Lahey Clinic Medical Center, Burlington, MA 1993-2007 Staff Cardiologist, Cleveland Clinic Foundation, Cleveland, Ohio 1997-2003 Co-Director, Cleveland Clinic Foundation Coronary Intensive Care Unit 1997-2007 Vice Chair, Cleveland Clinic Foundation Institution Review Board 1999-2007 Medical Director, Cleveland Clinic Foundation Exercise Stress Laboratory
  • 10.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 10 TEACHING AND LECTURE EXPERIENCE (selected examples): 1988 Lecturer in electrocardiography, Massachusetts General Hospital, Boston Lecturer in "Introduction to Clinical Medicine," Harvard Medical School and Massachusetts General Hospital, Boston 1993 Cardiology Grand Rounds, Cleveland Clinic Foundation, "Hypertension and Left Ventricular Hypertrophy" 1994 Medical Grand Rounds, Cleveland Clinic Foundation, "Medicine in Nazi Germany" 1994 Cleveland Clinic Health Talks, "Prevention and Regression of Heart Disease" Rainbow and Babies' Hospital Grand Rounds, "Medicine in Nazi Germany" 1995 Cleveland Clinic Coronary Club, "The Epidemiology of Coronary Artery Disease" 1993- Ernstene, Shirey, Consult and CCU Teaching Services, Cleveland Clinic 1995 Cleveland Clinic CME Course in Cardiovascular Risk Factors, "Left Ventricular Hypertrophy as a Risk Factor" 1996 MetroHealth Systems, Chronotropic Incompetence Cleveland Clinic Cardiology Grand Rounds, Chronotropic Incompetence John Carroll University, Medicine in Nazi Germany CNR, Pisa, Italy Exercise Hypertension University of Heidelberg, Heidelberg, Germany and Katholic University, Leuven, Belgium, Left Ventricular Hypertrophy 1997 Cleveland Clinic Ethics Committee Lessons from Nuremberg
  • 11.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 11 Cleveland Clinic Internal Medicine Review Course, The Electrocardiogram American College of Cardiology Annual Scientific Sessions: Info@ACC Enhancing Your Productivity: Evaluating Electronic Medical Records for Clinical Practice Cleveland Clinic Foundation Section of Heart Failure: Left Ventricular Hypertrophy as a Cardiovascular Risk Factor: an epidemiologic perspective Walt Disney World and Cleveland Clinic Foundation Cholesterol Summit, Directed Workshop on Early Detection of Coronary Artery Disease. Cleveland Clinic Division of Medicine, Course on Foundations of Clinical Medicine, Dealing with Data. Cardiology Grand Rounds, Cleveland Clinic Foundation, The Electronic Medical Record. 1998 Cleveland Clinic Foundation Executive Health: Prevention of Coronary Heart Disease. American College of Cardiology, GUSTO IV Scientific Investigators Committee John Carol University, University Heights, OH AMedicine in Nazi Germany. Cleveland Clinic Department of Pulmonary Medicine, Management of Acute Coronary Syndromes in the Intensive Care Unit. Cleveland Clinic Department of Pulmonary Medicine, Management of Pericardial Disease in the Intensive Care Unit. Marquette Annual ECG Analysis Seminar; Rehabilitating the Exercise Electrocardiogram: Asking the Right Questions and Getting the Right Answers. Duke Clinical Research Institute, GUSTO IV Mini-symposium; “Role of Glycoprotein IIb/IIIa Inhibitors in the Management of Acute Coronary Syndromes.”
  • 12.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 12 Cleveland Clinic Department of Cardiology: Introduction to Biostatistics Series of lectures to Cardiology Fellows Cleveland Clinic Division of Medicine, Journal Club Staff Supervisor 1999 Cleveland Clinic Division of Medicine Grand Rounds: Rehabilitating the Exercise Electrocardiogram. Sid Peterson Hospital, Kerville, Texas Long Term Management Strategies in Acute Coronary Syndromes: Risk Stratification of the Patient Who has had Coronary Artery Bypass Grafting. Cleveland Clinic Nursing Cardiac Care Symposium; Invited Speaker – Strategies for the Prevention and Treatment of Sudden Cardiac Death. Mt. Sinai Hospital, Cleveland, Medical Grand Rounds; Rehabilitating the Exercise Electrocardiogram. Duluth Clinic Annual Cardiovascular Conference, Keynote Speaker AUpdate in Heart Failure. New York Hospital Cornell Medical Center Cardiology Grand Rounds Chronotropic Incompetence: New Insights into an Old Sign. GUSTO IV Investigators Meeting: Introduction to the GUSTO IV Acute Myocardial Infarction Trial: 2 hour lecture on the background, rationale, and design of the trial as well as taking of questions from regional investigators. American Society of Echocardiography, Invited Speaker; Is Nuclear Ever Better. American Heart Association, Invited to Moderate How-to Session “Timing of Post-MI Risk Stratification.” Cleveland Clinic Foundation, Department of Rheumatology, Cardiac Imaging in Chronic Disease. Cleveland Clinic Foundation, Division of Surgery, Grand Rounds, “Preoperative Cardiac Evaluation of the Patient Undergoing Noncardiac Surgery: a Cardiologists Perspective.”
  • 13.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 13 General Electric-Marquette Corporation, Milwaukee, Wisconsin: New Developments in Exercise Testing. 2000 Cleveland Clinic Department of Hospital-Based Internal Medicine: New Developments in Exercise Testing. General Electric-Marquette Corporation Annual Meeting in Fort Lauderdale, Florida: The Future of Exercise Testing. American College of Cardiology Annual Meeting, Invited Speaker at Symposium on Clinical Evaluation of the Patient Undergoing Noncardiac Surgery. Invited Speaker at Symposium: Exercise Testing in the New Millennium, Featuring Who’s Who in Exercise Testing, organized by Dr. Myrvin H. Ellestad and Dr. Ronald Startt-Selvester, on Use of Chronotropic Response and Heart Rate Recovery in Exercise Testing. Cleveland Clinic Foundation Fellowship Lectures on Statistical Review of Journal Articles. Cleveland Clinic Foundation Symposium on Dimensions in Cardiac Care, lecture on Beyond the ST Segment: New Developments in Exercise Testing. Cleveland Clinic Foundation Cardiovascular Board Review Course; Clinical Epidemiology and Biostatistics: How to Interpret a Clinical Research Study and Exercise ECG Stress Testing: Diagnostic Utility and Prognostic Implications. American Heart Association Cardiovascular Seminar on Novel New Markers in the ECG Stress Test, invited lectures on Chronotropic and Blood Pressure Responses. 2001 American College of Cardiology Symposium, invited lecture on Post-MI Risk Stratification: The Role of Exercise Electrocardiography. American College of Cardiology Oral Presentation; Prognosis in Patients with an Excellent Exercise Capacity. American College of Cardiology Oral Presentation; Logical Data Analysis for Assessment of Prognosis Among Patient Undergoing
  • 14.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 14 Exercise Electrocardiography. Cleveland Clinic Foundation Symposium on Preventing Heart Disease; Resuscitating the Exercise Test. American College of Sports Medicine, invited clinical lecture: “Exercise Testing: A New Look at an Old Technology.” American College of Sports Medicine invited lecturer at Clinical Symposium on Detection of Silent Coronary Disease, “Use of Chronotropic Response and Heart Rate Recovery.” Cleveland Clinic Foundation Cardiology Review Course, “Clinical Trials and Population Studies: Things You Must Know” Cleveland Clinic Foundation Cardiology Review Course, “ECG Stress Testing—Outdated or Up-to-date?” Cleveland Clinic Foundation House Staff, “Introduction to Journal Reading (2 lectures)” 2002 American College of Cardiology, Invited Symposium Lecture, March, 2002: “Role of the Exercise ECG” American College of Cardiology, Invited Lecture, March 2002: “Maximizing the Use of Exercise Testing” American College of Cardiology, Oral Presentation, March 2002: “Ventricular Ectopic Activity Predicts Mortality When It Occurs During Recovery, but Not Just During Exercise.” Metro Health Center, Cleveland, Invited Lecture and Cardiology Grand Rounds, April 2002: “The Exercise Test: Looking Beyond the ST-Segment” Office of Human Research Protection and Cleveland Clinic Foundation Department of Bioethics Symposium on Research Protection, Invited Lecture, May 2002: “Issues Involving Authorship and Publication of Clinical Research” Brigham and Women’s Hospital, Harvard Medical School, Cardiology Grand Rounds, May 2002: “The Exercise Test: Looking Beyond the ST-segment”
  • 15.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 15 Maine Medical Center of Portland, Maine, Invited Lecture, Visiting Professor, Cardiology Grand Rounds, May 2002: “The Exercise Test: Looking Beyond the ST-Segment” Maine Medical Center of Portland, Maine, Invited Lecture, Visiting Professor, Fellows Noon Conference, May 2002: “Ethical Issues Regarding Authorship” Bikur Cholim Hospital, Jerusalem, Israel, June 2002: “The Exercise Test: Looking Beyond the ST-Segment” Hartford Hospital Department of Cardiovascular Medicine, Visiting Professor and Invited Speaker, July 2002: “The Exercise Test: Looking Beyond the ST-Segment” American College of Cardiology, Yellowstone Summit, West Yellowstone, Montana, August 2002, invited speaker: “Stress Testing: Which Modality to Choose” Cleveland Clinic Foundation Medical House Staff Journal Club, September 2002: “Introduction to Clinical Journal Reading” Cleveland Clinic Foundation Division of Medicine, September 2002: “Clinic Research Methods, Part I” (This was given twice, under the auspices of Dr. James Stoller) Cleveland Clinic Foundation Division of Medicine, September 2002: “Clinical Research Methods, Part II” (This lecture was given twice, under the auspices of Dr. James Stoller) Cleveland Clinic Foundation Cardiovascular Medicine Board Review Course, September 2002: “Statistics for the Clinical Cardiologist” Cleveland Clinic Foundation Cardiovascular Medicine Board Review Course, September 2002: “ECG Stress Testing---New Approaches to an Old Modality” Israeli Women’s Health Fellowship of the Jewish Community
  • 16.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 16 Federation of Cleveland, October 2002: Seminar in “Topics on Cardiovascular Disease in Women” American College of Rheumatology, New Orleans, October 2002, invited speaker: “Aspirin for Primary Prevention of Cardiovascular Disease” American Heart Association, November 2002: Moderator and Invited Speaker “Using the Heart Rate to Improve Stress Test Interpretation” Tel HaShomer Medical Center and Tel Aviv University, December 2002: Visiting Professor and lecture on “Exercise Testing” Looking Beyond the ST-Segment” John Carroll University Freshman Program Speaker, December 2002: “Ethical Issues in Research” 2003 Cleveland Clinic Foundation Imaging Fellows Conference, January Invited Speaker “Clinical Trials and Observational Studies: Things You Must Know” January 2003 Biostats Seminar – Two fellowship lectures on “Clinical Research Design” January 2003. University of North Carolina at Chapel Hill, invited speaker, UNC Heart Center Grand Rounds. Cleveland Clinic Foundation Imaging Fellows Conference, Core Fellows Lecture Series (Part I) Invited Speaker “Clinical Trials and Observational Studies: Things You Must Know.” Cleveland Clinic Foundation CTS Research Team Grand Rounds Speaker, “Exercise Testing: Looking Beyond the ST Segment February 2003. Lakewood Hospital, Cleveland, Ohio Grand Rounds Speaker, “Exercise Testing: Looking Beyond the ST Segment February 2003.
  • 17.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 17 Case Western Reserve University School of Medicine Grand Rounds, Invited Speaker, March 2003. “The Exercise Test: Beyond the ST Segment.” ACC Poster Session – “Heart Rate Recovery After Exercise and Mortality with Exercise Testing” ACC Meet the Experts – “Customizing the Image to the Patients: AKA What Test is for Whom?” ACC Oral Contributions – “Exercise Testing: Predicting Mortality,” and “Association of Abnormal Heart Rate Recovery and Chronotropic Incompetence with Obesity in a Healthy Cohort.” ACC Oral Contributions – “Stress Echocardiography: Ploughing New Ground” and Survival Benefits of Early Myocardial Revascularization after Stress Echocardiography: A Propensity Analysis.” ACC Oral Contribution – “The Old and the New” The ECT and Novel Biomarkers in Acute Coronary Syndromes” and Does the Presence of Electrocardiographic Left Ventricular Hypertrophy Predict One-Year Mortality in Non-ST Elevation Acute Coronary Syndromes.” Cleveland Clinic Foundation Heart Failure Invited Speaker – “Recent Innovations in Exercise Testing.” Annual Meeting of the Israel Heart Society, Tel Aviv, Israel, Invited Guest Lecturer, “Assessment of Prognostic Ambulatory Patients with Congestive Heart Failure,” April 2003. Cleveland Clinic Foundation Heart Failure Research Invited Speaker, April 2003. “Exercise Testing: Beyond ST Segment” Indiana University School of Medicine/Krannert Institute of Cardiology, Cardiovascular Research Conference, Invited Speaker, “Exercise Testing—Beyond the ST-Segment,” May 2003. 30th International Congress on Electrocardiology, Helsinki,
  • 18.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 18 Finland, Invited Speaker, “Recovery after Graded Exercise Testing: An Under-appreciated Time of Great Prognostic Value,” June 2003. Invited Speaker “Internal Medicine Noon Conference” Cleveland Clinic Foundation – “Introduction to Journal Club Part Deux.” Residents Conference – “Clinical Epidemiology and Biostatistics for the Clinical Practitioner.” Invited Speaker – Cardiovascular Board Review Course – “An Intensive Review of Cardiology” and “Statistics for the Clinical Cardiologists” and “ECG Stress Testing – New Approach to Old Modality,” InterContinental Hotel Amphitheater, CCF. Residency Conference – “Clinical Epidemiology and Biostatistics for the Clinical Practitioner.” Invited Speaker – “Women’s Health Seminar on Cardiovascular Disease” with visiting scholars and Israeli physicians, Jewish Community Federation of Cleveland Women’s Health Program. Cleveland Clinic Foundation Symposium on Men’s Health, Invited Lecture on Screening for Coronary Artery Disease.” Invited State-of-the-Art Speaker for the Annual Michael Pollock Lecture on “Exercise Testing---Still the First Choice” at the American Heart Association meeting on November 8, 2003, Orlando, Florida. 2004 Visiting Professor and Invited Speaker – Tufts University, Boston, Massachusetts – two lectures, one on “Methods in Clinical Epidemiology” and one on “New Insights into Exercise Testing.” Invited Speaker – Cardiovascular Board Review Coarse – “An Intensive Review of Cardiology” and “Statistics for the Clinical Cardiologists” and “ECG Stress Testing—New Approach to an Old Modality,” InterContinental Hotel Amphitheater, Cleveland Clinic Foundation.
  • 19.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 19 ACC Scientific Sessions 2004 Program Presenter, “Gender Differences in Diagnosis of Coronary Artery Disease” ACC Scientific Sessions 2004 Program Presenter “Stress Testing: Does It Have Any Role?” 5Th Scientific Forum on Quality of Care and Outcomes Research in Cardiology, Invited Lecturer, May 16, 2004, “How to Get Your Outcomes Research Published.” ACP (American College of Physicians) Two “Meet the Professor” Sessions as an Invited Speaker – “Stress Testing: “When” “Which One” “How Often” Heart Failure Therapeutics Meeting, Guest Speaker, July 21, 2004, “Metabolic Stress Testing.” Journal Club Part I and Part II, Invited Speaker, August 9 and September 15, 2004. Mayo Clinic, Rochester Minnesota, Grand Rounds Speaker, August 11, 2004, Two Lectures – Exercise Testing—Beyond the ST-Segment.” Symposium at AHA Physicians Outcomes Meeting and Invited Speaker – “Publishing Outcomes Research” Omni Shoreham Hotel, Washington, DC. Cardiovascular Board Review Course, Cleveland Clinic Foundation –Invited Speaker, “Statistics for the Clinical Cardiologist” and “ECG Stress Testing—New Approach to an Old Modality.” Human in Medicine Series – Cleveland Clinic Foundation Noon Conference – Invited Speaker, October 6, 2004, “Nazi Medicine.” Men’s Health Summit, Cleveland Clinic Foundation Symposium, October 14, 2004, Invited Speaker – “Treadmills and Scans: Screening for Coronary Artery Disease.”
  • 20.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 20 European Society of Cardiology Conference, Rome, Italy, October 17, 2004, Invited Speaker – “Roll of Exercise Testing After Acute Coronary Syndrome.” American Heart Association, Scientific Sessions 2004, November 8, 2004, Invited Speaker – “How to Interpret a Stress Test.” Department of Internal Medicine Residency Program, Invited Lecturer, December 1, 2004, - “Stress Testing.” NIH Workshop – NHLBI Working Group on “Subclinical Coronary Artery Disease: Functional Capacity as a Risk Marker,” Bethesda, MD, July 13-14, 2004 Fellows’ Noon Conference, Invited Speaker, “Exercise Stress Testing Part I,” July 29, 2004 Heart Failure Therapeutic Meeting – Invited Speaker – “Metabolic Stress Testing,” July 21, 2004 Introduction to Journal Club Part I Noon Conference, Medical House Staff, “Introduction to Journal Club.” August 8, 2004 Mayo Clinic Internal Medicine Grand Rounds, Rochester, Minnesota, Invited Speaker, Two talks, “Exercise Testing: Beyond the ST Segment, and “Ethical Issues in Medical Authorship,” August 11, 2004 Nephrology Grand Rounds, Cleveland Clinic Foundation, “Exercise Testing: Beyond the ST Segment,” August 27, 2004 Introduction to Journal Clubs Part II Noon Conference, Cleveland Clinic Foundation, “Introduction to Journal Club,” September 14, 2004 5th Annual Intensive Review in Cardiology, Cardiovascular Board Review Course, Invited Speaker, two talks – “Statistics for the Clinical Cardiologist” and “ECG Stress Testing –New Approach to an Old Modality,” September 22, 2004 Cleveland Clinic Foundation Division of Medicine – Invited Speaker, Cleveland Clinic Foundation, Humanities in Medicines Series Noon Conference, “Nazi Medicine,” October 5, 2004
  • 21.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 21 Men’s Health Summit, Cleveland Clinic Foundation, Invited Speaker, “Treadmills and Scans” and “Screening for Coronary Artery Disease, “October 14, 2004 European Society of Cardiology Working Group on Acute Cardiac Care, Rome, Italy, Invited Speaker, “Risk Stratification and Secondary Prevention in Post-Infarct Survivors in the Reperfusion Era,” October 17, 2004 Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Invited Speaker – Medical School Dean’s Dinner, “Heart Rate Recovery,” November 18, 2004 Internal Medicine Noon Conference, Internal Medicine Residency Program, Cleveland Clinic Foundation, Invited Speaker, “Cardiac Stress Testing.” December 1, 2004 2005 Cleveland Clinic Foundation, Department of Interventional Cardiology, Invited Speaker, “Pre-Operative Cardiac Evaluation with Special Emphasis on Ramifications of Recently Published CARP Trial,” January 19, 2005 Boston Medical Center Cardiology Grand Rounds, Boston, Massachusetts, Invited Speaker, “Risk Stratifying the Cardiac Patient with Exercise Testing” February 9, 2005 American College of Cardiology Annual Scientific Session 2005, Orlando, Florida, Co-Chair – “Meet the Experts:” – Medical Manuscripts: Editors’ Perceptive,” March 08, 2005 Cleveland Clinic Foundation Internal Medicine Noon Conference, Invited Speaker, “Pharmaceutical Industry and Medical Education: A Free Lunch?” March 22, 2005 Cleveland Clinic Foundation, Department of Infectious Disease, Retreat Presentation/Invited Speaker, “NIH Grants/External Research Funding.” March 22, 2005 American College of Physicians Annual Session (Faculty Member) and Invited Speaker, “Noninvasive Cardiac Imaging: Which Test for Which Patient?” San Francisco, California, April 14-16, 2005 Cleveland Clinic Foundation, Department of Cardiac Surgery,
  • 22.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 22 (CVIR) Invited Speaker, “Quantitative Electrocardiography and Prognosis after Cardiac Surgery,” May 10, 2005. Research Day 2005, Cleveland Clinic Foundation, Department of Thoracic and Cardiovascular Surgery, Visiting Professor Lecture – “Short- and Long-Term Outcomes of Cardiac Surgery for Observant Jehovah’s Witnesses” – Sponsor for Dr. Mariano Brizzio. June 10, 2005. Solon Family Health Center/CCF Chagrin Falls Physician Staff, Invited Speaker, “Non-invasive Cardiac Testing: Which Test for Which Patient?” August 31, 2005 Course Director, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Clinical Epidemiology (45 hour contact course for second year medical students), July-September, 2005 2005 Cardiovascular Board Review Course, invited speaker, “Cardiac Testing” – “ETT” Series of Cardiology Fellow Presentations in Epidemiology and Biostatistics (2005 – ongoing) Invited Speaker – CCF - An Intensive Review of Cardiology, (2 talks) “Exercise ECG Stress Testing: New Approach to an Old Modality” and “Statistics for the Cardiologist.” September 21, 2005. 4th International Meeting on Intensive Cardiac Care, Invited Speaker, “The Significance of Troponin Elevation in Patients with and without Renal Failure.” Tel Aviv, Israel September 27-29, 2005. Acute Care Nurse Practitioner Students, Invited Speaker, Cleveland Clinic, “Stress Testing.” November 1, 2005 Grand Round for Clinical Research at Cleveland Clinic – Invited Speaker, “Investigator Responsibilities and Academic Freedom in Clinical Research” Bunts Auditorium November 22, 2005. Numerous television and radio interviews (Fox, Metro-News, Men’s Health Magazine). Gill Heart Institute, University of Kentucky, Grand Rounds
  • 23.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 23 speaker at Fellow’s Conference. “Gill Seminar Series – IM and Associated Stress Testing.” December 2, 2005. 2006 Invited guest lecturer on Cardiovascular Chronic Disease for Seminar Course Lecture/Foundations in Research and Scholarship in Class 483. February 1, 2006. Invited Speaker – Clinical Ethics Symposium for First Year Medical Student, Fire Restaurant, Shaker Heights, OH “Ethics in Research,” March 5, 2006 Co-Chair (with Dr. Martha Gulati). “Meet the Experts Session, Modern Exercise Test Interpretations.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 13, 2006 Co-Chair. “Writing for Publication While in Training, Cardiac Care Associates and Young Academic Cardiologists.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA March 14, 2006. Invited Speaker for Symposium - “How Editors Approach Industry-Related Conflicts of Interest.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA March 14, 2006 Invited Speaker for Symposium – “Cardiologists on Trial: Reflection on Credible Evidence.” American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 14, 2006. “Asymptomatic diabetics and metabolic syndrome: role of imaging: - “Is there a role for the stress electrocardiogram?” Invited Speaker, American College of Cardiology Annual Scientific Meeting, Atlanta, GA, March 13, 2006. “Tuesday Morning Vascular Medicine Conference” Lecturer- Invited Speaker, “Pre-Operative Cardiovascular Risk Assessment and Management for Vascular Surgery.” Cleveland Clinic, March 21, 2006 CME Symposium “Updates on Cardiovascular Medicine” New Milford Hospital/New York Presbyterian Columbia and Cornell University Medical Center, Invited Speaker, “Exercise and
  • 24.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 24 Exercise Testing: not Enough Respect,” New Milford, CT, March 28, 2006. Invited Speaker – Cleveland Clinic Cardiovascular Medicine Athero-Thrombosis Group Meeting, “Autonomic Nervous System Research in the Stress Lab,” March 2006. Invited guest lecturer, Cleveland Clinic/Case Western Reserve Acute Care Nurse Practitioner Class – Stress talk, “Specialty Assessment and Diagnostics.” April 4, 2006 Baystate Medical Center, Plotkin Conference, Invited Speaker at the “Log Cabin Conference Center,” “Noninvasive Cardiac Testing: Which Test for Each Patient?” Holyoke, MA. April 7, 2006 Invited Speaker – Clinical Trials Course for the Department of Quantitative Health Sciences, “Clinical Trials from Viewpoint of Journal Editor,” Cleveland Clinic, May 4, 2006. 7th American Heart Association Forum on Quality of Care and Outcomes in CVD and Stroke, Washington, DC, Invited Speaker, “Writing for Medical Journals: A Session with the Editors,” “Publication in JAMA: An Editor’s Perspective.” May 8, 2006. Krannert Institute of Cardiology of Indiana University, Invited Speaker, Indianapolis, IN, Grand Rounds. “Ethical Issues in Biomedical Authorship” and “Author Responsibilities and Academic Freedom: an Editor’s Perspective.” May 9, 2006. University of Alberta, Edmonton Canada, Invited Distinguished Speaker/Grand Rounds, “Contemporary Ethical Issues in Biomedical Authorship” May 17, 2006. Spring Ohio College of Clinical Pharmacy Meeting, Cleveland, OH, Invited Speaker – Keynote Address, “Conflict of Interest: Perspectives of a Physician and a Medical Editor,” May, 24, 2006. Invited Speaker – Cleveland Clinic Intensive Review in Internal Medicine, “Board Simulation in Biostatistics” Intercontinental Hotel, Cleveland Clinic. June 13, 2006. Invited Speaker – 2006 Clinical Research Grand Rounds, “Designing Clinical Trials.” Center for Clinical Trials, Cleveland Clinic, June 27, 2006.
  • 25.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 25 Conflict of Interest Concerns in Biostatistical Work, invited as “Special Contributed Panel” member, Montreal Canada, July 20, 2006. IBC Meeting, invited speaker, “Editors’ Approach to Industry Related Conflict of Interest: JAMA, July 26, 2006, Montreal Canada. The American College of Cardiology Foundation, Cardiovascular Board Review, invited speaker/faculty. “Exercise Treadmill Testing.” September 7, 2006, Dallas, TX Case Western Reserve EPBI 510 Class Health Disparities Graduate Course, invited speaker, “SES and Cardiac Parameters.” September 11, 2006. Inventors’ Forum on Managing Innovation/COI 2006-2007, invited speaker, “Do’s and Don’ts of IRB.” September 14, 2006. Beterson 16-Year Long-Term Followup Study - Mortality in MS Workshop, invited speaker for meeting on Survival in MS. “Exercise Treadmill Testing.” September 17, 2006, New York, NY Annual Intensive Review of Cardiology, Cleveland Clinic, invited speaker, 2 talks, “Electrocardiogram Stress Testing – A New Approach to an Old Modality” and “Statistics for the Cardiologist.” September 20, 2006. CCLCM invited speaker for medical student class. “Authorship,” September 22, 2006. American Association for Thoracic Surgery and Directors of the Cleveland Clinic Kaufman Center for Heart Failure 21st Century 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical therapies for Better Outcomes, Invited Speaker. “Predicting outcomes in patients with heart failure: Clinical characteristics, peptides perfusion and function. October 20, 2006 “A New Dimension in Leadership: Emotional Intelligence” Workshop, Cleveland Clinic Center for Leadership and Learning, Cleveland OH, October 23, 2006 American Association for Thoracic Surgery – 21st Century Treatment of Heart Failure: Synchronizing Surgical and Medical
  • 26.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 26 Therapies for Better Outcomes - Invited Speaker - Predicting Outcomes in Patients with Heart Failure: clinical Characteristics, peptides, perfusion and Function.” MBNA Conference Center, Cleveland Clinic InterContinental Hotel, Cleveland Ohio Acute Cardiac Care Congress 2006, European Cardiac Society and Israel Heart Association, Czech Republic, October 21-24, 2006, Scientific Committee and Invited Speaker. Swedish Society of Clinical Physiology – Invited Speaker – “Torgny Sjostrand Honorary Lecture in Clinical Physiology, Annual Meeting of the Swedish Society of Medicine, Goteborg, Sweden. “Exercise Testing—An Integrated Physiological Approach of High Prognostic Value in Clinical Medicine” and “Exercise Testing and Autonomic Function in Cardiovascular Disease.” November 30, 2006. The Department of Bioethics, invited guest lecturer, “Contemporary Ethical Issues in Biomedical Authorship: An Editor’s Perspective.” Cleveland Clinic. December 5, 2006. Cerebrovascular Research invited speaker. “Introduction to Diagnostic Tests.” December 14, 2006. 2007 Cleveland Clinic, Division of Medicine Grand Rounds Speaker. “Cardiovascular Medicine Department Update.” January 4, 2007. MetroHealth Heart & Vascular Center Grand Rounds, invited speaker, “Ethical Issues in Biomedical Authorship, January 10, 2007. Invited Clinical Trials Course Speaker (with Drs. Gerald Beck and A. Michael Lincoff) – Cleveland Clinic. “Authorship and Clinical Trials.” January 11, 2007. Framingham Heart Study, Invited speaker, “Advances in Exercise Testing,” Framingham, MA. February 8, 2007. Planning and Implementation of Performance Management Systems in Healthcare Organizations, Weatherhead Executive Education, Weatherhead School of Management, Case Western Reserve University. March 9, 2007.
  • 27.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 27 Keynote Speaker, Cleveland Clinic Lerner College of Medicine, March 22, 2007. Invited Speaker and Faculty Member – American College of Physicians, “Meet the Professor Courses,” and “Noninvasive Testing for Coronary Artery Disease.” San Diego, CA April 19, 2007. ACC 56th Annual Scientific Session – invited speaker and faculty. Four talks: “How to Get Your Paper Published,” “Screening for Coronary Artery Disease in High-risk Asymptomatic Patients,” “Modern Exercise Testing Interpretation: An Oxymoron,” and “Meet Your Medical Editors.” March 24-27, 2007 Invited “Noon Conference” Speaker – Internal Medicine, Cleveland Clinic. “Update on Stress Testing – Exercise Treadmill Testing.” April 23, 2007. Various radio and television interviews, HealthNews, Heart Advisor, BBC. Fox, The Heart.Org., Cleveland Clinic ACC Think Tank on Cardiovascular Imaging, presentation on new research paradigms, Tyson’s Corner, VA, October, 2007 Invited plenary session comment on CORE-64 Trial, American Heart Association Scientific Sessions, November 4, 2007, Orlando, FL 2008 (selected) “Data Primarily Collected for New Insights.” February 28, 2008 Institute of Medicine Roundtable on Evidence-Based Medicine Washington, DC Washington Business & Health CEO Summit in conjunction with the University of Washington, Seattle, WA, March 26, 2008. “Prevention of Coronary Artery Disease.” Visiting Professor, Duke University and Duke Clinical Research Institute, Durham, NC, April 13-15, 2008. Three lectures: “Evidence-Based Overview of Noninvasive Cardiac Testing,” “Novel Statistical Approaches for Analyzing Large Databases,” and “Ethics of Biomedical Authorship” Visiting Professor, Boston University, Boston, MA, May 21-22,
  • 28.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 28 2008. “Evidence-Based Overview of Noninvasive Cardiac Testing.” Baaken Heart-Brain Summit, Cleveland Clinic, Cleveland, OH, June 3, 2008. “Vagal Tone and Outcomes in Patients with Cardiovascular Disease.” NIH OBSSR Summer Course in Clinical Trials, Airlie, VA. July 16, 2008. Featured lecture: “Ethical Issues in Biomedical Authorship and Peer Review.” Ancel Keys Memorial Lecture of the American Heart Association, New Orlean, LA, November 10, 2008. “Discarding Logic.” 2009 (selected) Visiting Professor, Indiana University, Indianapolis, Indianna. February 3, 2009. “A Research Agenda for Cardiovascular Disease: Crossroads of Evidence and Public Policy.” Cleveland Clinic Cardiovascular Summit, Cleveland, Ohio. June 3, 2009. Two lectures: “Does Non-invasive Imaging Prevent Death,” and “Does Exercise Help Patients with Heart Failure?” NIH OBSSR Summer Course in Clinical Trials, Airlie, VA. July 16, 2008. Featured lecture: “Ethical Issues in Biomedical Authorship and Peer Review.” American Heart Association Basic Science Conference, July 21, 2009, Las Vegas, NV. “NHLBI Research Funding and Update on Priorities.” Visiting Professor, Christiana Medical Center, July 22, 2009, Newark, DE. “Reflections on Comparative Effectiveness.” World Hemophilia Federation, September 24, 2009, Montreal, Quebec, Canada. “Economics and Comparative Effectiveness: Threats to Care?” Invited Lecturer, Institute of Medicine Forum on Drug Discovery, Development, and Translation, Transforming Clinical Trials in the United States, October 7, 2009, Washington, DC. “Clinical Research in Acute and Chronic Life-threatening Conditions: A Government Perspective.”
  • 29.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 29 Visiting Professor, Henry Ford Hospital, October 13, 2009, Detroit, MI. “Reflections on Comparative Effectiveness.” Invited Lecturer, Personalized Medicine Coalition and the National Pharmaceutical Council, October 28, 2009, Arlington, VA. “Thoughts about Personalized Medicine and Comparative Effectiveness Research.” American Association of Medical Colleges Convention, November 9, 2009, Boston, MA. “Comparative Effectiveness: Views from the National Institutes of Health.” Moderator, Plenary Session, American Heart Association Annual Scientific Sessions, November 16, 2009, Orlando, FLA. “The Challenges of Imaging Wisely and Responsibly.” Sixth Annual Global Cardiovascular Clinical Trialists’ Forum, December 2-5, 2009, Paris, France, and Luxembourg City, Luxembourg. Two talks: “Comparative Effectiveness Research and Pragmatic Trials,” and “Nonindustry Sponsored Trials and the Role of NHLBI and EU Public Institutions.” US Critical Illness and Clinical Trials Group, December 9, 2009, Bethesda, MD. “Comparative Effectiveness Research: NIH Perspectives.” 2010 (selected) NCI ARRA Comparative Effectiveness Symposium, January 5, 2010, Bethesda, MD. “The 2010 NIH Vision for Comparative Effectiveness Research.” Invited Guest Lecturer, Centers for Medicare and Medicaid Services, January 13, 2010, Baltimore, MD. “Evidence- Development: Perspectives from the NIH” Visiting Professor, Massachusetts General Hospital, March 3, 2010, Boston, MA. “Comparative Effectiveness Research One Year Later.” Keynote Speaker, 3rd Annual NIH Conference on Dissemination and Implementation Research, March 15, 2010, Bethesda, MD. “Where Does Comparative Effectiveness Research Fit in the Domains of Dissemination and Implementation.”
  • 30.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 30 Invited Speaker, American College of Cardiology Annual Sessions, March 16, 2010, Atlanta, GA. “Cardiovascular Risk in Asymptomatic Adults, Use of Noninvasive Tests, ECG, IMT, CAC.” Invited Meet-the-Expert Speaker, American College of Physicians Annual Meeting, April 23, 2010, Toronto, Ontario, Canada. “Noninvasive Cardiac Imaging, Which Test for Which Patient?” Invited Panelist, University of Pennsylvania R13 Special Conference, April 27, 2010, Philadelphia, PA. “Statistical Issues in Comparative Effectiveness Research.” Keynote Speaker, Delaware Health Alliance Annual Meeting, May 4, 2010, Newark, DE. “Comparative Effectiveness Research: One Year Later.” Invited Symposium Speaker, American Thoracic Society Annual Scientific Meeting, May 17, 2010, New Orleans, LA. “Comparative Effectiveness Research at NHLBI: Opportunities and Challenges.” Sharma Visiting Professor, Mt Sinai Medical Center Cardiovascular Institute, May 24, 2010, New York City, NY. Invited Speaker, NHLBI Public Interest Organizations Annual Meeting, May 25, 2010, Bethesda, MD. “Cardiovascular Highlights from the American Recovery and Reinvestment Act.” Invited Speaker for Highlighted Symposium, American College of Sports Medicine Annual Scientific Meeting, June 3, 2010, Baltimore, MD. “Autonomic Function and Outcomes in Patients with Cardiovascular Disease.” Invited Speaker for Symposium, American Health Insurance Plans Institute Annual Meeting, June 10, 2010, Las Vegas, NV. “Using Science to Improve the Nation’s Health System: The Case of Comparative Effectiveness Research.” Invited Speaker for Lewin Group Symposium on Responding to the National Comparative Effectiveness Research Agenda: Evolving Data Sources and Analytics, June 15, 2010, Washington, DC. “What are the Limits of Randomized Clinical Trials: Then What?”
  • 31.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 31 Invited Speaker and Panelist for National Pharmaceutical Council on Shaping Convergent Strategies for Comparative Effectiveness Research, June 24, 2010, Washington, DC. “The Patient-Centered Outcomes Research Institute (PCORI).” Invited Speaker for NHLBI Workshop on Comparative Effectiveness, July 13, 2010, Bethesda, MD. “Comparative Effectiveness Research at NHLBI: Opportunities and Challenges.” Invited Speaker, Market Access World, October 6, 2010, Washington DC. “How is the stimulus being invested by NIH – Timelines, Implemention, Pathway, Structure?” Invited Keynote Speaker, American Geriatric Society CER conference, November 2, 2010, Bethesda, MD. Invited Speaker, CBI 4th Annual CER Summit, Thursday, November 18, 2010, Philadephia, PA. Invited Keynote Speaker, NIH CTSA Consortium CER Symposium, December 1, 2010, Bethesda, MD. “How Can CTSAs and External Partners Collaborate to Support a National CER Agenda?” Invited Visiting Professor and Grand Rounds Speaker, Cleveland Clinic Heart and Vascular Institute, December 3, 2010, Cleveland, OH. “Cardiovascular Comparative Effectiveness Research in the Era of Health Care Reform.” Invited Speaker, Heart Rhythm Society Research Meeting, December 15, 2010, Washington, DC. Grand Rounds Speaker and Visiting Professor, George Washington University Department of Cardiology, December 16, 2010, Washington, DC. “A Philosophy of Non-Invasive Diagnostic Testing” Grand Rounds Speaker, George Washington University Department of Medicine, December 17, 2010, Washington, DC. “Comparative Effectiveness Research: Two Years Later.” 2011 (selected) Invited Plenary Speaker, International Society for Cardiac Magnetic Resonance, February 4, 2011, Nice, France.
  • 32.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 32 “Cardiovascular Imaging: Why Randomized Trials are Needed.” Invited Grand Rounds Speaker and Visiting Professor, Oregon Health Sciences University, February 8, 2011, Portland Oregon. Two lectures, one on “Ethics in Authorship and Peer Review” and one on “The Case for Comparative Effectiveness Research.” Invited Speaker and Visiting Professor, Rockefeller University, February 16, 2011, New York, NY. “The Case for Comparative Effectiveness Research.” Invited Speaker, Late Phase Drug Development Symposium, March 23, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Speaker, American Occupational Health Conference, March 29, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Speaker, American College of Cardiology, April 3, 2011, New Orleans, LA. “What Parameters Should be Used to Assess Improved Patient Outcomes of Cardiovascular Imaging?” Invited Speaker, NHLBI WHI Investigators Meeting, May 5, 2011, Seattle, WA. “The Case for Comparative Effectiveness Research.” Invited Speaker, Harvard Medical School Post-Approval Summit, May 11, 2011, Boston, MA. “The Case for Comparative Effectiveness Research.” Invited Grand Rounds Speaker, Indiana University Krannert Institute, May 31, 2011, Indianapolis, IN. “The Economics of Cardiovascular Research.” Invited Speaker, NCCAM Advisory Council Meeting, June 3, 2011, Bethesda, MD. “The Case for Comparative Effectiveness Research.” Invited Speaker, Drug Information Association (DIA) Meeting, June 20, 2011, Chicago, IL. “Comparative Effectiveness and Health Technology Assessment: How NIH is Addressing the Challenge.” Invited Speaker, National Health Leadership Council Forum and National Business Coalition on Health, June 22, 2011,
  • 33.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 33 Minneapolis, MN. “Science for the Benefit of the Nation’s Health Care: The Case for Comparative Effectiveness Research.” Invited Speaker, North American Conference of Epidemiology, June 23, 2011, Montreal, Quebec, CA. “NIH Perspective: Observations (on Observations) and Experiments.” Invited Speaker, National Institute on Minority and Health Disparities, Special Course on Integrating Principles of Science, Practice, and Policy in Health Disparities Research, June 29, 2011, Bethesda, MD. “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited speaker, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, July 6, 2011, White Oak, MD. “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited speaker, NHLBI Workshop on Heart Failure Prevention, July 14, 2011, Bethesda, MD. “NHLBI Perspective: Thoughts about Inputs and Outputs.” Invited speaker, Center for Medical Technology and Policy (CMTP) CER Institute, July 25, 2011, Santa Fe, NM. “Comparative Effectiveness Research: Federal NIH Perspectives on Science, Practice, and Policy.” Invited speaker, NHLBI Office of Administrate Management Seminar Series presentation, August 17, 2011, Bethesda, MD. “What’s the Story Behind the Explosion of Diagnostic Tests and Imaging?” Invited Keynote speaker, American Heart Association Pharmaceutical Roundtable Outcomes Center Steering Committee Annual Meeting, September 12, 2011, Palo Alto, CA. “Cardiovascular Outcomes Research: Going Forward.” Invited speaker, CBI 14th Registries and Post-Approval Studies Congress, September 21, 2011, Philadelphia, PA. “NIH Address: Advancing Comparative Effectiveness Research through the Patient-Centered Outcomes Research Institute (PCORI).” Visiting Professor and invited speaker for Medical Grand Rounds, University of Wisconsin, September 23, 2011, Madison, WI.
  • 34.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 34 “Comparative Effectiveness Research: Implications for Science, Practice, and Policy.” Invited guest speaker, National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) Advisory Council Meeting, September 27, 2011, Bethesda, MD. “Science to Improve the Nation’s Health Care: The Case for Comparative Effectiveness Research.” Invited Keynote speaker, Market Access World USA 2011, October 5, 2011, Washington DC. “Comparative Effectiveness Research: Updates from the NIH.” Invited speaker, Duke University Think Tank on Rescuing Clinical Trials, October 6, 2011, Tysons Corner, VA. “Patient and Physician Perceptions on Clinical Research and Trials,” and “NIH and VA investment in funding trials and funding research networks: is it helping, and is it paying off?” Invited Keynote speaker, 3rd Annual CER Summit, October 12, 2011, Washington DC. “The Role of the NIH in Comparative Effectiveness Research.” Invited speaker, Institute of Medicine Forum on Drug Discovery, November 7, 2011, Washington DC. “Developing a Robust Clinical Trials Workforce.” Invited speaker and Distinguished Visiting Professor, Cedars-Sinai Heart Institute (UCLA), November 8, 2011, Los Angeles, CA. “The Case for Comparative Effectiveness Research.” Invited speaker, American College of Cardiology Cardiovascular Symposium, November 13, 2011, Orlando, Fla. “Comparative Effectiveness in Heart Failure: Are Randomized Trials Necessary?” Invited guest speaker, FAES Public Health, November 16, 2011, Bethesda, MD. “The Case for Comparative Effectiveness Research.” Invited speaker, NIH Centers for Population Health and Health Disparities, November 29, 2011, Bethesda, MD. “Biomedical Research: How Do We Know We are on Track?” Invited speaker, Global Cardiovascular Clinical Trialists Forum,
  • 35.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 35 December 5, 2011, Paris, France. “New Designs and Paradigms for Large Simple Trials.” Invited speaker, Gilbert Beebe Symposium on Tracking Radiation Exposure from Medical Diagnostic Procedures, National Academies of Science, December 8, 2011, Washington, DC. “The Physician’s Perspective on What to Report.” 2012 (selected) Invited speaker, Health Sector Management Program of the Fuqua School of Business and Duke University, January 11, 2012, Bethesda, MD. “Biomedical Research: How Do We Know we are on Track?” Invited speaker and Visiting Professor, Cleveland MetroHealth Cardiology Grand Rounds, February 1, 2012, Cleveland, OH. “National Policy Issues Surrounding Comparative Effectiveness Research.” Invited speaker, Cleveland MetroHealth Medical Grand Rounds, February 2, 2012, Cleveland, OH. “Evaluation and Screening of Asymptomatic People.” Invited speaker and Visiting Professor, Yale University School of Medicine Cardiology Grand Rounds, February 7, 2012, New Haven, CT. “Cardiovascular Outcomes Research Going Forward.” Invited speaker, Cleveland Clinic Medical Grand Rounds, February 23, 2012, Cleveland, OH. “A National Agenda for Comparative Effectiveness Research: PCORI and Beyond.” Keynote speaker, Washington University Symposium on Comparative Effectiveness and Shared Decision Making, March 13, 2012, St. Louis, MO. “Challenges and Successes in CER Implementation: Examples from Pragmatic Trials.” Invited speaker for cardiovascular symposium, American College of Cardiology, March 25, 2012, Chicago, IL. “The Year in Review: Diagnostic Testing.” Invited speaker, American College of Cardiology, March 25, 2012, Chicago, IL. “Risk Stratification: Looking Beyond the ECG During Stress Testing.”
  • 36.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 36 Invited speaker, ExL Pharma Symposium, April 2, 2012, Washington, DC. “NIH’s Expectations for Using CER Evidence for Commercialization.” Invited speaker, University of Missouri at Kansas City, April 17, 2012, Kansas City, MO. “A National Agenda for Comparative Effectiveness Research: PCORI and Beyond.” Keynote Speaker, Cardiovascular Molecular Imaging Symposium, Society of Nuclear Medicine, April 19, 2012, Bethesda, MD. “Comparative Effectiveness: Where Does Molecular Imaging Fit in Relation to Biomarkers?” Invited speaker, Inova Summit, April 27, 2012, Tysons Corner, VA. “Appropriateness of Imaging: The Use and Abuse of Noninvasive Imaging.” Invited speaker, Christiana Care’s Value Symposium, April 30, 2012, Newark, DE. “Creating Value Through Science.” Invited speaker, Institute of Medicine Clinical Effectiveness Research Innovation Collaborative of the IOM Roundtable on Value and Science-Driven Health Care, May 8, 2012, Washington, DC. “Implications of the Digital Infrastructure for Clinical Research: Simplified Trial Design.” Invited Plenary Speaker, International Research Congress on Integrative Medicine and Health, May 17, 2012, Portland, OR. “Comparative Effectiveness Research: Implications for Practice and Policy.” Keynote Speaker, Cardiovascular Research Roadmap Symposium, Ohio State University, June 1, 2012, Columbus, OH. “Biomedical Research: How Do We Know We are on Track?” Invited speaker, Cardiac Safety Research Consortium Thinktank, FDA, June 4, 2012, White Oak, MD. “Efficient Electronic Infrastructure: an NIH View.” Invited speaker, NHLBI Advisory Council, June 13, 2012, Bethesda, MD. “Biomedical Research: How Do We Know We are on Track?” Keynote speaker, Center for Business Intelligence Forum on Investigator-initiated Research Studies and Grants, June 14, 2012,
  • 37.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 37 Philadelphia, PA. “NIH Perspectives on Investigator-Initiated Clinical Research.” Invited speaker, American Society for Echocardiography, July 3, 2012, National Harbor, Maryland. “Comparative Effectiveness Trials for Imaging in Coronary Artery Disease: Is there Evidence?” Invited speaker, NHLBI Division of Intramural Research Grand Rounds, July 2012, Bethesda, MD. “Two Case Studies of Exercise Testing with NIH Patients” Invited Keynote Speaker, 12th Annual NIH OBSSR Summer Institute on Randomized Behavioral Clinical Trials, July 2012, Airlie Conference Center, Warrenton, VA. “Biomedical Research: How Do We Know We Are On Track?” Invited Speaker, New York University School of Medicine Cardiology Grand Rounds, September 7, 2012, New York City, NY. “Biomedical Research: How Do We Know We are on Track?” Invited Speaker, Northwestern University Conference on Path to Improved Risk Stratification in Sudden Cardiac Death, September 2012, Chicago, IL. “Funding Risk Stratification Research – Addressing the Challenges - NIH perspective” Invited speaker, NHLBI Board of External Experts Semi-Annual Meeting, October 10, 2012, Rockville, MD. “Transformative Change in Epidemiology.” Invited Speaker, Cleveland Clinic Foundation Heart Failure Summit, October 17, 2012, Cleveland OH. “Comparative Effectiveness Research in Heart Failure.” Invited Speaker, US Conference on Rare Diseases and Orphan Products, October 22, 2012, Washington, DC. “Comparative Effectiveness Research in Rare Diseases.” Invited Opening Address, NIH Common Fund Health Care Systems Collaboratory Steering Committee Inaugural Meeting, October 26, 2012, Bethesda, MD. “Pragmatic Trials: Back into a Future Disruptive Technology.” Invited Speaker, Summit on Eliminating Health Disparities, November 1, 2012, National Harbor, MD. “NIH Patient Centered Outcomes and Effectiveness Research.”
  • 38.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 38 Invited Keynote Speaker, National Comparative Effectiveness Research Summit, November 5, 2012, Washington, DC. “Current CER Landscape and NIH Activities” Invited Speaker, CBI Conference November 16, 2012, Philadelphia, PA. “Government-Funded Research on Patient- Reported Outcomes.” Invited Opening Speaker, Institute of Medicine Workshop, November 26, 2012, Washington, DC. “A Vision of Large Simple Trials in a Learning Health Care System.” Invited Speaker, Cardiovascular Clinical Trialists Forum, December 3, 2012, Paris, France. “Registries and Post-Market Surveillance as Complements to Randomized Trials.” Invited Speaker, FDA Symposium on Cardiac Safety, December 10, 2012, White Oak, MD. “Current Heuristic Approaches.” Invited Speaker, NHLBI Centers for Cardiovascular Outcomes Research Steering Committee Meeting, December 11, 2012, Arlington, VA. “Large Simple Trials in Learning Health Care Systems.” 2013 (selected) January 28, 2013: Columbia University Dean’s Symposium Keynote-equivalent Presentation on Funding Research in Dynamic and Disruptive Fiscal Times, New York, NY January 29, 2013: DHHS ASPE Invited Presentation on NIH Role in Comparative Effectiveness Research, Humphrey Building, Washington, DC February 7, 2013: DCVS Clinical Trials Group on Our Innovator’s Dilemma, Rockville, MD April 13, 2013: American College of Physicians Annual Scientific Meeting Meet The Professor Symposium sole presenter on Screening for Coronary Artery Disease, San Francisco, CA
  • 39.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 39 April 17, 2013: NHLBI BEE Presentation on Transforming Epidemiology, Rockville, MD May 2, 2013: NIDDK Presentation on Transforming Clinical Trials, Bethesda, MD May 9, 2013: Virtual Symposium on Radiation Safety in Computed Tomography Presentation on Evidence Gap Problem, San Francisco, CA May 9, 2013: Virtual Symposium on Radiation Safety in Computed Tomography Presentation on Problems due to Downstream Procedures, San Francisco, CA May 13, 2013: Clinical Trials Transformation Initiative Presentation on Perspectives on Large, Simple Trials, Rockville, MD July 21, 2013: OBSSR Course on Randomized Trials, Keynote address on “Our Innovator’s Dilemma,” Airlie Conference Center, Warrenton, VA May 15, 2013 (in absentia, talk given by Larry Fine): NHLBI Leadership Retreat Presentation on Map of Implementation Research at NHLBI, Bethesda, MD May 28, 2013: DCVS Journal Club presentation on angioedema, mini-Sentinel June 5, 2013: NCI Brain Tumor Epidemiology Consortium, Keynote address on Transforming Epidemiology, Chicago, IL June 19, 2013: NHLBAC Presentation on Transforming Epidemiology, Bethesda, MD June 19, 2013: NHLBAC Presentation on Guidelines, Bethesda, MD
  • 40.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 40 June 23, 2013: Academy Health Presentation on NHLBI Support of Health Services Research, Baltimore, MD June 27, 2013: National Pharmaceutical Council ISPOR Roundtable on Observational Studies and Guidelines, Washington, DC July 17, 2013: NIH Office of Science Policy Program and Evalaution Committee Presentation on Patient-Centered Outcomes Research Institute (PCORI) activities July 21, 2013: OBSSR Course on Randomized Trials, Keynote address on “Our Innovator’s Dilemma,” Airlie Conference Center, Warrenton, VA July 22, 2013: NHLBI Annual K-awardees Meeting, invited talk on “NHLBI Research: A Vision of the Future,” Natcher Conference Center, Bethesda, MD August 2, 2013: NHLBI Heart Failure Network Strategy Planning Meeting, invited opening talk on “NHLBI Perspectivies: Turn the Curve,” Bethesda, MD August 20, 2013: Stanford University School of Medicine Cardiovascular Grand Rounds on “Economic Perspectives on Government-Sponsored Research,” Palo Alto, CA August 21, 2013: Stanford University School of Medicine Department of Medicine Grand Rounds on “Transforming Clinical Trials in an Era of Big Data and Small Budgets,” Palo Alto, CA November 5, 2013: Invited Faculty, NIH PBHL 571-NIH Graduate School of Public Health, “The Case for Comparative Effectiveness Research,” Bethesda, MD November 17, 2013: Invited Special Lecture, American Heart Association Annual Scientific Sessions, “A Tribute to Dr. Sonia Skarlatos,” Dallas, TX
  • 41.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 41 November 19, 2013: Invited Speaker, American Heart Association Annual Scientific Sessions, Cardiovascular Seminar CVS.809ic, “Cardiorespiratory Fitness as a Therapeutic Target,” Dallas, TX November 18, 2013: Invited Speaker, American Heart Association Annual Scientific Sessions, Cardiovascular Seminar CVS.213, “Practical Trials in Outcome Science,” Dallas, TX November 21, 2013: Invited Speaker, GenTAC Steering Committee Meeting, “Let Me Tell You Two Stories: Perspectives in a Time of Big Data and Small Budgets,” Bethesda, MD December 6, 2013: Invited Webinar Presentation, NHLBI BEE Council Working Group on Epidemiology and Population Sciences, “Thoughts about NHLBI and Epidemiology: ‘Big Picture’ Fiscal Challenges,” Bethesda, MD 2014 (Selected): February 6, 2014: Invited Speaker and Visiting Professor, University of Pennsylvania Perelman School of Medicine, “Cardiology Grand Rounds: Supporting Biomedical Research – An Economic Perspective,” Philadelphia, PA February 7, 2014: Invited Speaker, NHLBI MESA Steering Committee, “Thoughts about NHLBI and 21st Century Epidemiology – ‘Big Picture’ Challenges,” Washington, DC February 20, 2014: Invited Speaker, ISCTM 10th Annual Meeting, “The Necessity for Clinical Trials Innovation: Making it Work at the National Heart, Lung, and Blood Institute,” Washington, DC March 13, 2014: Invited Speaker, NIH IC Directors’ Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD March 26, 2014: Invited Speaker, White House OMB Roundtable on Exploring the the Use of Low-Cost Randomized Experiments to
  • 42.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 42 Advance Evidence-Based Government, “Rediscovering Low-Cost Randomized Trials in an Era of Big Data and Small Budgets,” Washington, DC March 31, 2014: Invited Speaker, American College of Cardiology session on the Impact of the Evolving Health Landscape on the Academic Mission, “Perspective of the NHLBI,” Washington, DC April 2, 2014: Invited Speaker, Workshop on Innovative Study Designs and Methods for Developing, Testing, and Implementing Behavioral Interventions to Improve Health, “The Need for Creative New Methods in Clinical Research,” Washington, DC April 9, 2014: Invited Speaker, American Society of Hematology Government Affairs Committee, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Washington, DC April 29, 2014: Invited Speaker, Workshop on Pathways to Improved Risk Stratification, “Supporting Biomedical Research in Tough Fiscal Times – Throughts from the NHLBI,” Crystal City, VA May 16, 2014: Invited Speaker for the 4th Shiu Kwong Ho Memorial Lecture at the Beth Israel Deaconess Hospital, “Supporting Biomedical Research in Tough Fiscal Times … Thoughts from the NHLBI,” Boston, MA May 29, 2014: Invited Speaker, NHLBI Workshop on Salt in Human Health and Sickness, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD June 20, 2014: Invited Speaker, NIH Scientific Program and Review Interest Group (SPRIG), “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD June 22, 2014: Invited Plenary Speaker, American Society of Echocardiography, “The Cost of Innovation: NHLBI Perspectives,” Portland, OR
  • 43.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 43 July 11, 2014: Invited Grand Rounds Speaker, NIH Common Fund HCS Collaboratory, “Portfolio Evaluation from the Field – Perspective of the NHLBI,” Bethesda, MD July 28, 2014: Invited presentation at the White House, White House Office of Science and Technology Policy (OSTP) Conference on Low-Cost Randomized Controlled Trials, “Rediscovering Low-Cost Randomized Trials in an Era of Big Data and Small Budgets,” Washington, DC July 29, 2014: Invited Speaker, MCRN Scientific Lead and Investigator Retreat, “Barriers of Clinical Trials in the US to Meet Public Health Needs,” Washington, DC August 19, 2014: Invited Speaker, NIH Common Fund HCS Collaboratory Steering Committee, “The Collaboratory at Age 2: Back to the Future,” Bethesda, MD September 15, 2014: Invited Speaker, American College of Cardiology Legislative Conference, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Washington, DC September 19, 2014: Invited Speaker, Building Industry Government Academic Partnerships Workshop, National Academy of Sciences, “Welcome and Thoughts from the NHLBI,” Washington, DC September 22, 2014: Invited Keynote Address, Southeastern Conference Symposium on Prevention of Obesity, Overcoming a 21st Century Public Health Challenge, “Setting an Agenda for Obesity Prevention – Asking the Right Questions,” Atlanta, GA September 29, 2014: Invited Speaker, NHLBI K Award Investigators’ Meeting, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Bethesda, MD
  • 44.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 44 September 30, 2014: Invited Speaker, NHLBI Arterial Stiffness Grantees Meeting, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Bethesda, MD October 1, 2014: Invited Speaker and Visting Professor, University of Maryland School of Medicine, Medical Grand Rounds, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from the NHLBI,” Baltimore, MD October 7, 2014: Invited Speaker, National Cancer Institute (NCI) Community Oncology Research Program, “Practical Trials in Outcomes Science – Thoughts from the NHLBI,” Rockville, MD October 9, 2014: Invited Speaker, NIH National Children’s Study Review Committee, “Preliminary Test Analyses of Birth Weight in the National Children’s Vanguard Study,” Bethesda, MD October 15, 2014: Invited Speaker, NHLBI Office of Biostatistics Research Seminar, “Perspectives on Portfolio Prediction and Performance,” Bethesda, MD October 20, 2014: Invited Speaker, CSR Advisory Council Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD October 28, 2014: Invited Speaker, NIGMS Seminar, “Portfolio Productivity, Field Stories from NHLBI,” Bethesda, MD October 28, 2014: Invited (Remote) Speaker, Framingham Heart Study Research Conference, “Funding Epidemiology and Population Science in Times of Bigger Data and Smaller Budgets,” Framingham, MA November 4, 2014: Invited Seminar Speaker, NIH FAES Graduate School of Public Health, “The Case for Comparative Effectiveness Research,” Bethesda, MD
  • 45.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 45 November 17, 2014: Invited Plenary Speaker, American Heart Association, “Risk Assessment in Primary Prevention – Future Directions,” Chicago, IL November 17, 2014: Invited Cardiovascular Symposium Speaker, American Heart Association, “NHLBI and Its Role [in the AHA CV GPS Project],” Chicago, IL 2015 (Selected): January 23, 2015: Invited Speaker, NIBIB Advisory Council Meeting, “Perspectives from the NHLBI on Portfolio Prediction and Performance,” Bethesda, MD February 3, 2015: Invited Speaker, NHLBI Pragmatic Trials Grantee Meeting, “A Tale of Two Books (and Some Journal Articles, and a Poem),” Rockville, MD February 11, 2015: Invited Speaker, NIH Workshop on Precision Medicine, “Building a Large US Cohort,” Bethesda, MD March 2, 2015: Keynote Speaker, 25th Anniversay Celebration of the Welch Center, Johns Hopkins University Bloomberg School of Public Health, “The Future of Observational Studies and Clinical Trials,” Baltimore, MD March 4, 2015: Invited Plenary Speaker, American Heart Assocation Epi/Lifestyle Meeting, “eData Sciences and Epidemiology,” Baltimore, MD March 10, 2015: Invited Speaker, Institute of Medicine Roundtable on Translating Genomic-Based Research for Health, “Precision Medicine: NIH Perspectives,” Washington, DC March 19, 2015: Invited Speaker, NHLBI Office of Management Senior Leadership Team, “Developing an Evidence-Based, Data- Driven Culture – Field Stories from DCVS,” Bethesda, MD
  • 46.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 46 March 30, 2015: Invited Speaker, MRCT Conference on Promoting Clinical Trial Data Transparency at the Harvard Faculty Club, “NHLBI Data Repository (BioLINCC),” Cambridge, MA April 1, 2015: Invited Speaker, NIDDK Meeting on Urinary Stone Disease, “Pragmatic Clinical Trials: Databases, Registries, and Electronic Health Records,” Bethesda, MD April 16, 2015: Invited Grand Rounds Speaker, Johns Hopkins University Department of Anesthesiology and Critical Care Medicine, “Supporting Biomedical Research in Tough Fiscal Times – Thoughts from NHLBI,” Baltimore, MD April 27, 2015: Invited Speaker, American Heart Association Data Summit, “NHLBI and NIH Data Repositories – BioLINCC and dbGaP,” Baltimore, MD May 7, 2015: Invited Speaker, Women’s Health Initiative Annual Meeting, “Supporting Clinical Research in Tough Fiscal Times,” Bethesda, MD May 13, 2015: Invited Speaker, NIH Committee on Efficient and Sustainable Funding Policies, “Developing Efficient and Sustainable Funding Policies: An Analysis of the Productivity of NHLBI Cardiovascular Scientists,” Bethesda, MD May 14, 2015: Invited Speaker, NIA Extramural Seminar, “Efficient and Sustainable Funding – Analyses of the Productivity of NHLBI Cardiovascular Scientists,” Bethesda, MD May 20,2015: Invited Keynote Speaker (Founders Lecture), Society for Clinical Trials, “Is There a Future for Clinical Trials?,” Arlington, VA
  • 47.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 47 EDITORIAL WORK: 1994-2000 Associate Editor, Journal Watch in Cardiology, Massachusetts Medical Society 1994- Abstract Grader, American College of Cardiology 1995- Peer Review: New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Lancet, Annals of Internal Medicine, Preventive Medicine, Hypertension, American Journal of Physiology, Journal of General Internal Medicine, Circulation, American Journal of Cardiology, American Heart Journal, American Journal of Medicine, Journal of the American College of Cardiology, Journal of Thoracic and Cardiovascular Surgery, Coronary Artery Disease, American Journal of Gastroenterology, Kidney International 1998 Reviewer for American Medical Informatics Society Annual Symposium 2000- Abstract Grader, American Heart Association 2000-2007 Contributing Editor, Journal of the American Medical Association (JAMA) 2003-2007 Clinical Reviews Editor, Journal of the American Medical Association (JAMA) 2009- Editorial Board, Annals of Internal Medicine 2012- Consulting Editor, Journal of the American College of Cardiology 2013- Consulting Editor, Circulation Research 2015- Consulting Editor, Scientific Data (Nature Publishing Group) ACADEMIC APPOINTMENTS: 1992-1993 Clinical Instructor in Medicine, Harvard Medical School 1995-1998 Clinical Assistant Professor of Medicine in the College of Medicine, Pennsylvania State University 1998-2007 Clinical Associate Professor Medicine in the College of Medicine,
  • 48.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 48 Pennsylvania State University 2000-2007 Director of Clinical Research, Department of Cardiology, Cleveland Clinic Foundation 2003-2007 Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University 2005-2007 Professor of Epidemiology and Biostatistics in the School of Medicine of Case Western Reserve University CLINICAL TRIALS: 1996 Clinical Events and ECG Committee, EPILOG Trial 1996-1999 Clinical Endpoints Committee, ACUTE Trial 1997-1999 Cleveland Clinic Foundation PI, ASSENT II Trial National Steering Committee, GUSTO IV Trial 1997-2002 Associate Chairman, Cleveland Clinic Cardiovascular Coordinating, Center, Electrocardiogram Core Laboratory 2003-2005 Member, DSMB of TAXUS V and TAXUS V ISR Trials GRANT SUPPORT: 1998-2001 Screening for left ventricular dysfunction in asymptomatic, high risk subjects with abbreviated echocardiography: American Heart Association National Grant, David Baker, MD, Principal Investigator, Michael S. Lauer, MD, Consultant. Cleveland Clinic Foundation is receiving $25,000 for core laboratory echocardiography interpretation. 1999-2002 Association of myocardial ischemia as assessed by dobutamine echocardiography with plasma ANP and BNP levels obtained before and after stress: grant from Promotion and Mutual Aid Corporation for Private Schools of Japan and the Kansai Medical University, 2nd Department of Internal Medicine, Osaka, Japan, Hisako Tsuji, MD, and Michael S. Lauer, MD, Principal Investigators. Cleveland Clinic Foundation is receiving $23,000 for recruiting patients and coordinating the project.
  • 49.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 49 2000-2002 Computerized, heart rate adjusted exercise ST-segment analyses and prediction of all-cause mortality. Established Investigator Grant, American Heart Association, Michael S. Lauer, MD, Principal Investigator, approximately $140,000 over three years. 2001-2004 Heart rate recovery and mortality. National Institutes of Health R01HL66004-01, initiating March 1, 2001, $660,000 over three years. 2003-2004 The Association of the Mediwave Ischemic Index with Myocardial Perfusion Abnormalities: A Prospective Pilot Study. $35,000 over one year. 2004-2008 Logical Analysis of Data and Cardiac Surgical Risk. National Institutes of Health R01HL-072771, $1,032,000 over 3-4 years. 2005-2010 PI of Core E (Clinical Research Skills and Development Core) of National Institutes of Health SCCOR grant P50 HL77107 (Eric J. Topol, MD, PI), $500,000 over 5 years for this Core. 2005-2007 American Arthritis Foundation Grant, “Mortality Outcomes in Pediatric Rheumatology” – PI – Philip Hashkes, Consultant. OUTSIDE/COMMUNITY ACTIVITIES: I am actively involved in the Kemp Mill Synagogue, a Modern Orthodox Jewish congregation attending daily minyanim, leading services, and on an occasional basis reading Torah (“leining”) and giving Torah-oriented talks. I completed a 4-year term as a Member of the Beachwood Kehilla Board of Trustees, serving as Recording Secretary. I regularly participate in Torah study, including the daily Daf Yomi program. I enjoy reading books about economics, history, science, and cognitive/organizational psychology.
  • 50.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 50 Bibliography1–305 1. Danthi NS, Wu CO, DiMichele DM, Hoots WK, Lauer MS. Citation Impact of NHLBI R01 Grants Funded Through the American Recovery and Reinvestment Act as Compared to R01 Grants Funded Through a Standard Payline. Circ Res. 2015;116:784–8. 2. Harrington RA, Barac A, Brush JE, Hill JA, Krumholz HM, Lauer MS, Sivaram CA, Taubman MB, Williams JL. COCATS 4 Task Force 15: Training in Cardiovascular Research and Scholarly Activity. J Am Coll Cardiol. 2015;65:1899–906. 3. Lauer MS, Gordon D, Olive M. Matching Taxpayer Funding to Population Health Needs: Not so Simple. Circ Res. 2015;116:1301–3. 4. Lauer MS, Kiley JP, Mockrin SC, Mensah GA, Hoots WK, Patel Y, Cook NL, Patterson AP, Gibbons GH. National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning: Setting an Agenda Together for the NHLBI of 2025. Circulation. 2015;131:1106–9. 5. Sorlie PD, Sholinsky P, Lauer MS. Reinvestment in Government-Funded Research: A Great Way to Share. Circulation. 2015;131:17–8. 6. Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality. J Am Med Inf Assoc. 2014;21:576–577. 7. Danthi N, Wu CO, Shi P, Lauer M. Percentile ranking and citation impact of a large cohort of national heart, lung, and blood institute-funded cardiovascular R01 grants. Circ Res. 2014;114:600–606. 8. Eapen ZJ, Lauer MS, Temple RJ. The imperative of overcoming barriers to the conduct of large, simple trials. JAMA. 2014;311:1397–1398. 9. Kaltman JR, Evans FJ, Danthi NS, Wu CO, DiMichele DM, Lauer MS. Prior publication productivity, grant percentile ranking, and topic-normalized citation impact of NHLBI cardiovascular R01 grants. Circ Res. 2014;115:617–24. 10. Lauer MS. Personal reflections on big science, small science, or the right mix. Circ Res. 2014;114:1080–1082. 11. Lauer MS. Investing in clinical science: make way for (not-so-uncommon) outliers. Ann Intern Med. 2014;160:651–652. 12. Lauer MS, Bonds D. Eliminating the “expensive” adjective for clinical trials. Am Hear J. 2014;167:419–420. 13. Lauer MS. Commentary on Vickers. Clin Trials. 2014;11:622–623.
  • 51.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 51 14. Lauer MS. Time to bring the “electrocardio-ome” into modern cardiovascular epidemiology? J Am Coll Cardiol. 2014;64:907–909. 15. Gordon DJ, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2014;370:782. 16. Lauer MS. The basic science that is epidemiology. JACC Cardiovasc Imaging. 2014;7:879–881. 17. Witt CM, Rafferty Withers S, Grant S, Lauer MS, Tunis S, Berman BM. What can comparative effectiveness research contribute to integrative health in international perspective? J Altern Complement Med. 2014;20:874–880. 18. Dubois RW, Lauer M, Perfetto E. When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. J Compar Eff Res. 2013;2:383–391. 19. Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2013;62:1396–8. 20. Gordon D, Taddei-Peters W, Mascette A, Antman M, Kaufmann PG, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2013;369:1926–1934. 21. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013;22:508–516. 22. Lauer MS. Rigorous science as the road to better public health. Popul Heal Metr. 2013;11:10. 23. Lauer MS, D’Agostino Sr. RB. The randomized registry trial--the next disruptive technology in clinical research? N Engl J Med. 2013;369:1579–1581. 24. Pearson GD, Kaltman JR, Lauer MS. Evidence-based medicine comes of age in pediatric cardiology. J Am Coll Cardiol. 2013;61:2565–7. 25. Sorlie PD, Bild DE, Lauer MS. Cardiovascular Epidemiology in a Changing World- Challenges to Investigators and the National Heart, Lung, and Blood Institute. Am J Epidemiol. 2012;175:597–601.
  • 52.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 52 26. Blajchman MA, Carson JL, Eikelboom JW, Heddle NM, Lacroix J, Lauer MS, Platt R, Tilley B, Triulzi D, Vickers AJ, Yusuf S, Glynn S, Mondoro TH, Wagner E. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 2012;52:1363–1378. 27. Galis ZS, Hoots WK, Kiley JP, Lauer MS. On the value of portfolio diversity in heart, lung, and blood research. Am J Respir Crit Care Med. 2012;186:575–578. 28. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby J V, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2012;60:569–580. 29. Lauer MS. Lemons for Obesity. Ann Intern Med. 2012; 30. Lauer MS. Responses to commentaries. Stat Med. 2012; 31. Lauer MS. A policy for science. J Am Coll Cardiol. 2012;59:2154–2156. 32. Lauer MS. Advancing Cardiovascular Research. Chest. 2012;141:500–505. 33. Lauer MS. From hot hands to declining effects: the risks of small numbers. J Am Coll Cardiol. 2012;60:72–74. 34. Lauer MS. And what about exercise? Fitness and risk of death in “low-risk” adults. J Am Hear Assoc. 2012;1:e003228. 35. Lauer MS. Time for a creative transformation of epidemiology in the United States. JAMA. 2012;308:1804–1805. 36. Lauer MS. Commentary: How the debate about comparative effectiveness research should impact the future of clinical trials. Stat Med. 2012;31:3051–3053. 37. Pattakos G, Koch CG, Brizzio ME, Batizy LH, Sabik JF, Blackstone EH, Lauer MS. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med. 2012;172:1154–1160. 38. Schwartz S, Lauer M, McNeil B, Tunis S, Diamond G, Silber J, Herzig A, Temple B, Lee J, Rhodes K, Morton S, Rotelli M. Panel discussion 1. Clin Trials. 2012;9:13–21. 39. Lauer MS. Advancing the paradigm for cardiovascular imaging research. J Nucl Cardiol. 2012;19:5–8.
  • 53.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 53 40. Cook NL, Lauer MS. The socio-geography of heart failure: why it matters. Circ Hear Fail. 2011;4:244–245. 41. Gorodeski EZ, Ishwaran H, Kogalur UB, Blackstone EH, Hsich E, Zhang ZM, Vitolins MZ, Manson JE, Curb JD, Martin LW, Prineas RJ, Lauer MS. Use of Hundreds of Electrocardiographic Biomarkers for Prediction of Mortality in Postmenopausal Women The Women’s Health Initiative. Circ Qual Outcomes. 2011;4:521–532. 42. Hattori N, Carrino DA, Lauer ME, Vasanji A, Wylie JD, Nelson CM, Apte SS. Pericellular versican regulates the fibroblast-myofibroblast transition: a role for ADAMTS5 protease-mediated proteolysis. J Biol Chem. 2011;286:34298–34310. 43. Hsich E, Gorodeski EZ, Blackstone EH, Ishwaran H, Lauer MS. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes. 2011;4:39–45. 44. Lauer MS. Cardiovascular Science in the Service of National Strength. Jama-Journal Am Med Assoc. 2011;306:2145–2146. 45. Lauer MS. Advancing the paradigm for cardiovascular imaging research. J Nucl Cardiol. 2011; 46. Lauer MS. What Now With Screening Electrocardiography? Ann Intern Med. 2011;155:395–397. 47. Lauer MS. How will exercise capacity gain enough respect? Circulation. 2011;123:1364– 1366. 48. Lauer MS. Thought exercises on accountability and performance measures at the National Heart, Lung, and Blood Institute (NHLBI): an invited commentary for circulation research. Circ Res. 2011;108:405–409. 49. Lauer MS. Commentary: Will academia embrace comparative effectiveness research? Acad Med. 2011;86:671–673. 50. Lauer MS. Heart rate recovery: what now? J Intern Med. 2011;270:597–599. 51. Lauer MS. Pseudodisease, the Next Great Epidemic in Coronary Atherosclerosis? Arch Intern Med. 2011;171:1268–1269. 52. Lauer MS. Pseudodisease, the next great epidemic in coronary atherosclerosis?: comment on “Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.” Arch Intern Med. 2011;171:1268–1269.
  • 54.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 54 53. Lauer MS, Hodes R. Epidemiology, Comparative Effectiveness Research, and the National Institutes of Health Forces for Health. Epidemiology. 2011;22:625–628. 54. Rader F, Costantini O, Jarrett C, Gorodeski EZ, Lauer MS, Blackstone EH. Quantitative electrocardiography for predicting postoperative atrial fibrillation after cardiac surgery. J Electrocardiol. 2011;44:761–767. 55. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL. Survival Rates of Children With Acute Lymphoblastic Leukemia Presenting to a Pediatric Rheumatologist in the United States. J Pediatr Hematol Oncol. 2011;33:424–428. 56. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr. SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748–2764. 57. Ishwaran H, Kogalur UB, Gorodeski EZ, Minn AJ, Lauer MS. High-dimensional variable selection for survival data. J Am Stat Assoc. 2010;105:205–217. 58. Lauer MS. The historical and moral imperatives of comparative effectiveness research. Stat Med. 2010;29:1982–1987. 59. Lauer MS. National Heart, Lung, and Blood Institute and the American Recovery and Reinvestment Act of 2009: 1 year later. J Am Coll Cardiol. 2010;56:234–236. 60. Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol. 2010;56:106–108. 61. Lauer MS, Collins FS. Using science to improve the nation’s health system: NIH's commitment to comparative effectiveness research. JAMA. 2010;303:2182–2183. 62. Lauer MS, Skarlatos S. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community. Circulation. 2010;121:929–933. 63. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond. Circulation. 2010;
  • 55.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 55 64. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Jacobs AK, Kaul S, Moliterno DJ, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121:2509–2543. 65. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr. SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584–636. 66. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, Bowyer SL. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62:599– 608. 67. Lauer MS. Risk stratification for sudden cardiac death: a puzzle beyond p values. J Am Coll Cardiol. 2010;56:1484–1485. 68. Bild DE, Lauer MS. How one program at the National Heart, Lung, and Blood Institute establishes its scientific priorities. J Am Coll Cardiol. 2009;53:2259–2261. 69. Douglas PS, Taylor A, Bild D, Bonow R, Greenland P, Lauer M, Peacock F, Udelson J. Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. Circ Cardiovasc Imaging. 2009;2:339–348. 70. Gorodeski EZ, Cantillon DJ, Goel SS, Kaufman ES, Martin DO, Hsich EM, Blackstone EH, Lauer MS. Microvolt T-wave alternans, peak oxygen consumption, and outcome in patients with severely impaired left ventricular systolic function. J Hear Lung Transpl. 2009;28:689–696. 71. Gorodeski EZ, Ishwaran H, Blackstone EH, Lauer MS. Quantitative electrocardiographic measures and long-term mortality in exercise test patients with clinically normal resting electrocardiograms. Am Hear J. 2009;158:61–70 e1. 72. Hsich E, Gorodeski EZ, Starling RC, Blackstone EH, Ishwaran H, Lauer MS. Importance of treadmill exercise time as an initial prognostic screening tool in patients with systolic left ventricular dysfunction. Circulation. 2009;119:3189–3197. 73. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ,
  • 56.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 56 Collins FS, Croyle RT, Davis BR, Downing GJ, Duross A, Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH, Greenland P, Gulcher JR, Hsu A, Hudson KL, Kardia SL, Kimmel PL, Lauer MS, Miller AM, Offit K, Ransohoff DF, Roberts JS, Rasooly RS, Stefansson K, Terry SF, Teutsch SM, Trepanier A, Wanke KL, Witte JS, Xu J. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med. 2009;11:559–567. 74. Lauer MS. CT angiography: first things first. Circ Cardiovasc Imaging. 2009;2:1–3. 75. Lauer MS. Elements of danger--the case of medical imaging. N Engl J Med. 2009;361:841–843. 76. Lauer MS. Discarding logic: 2008 Ancel Keys Memorial Lecture. Circulation. 2009;119:1533–1537. 77. Lauer MS. Autonomic function and prognosis. Cleve Clin J Med. 2009;76 Suppl 2:S18– 22. 78. Lauer MS. Comparative effectiveness research: the view from the NHLBI. J Am Coll Cardiol. 2009;53:1084–1086. 79. Lauer MS, Skarlatos SI, Bild DE. The Extramural Division of Cardiovascular Sciences of the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2009;54:265–268. 80. Lauer MS, Sorlie P. Alcohol, cardiovascular disease, and cancer: treat with caution. J Natl Cancer Inst. 2009;101:282–283. 81. Nabel EG, Lauer MS. The cardiovascular programs of the National Heart, Lung, and Blood Institute: from vision to action to impact. J Am Coll Cardiol. 2009;53:1082–1083. 82. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, Kapadia SR, Lauer MS, Topol EJ. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2009;2:46– 53. 83. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP. American Heart Association/american College of Cardiology Foundation/heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the America. Hear Rhythm. 2008;5:e1– 21.
  • 57.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 57 84. Adams BJ, Carr JG, Ozonoff A, Lauer MS, Balady GJ. Effect of exercise training in supervised cardiac rehabilitation programs on prognostic variables from the exercise tolerance test. Am J Cardiol. 2008;101:1403–1407. 85. Aronow HD, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, Houghtaling PL, Granger CB, Harrington RA, Van de Werf F, Topol EJ, Lauer MS. Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008;102:1119–1124. 86. Lauer MS. Review: 64-slice computed tomography coronary angiography accurately diagnoses coronary artery disease. ACP J Club. 2008;149:13. 87. Myerburg RJ, Chaitman BR, Ewy GA, Lauer MS. Task force 2: training in electrocardiography, ambulatory electrocardiography, and exercise testing. J Am Coll Cardiol. 2008;51:348–354. 88. Peterson PN, Magid DJ, Ross C, Ho PM, Rumsfeld JS, Lauer MS, Lyons EE, Smith SS, Masoudi FA. Association of exercise capacity on treadmill with future cardiac events in patients referred for exercise testing. Arch Intern Med. 2008;168:174–179. 89. Shishehbor MH, Oliveira LP, Lauer MS, Sprecher DL, Wolski K, Cho L, Hoogwerf BJ, Hazen SL. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol. 2008;101:1741–1746. 90. Ho PM, Rumsfeld JS, Peterson PN, Masoudi FA, Strunk A, Ross C, Lyons EE, Smith SS, Lauer MS, Magid DJ. Chest pain on exercise treadmill test predicts future cardiac hospitalizations. Clin Cardiol. 2007;30:505–510. 91. Hsich E, Chadalavada S, Krishnaswamy G, Starling RC, Pothier CE, Blackstone EH, Lauer MS. Long-term prognostic value of peak oxygen consumption in women versus men with heart failure and severely impaired left ventricular systolic function. Am J Cardiol. 2007;100:291–295. 92. Kim ES, Ishwaran H, Blackstone E, Lauer MS. External prognostic validations and comparisons of age- and gender-adjusted exercise capacity predictions. J Am Coll Cardiol. 2007;50:1867–1875. 93. Koch CG, Li L, Lauer M, Sabik J, Starr NJ, Blackstone EH. Effect of functional health- related quality of life on long-term survival after cardiac surgery. Circulation. 2007;115:692–699. 94. Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297:1376–1378. 95. Lauer MS. Choosing the right coronary test. Cleve Clin J Med. 2007;74:122.
  • 58.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 58 96. Lauer MS. What is the best test for a patient with classic angina? Cleve Clin J Med. 2007;74:123–126. 97. Lauer MS. Cardiovascular medicine update 2007: perioperative risk, carotid angioplasty, drug-eluting stents, stronger statins. Cleve Clin J Med. 2007;74:505–511. 98. Lauer MS. Screening for coronary heart disease: has the time for universal imaging arrived? Cleve Clin J Med. 2007;74:645–650,653–654,656. 99. Lauer MS, Blackstone EH. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine, 3rd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2007. p. 756(e). 100. Lauer MS, Martino D, Ishwaran H, Blackstone EH. Quantitative measures of electrocardiographic left ventricular mass, conduction, and repolarization, and long-term survival after coronary artery bypass grafting. Circulation. 2007;116:888–893. 101. Lauer MS, Murthy SC, Blackstone EH, Okereke IC, Rice TW. [18F]Fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: impact of verification bias. Arch Intern Med. 2007;167:161–165. 102. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med. 2007;147:821– 828. 103. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM, Blackstone EH, Lytle BW. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. 2007;49:2191– 2201. 104. Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, Moliterno DJ, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit- only stenting? J Am Coll Cardiol. 2007;49:849–854. 105. Thambidorai SK, Jaffer SJ, Shah TK, Stewart WJ, Klein AL, Lauer MS. Association of atheroma as assessed by intraoperative transoesophageal echocardiography with long-term mortality in patients undergoing cardiac surgery. Eur Hear J. 2007;28:1454–1461. 106. Westerhout CM, Lauer MS, James S, Fu Y, Wallentin L, Armstrong PW. Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. Eur Hear J. 2007;28:2064–2069.
  • 59.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 59 107. Yamada H, Tabata T, Jaffer SJ, Drinko JK, Jasper SE, Lauer MS, Thomas JD, Klein AL. Clinical features of mixed physiology of constriction and restriction: echocardiographic characteristics and clinical outcome. Eur J Echocardiogr. 2007;8:185–194. 108. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Cl. J Am Coll Cardiol. 2007;49:378–402. 109. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Harrington RA, Abrams J, Anderson JL, Bates ER, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks Jr. SJ, Stein JH, Tracy CM, Vogel RA, Wesley DJ. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Cl. Circulation. 2007;115:402–426. 110. Bis KG, Shetty AN, Brewington S, Arpasi P, Kosuri R, Stein W, Lauer M, O’Neill W. Coronary 64-slice computed tomographic angiography models employing aortic root and selective catheter directed contrast enhancement in swine: technical feasibility and preliminary results using 3D and 4D reconstructions. Int J Cardiovasc Imaging. 2006;22:517–531. 111. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Hear J. 2006;27:413–418. 112. Heerey A, Lauer M, Alsolaiman F, Czerr J, James K. Cost effectiveness of biventricular pacemakers in heart failure patients. Am J Cardiovasc Drugs. 2006;6:129–137. 113. Kligfield P, Lauer MS. Exercise electrocardiogram testing: beyond the ST segment. Circulation. 2006;114:2070–2082. 114. Latif AA, Almahameed A, Lauer MS. Should we screen for abdominal aortic aneurysms? Cleve Clin J Med. 2006;73:9–10, 13, 16–7 passim. 115. Lauer MS. Believability of clinical trials: a diagnostic testing perspective. J Thorac Cardiovasc Surg. 2006;132:249–251. 116. Lauer MS, Ellis S. Is routine functional testing after coronary bypass surgery worthwhile? J Invasive Cardiol. 2006;18:153–154.
  • 60.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 60 117. Lauer MS, Pothier CE, Chernyak YB, Brunken R, Lieber M, Apperson-Hansen C, Starobin JM. Exercise-induced QT/R-R-interval hysteresis as a predictor of myocardial ischemia. J Electrocardiol. 2006;39:315–323. 118. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch KP. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry. 2006;11:514–522. 119. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA. 2006;295:784–792. 120. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, Blackstone EH, Lauer MS. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation. 2006;113:230– 237. 121. Westerhout CM, Fu Y, Lauer MS, James S, Armstrong PW, Al-Hattab E, Califf RM, Simoons ML, Wallentin L, Boersma E. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol. 2006;48:939–947. 122. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, Thompson PD, Williams MA, Lauer MS. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nut. Circulation. 2005;111:369–376. 123. Bhatheja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol. 2005;95:1159–1164. 124. Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138–145. 125. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Thisted RA. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005;353:468–475. 126. Hesse B, Morise A, Pothier CE, Blackstone EH, Lauer MS. Can we reliably predict long- term mortality after exercise testing? An external validation. Am Hear J. 2005;150:307– 314.
  • 61.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 61 127. Khan MN, Pothier CE, Lauer MS. Chronotropic incompetence as a predictor of death among patients with normal electrograms taking beta blockers (metoprolol or atenolol). Am J Cardiol. 2005;96:1328–1333. 128. Lauer MS. Can the ST segment be saved? J Nucl Cardiol. 2005;12:622–624. 129. Lauer MS. Coronary artery disease in diabetes: which (if any) test is best? Cleve Clin J Med. 2005;72:6,8–9. 130. Lauer MS. Cardiac troponins and renal failure: the evolution of a clinical test. Circulation. 2005;112:3036–3037. 131. Lauer M, Froelicher ES, Williams M, Kligfield P. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2005;112:771–776. 132. O’Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation. 2005;111:2313– 2318. 133. Pereira JJ, Balaban K, Lauer MS, Lytle B, Thomas JD, Garcia MJ. Aortic valve replacement in patients with mild or moderate aortic stenosis and coronary bypass surgery. Am J Med. 2005;118:735–742. 134. Rajagopal V, Gurm HS, Brunken RC, Pothier CE, Bhatt DL, Lauer MS. Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting. Am Hear J. 2005;149:534–540. 135. Troughton RW, Prior DL, Frampton CM, Nash PJ, Pereira JJ, Martin M, Fogarty A, Morehead AJ, Starling RC, Young JB, Thomas JD, Lauer MS, Klein AL. Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). Am J Cardiol. 2005;96:257–262. 136. Ziada KM, Yadav JS, Mukherjee D, Lauer MS, Bhatt DL, Kapadia S, Roffi M, Vora N, Tiong I, Bajzer C. Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). Am J Cardiol. 2005;96:519–523. 137. Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA. 2004;292:1462–1468.
  • 62.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 62 138. Asada J, Tsuji H, Iwasaka T, Thomas JD, Lauer MS. Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia. Am J Cardiol. 2004;93:702–704. 139. Bertog SC, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, Lytle BW, Blackstone EH, Lauer MS, Klein AL. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol. 2004;43:1445–1452. 140. Blackstone EH, Lauer MS. Caveat emptor: the treachery of work-up bias. J Thorac Cardiovasc Surg. 2004;128:341–344. 141. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109:2290– 2295. 142. Chen MS, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery and impact of myocardial revascularization on long-term mortality. Circulation. 2004;110:2851–2857. 143. Christopher Jones R, Pothier CE, Blackstone EH, Lauer MS. Prognostic importance of presenting symptoms in patients undergoing exercise testing for evaluation of known or suspected coronary disease. Am J Med. 2004;117:380–389. 144. Cura FA, Roffi M, Pasca N, Wolski KE, Lincoff AM, Topol EJ, Lauer MS. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST- segment after reperfusion therapy substudy). Am J Cardiol. 2004;94:859–863. 145. Ellis K, Pothier CE, Blackstone EH, Lauer MS. Is systolic blood pressure recovery after exercise a predictor of mortality? Am Hear J. 2004;147:287–292. 146. Gardin JM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 2004;292:2396–2398. 147. Ishwaran H, Blackstone EH, Pothier CE, Lauer MS. Relative risk forests for exercise heart rate recovery as a predictor of mortality. J Am Stat Assoc. 2004;99:591–600. 148. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol. 2004;44:1025–1029. 149. Lauer MS. Clinical epidemiology, clinical care, and the public’s health. Mayo Clin Proc. 2004;79:975–976.
  • 63.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 63 150. Lauer MS. Chronotropic incompetence: ready for prime time. J Am Coll Cardiol. 2004;44:431–432. 151. Mills RM, Lauer MS. Endomyocardial biopsy: a procedure in search of an indication. Am Hear J. 2004;147:759–760. 152. O’Neill JO, Young JB, Pothier CE, Lauer MS. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol. 2004;44:820–826. 153. Pothier CE, Lauer MS. Functional capacity and activities of daily living in women. In: Shaw LJ, Redberg RD, editors. Coronary disease in women: evidence-based diagnosis and treatment. Totowa, NJ: Humana Press; 2004. p. 103–118. 154. Seshadri N, Gildea TR, McCarthy K, Pothier C, Kavuru MS, Lauer MS. Association of an abnormal exercise heart rate recovery with pulmonary function abnormalities. Chest. 2004;125:1286–1291. 155. Shishehbor MH, Hoogwerf BJ, Lauer MS. Association of triglyceride-to-HDL cholesterol ratio with heart rate recovery. Diabetes Care. 2004;27:936–941. 156. Yamani MH, Lauer MS, Starling RC, Pothier CE, Tuzcu EM, Ratliff NB, Cook DJ, Abdo A, McNeil A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Impact of donor spontaneous intracranial hemorrhage on outcome after heart transplantation. Am J Transpl. 2004;4:257–261. 157. Mark DB, Shaw LJ, Lauer MS, O’Malley PG, Heidenreich P. 34th Bethesda Conference: Task force #5--Is atherosclerosis imaging cost effective? J Am Coll Cardiol. 2003;41:1906–1917. 158. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med. 2003;163:2576– 2582. 159. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–3010. 160. Baker DW, Bahler RC, Finkelhor RS, Lauer MS. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. Am Hear J. 2003;146:736– 740. 161. Beyer DR, Lauer MS, Davis S. Readability of informed-consent forms. N Engl J Med. 2003;348:2262–2263.
  • 64.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 64 162. Cheng YJ, Lauer MS, Earnest CP, Church TS, Kampert JB, Gibbons LW, Blair SN. Heart rate recovery following maximal exercise testing as a predictor of cardiovascular disease and all-cause mortality in men with diabetes. Diabetes Care. 2003;26:2052–2057. 163. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med. 2003;348:781–790. 164. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Hear J. 2003;146:692– 698. 165. Gurm HS, Lauer MS. Predicting incidence of some critical events by sun signs -- The PISCES study. ACC Curr J Rev. 2003;12:22–24. 166. Lauer MS. Is heart rate recovery a modifiable risk factor? J Cardiopulm Rehabil. 2003;23:88–89. 167. Lauer MS. Recovery after graded exercise testing: an under-appreciated time of great prognostic value. Int J Bioelectromagn. 2003;5:90. 168. Lauer MS. Who should be taking aspirin to prevent coronary events? Cleve Clin J Med. 2003;70:1076–1080. 169. Mark DB, Lauer MS. Exercise capacity: the prognostic variable that doesn’t get enough respect. Circulation. 2003;108:1534–1536. 170. Messinger-Rapport B, Pothier Snader CE, Blackstone EH, Yu D, Lauer MS. Value of exercise capacity and heart rate recovery in older people. J Am Geriatr Soc. 2003;51:63– 68. 171. Seshadri N, Acharya N, Lauer MS. Association of diabetes mellitus with abnormal heart rate recovery in patients without known coronary artery disease. Am J Cardiol. 2003;91:108–111. 172. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, Krawczynska E, Cerqueira M, Maddahi J. Prognostic value of normal exercise and adenosine (99m)Tc- tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med. 2003;44:134–139. 173. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol. 2003;42:831–838. 174. Lauer MS, Topol EJ. Clinical trials--multiple treatments, multiple end points, and multiple lessons. JAMA. 2003;289:2575–2577.
  • 65.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 65 175. Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: coronary risk scores. Lancet. 2003;362:1776–1777. 176. Lauer MS, Blackstone EH. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine, 2nd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p. 981–1004. 177. Acevedo M, Sprecher DL, Lauer MS, Francis G. Routine statin treatment after acute coronary syndromes? Am Hear J. 2002;143:940–942. 178. Aronow HD, Lauer MS. Reducing early mortality after acute coronary syndromes. Cardiol Rev. 2002;19:11–16. 179. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346:2047–2052. 180. Aviles RJ, Wright RS, Aviles JM, McDonald F, Ballman K, Harker-Murray A, Scott C, Lauer MS, Kopecky SL, Jaffe AS. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. Am J Cardiol. 2002;90:875–878. 181. Cole CR, Lauer MS, Bigger JT. Clinical assessment of the autonomic nervous system. In: Topol EJ, editor. Textbook of cardiovascular medicine, 2nd edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p. 1615–1655. 182. Lauer MS. Cardiologist on trial: reflections on credible evidence. J Am Coll Cardiol. 2002;40:563–564. 183. Lauer MS. Exercise testing for assessment of autonomic function. Am Hear J. 2002;144:580–582. 184. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468–1474. 185. Lauer MS. Health toll of the Middle East crisis. Lancet. 2002;359:1860–1861. 186. Lauer MS. Chronotropic incompetence and heart rate recovery. In: Ellestad M, editor. Exercise testing: new concepts for the new century. Norwell, MA: Kluwer Academic; 2002. p. 38–48. 187. Lauer MS. The “exercise” part of exercise echocardiography. J Am Coll Cardiol. 2002;39:1353–1355.
  • 66.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 66 188. Lauer MS, Alexe S, Pothier Snader CE, Blackstone EH, Ishwaran H, Hammer PL. Use of the logical analysis of data method for assessing long-term mortality risk after exercise electrocardiography. Circulation. 2002;106:685–690. 189. Lauer MS, Froelicher V. Abnormal heart-rate recovery after exercise. Lancet. 2002;360:1176–1177. 190. Lauer MS, Pothier CE. Exercise training in heart failure patients: a brief review. Am J Med Sport. 2002;4:302–308. 191. Mahon NG, Blackstone EH, Francis GS, Starling 3rd RC, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;40:1106–1113. 192. Marwick TH, Case C, Sawada S, Vasey C, Short L, Lauer M. Use of stress echocardiography to predict mortality in patients with diabetes and known or suspected coronary artery disease. Diabetes Care. 2002;25:1042–1048. 193. Morise AP, Lauer MS, Froelicher VF. Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease. Am Hear J. 2002;144:818–825. 194. Panzer C, Lauer MS, Brieke A, Blackstone E, Hoogwerf B. Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes. 2002;51:803–807. 195. Pereira JJ, Lauer MS, Bashir M, Afridi I, Blackstone EH, Stewart WJ, McCarthy PM, Thomas JD, Asher CR. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356–1363. 196. Shishehbor MH, Baker DW, Blackstone EH, Lauer MS. Association of educational status with heart rate recovery: a population-based propensity analysis. Am J Med. 2002;113:643–649. 197. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all- cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA. 2001;286:1187–1194. 198. Anderson ST, Pahlm O, Bacharova L, Barbagelata A, Chaitman BR, Clemmensen P, Goodman S, Heden B, Klootwijk PJ, Lauer M, MacFarlane PW, Rautaharju P, Reddy S, Selvester RH, Sgarbossa EB, Underwood D, Warner RA, Wagner GS. Standards for the function of an academic 12-lead electrocardiographic core laboratory. J Electrocardiol. 2001;34:41–47.
  • 67.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 67 199. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063–1068. 200. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992–997. 201. Cole CR, Lauer MS. Exercise testing and risk assessment. In: Foody JM, editor. Preventive cardiology: strategies for the prevention and treatment of coronary artery disease. Totowa, NJ: Humana Press; 2001. p. 238–301. 202. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol. 2001;37:1558–1564. 203. Foody JM, Cole CR, Blackstone EH, Lauer MS. A propensity analysis of cigarette smoking and mortality with consideration of the effects of alcohol. Am J Cardiol. 2001;87:706–711. 204. Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med. 2001;110:253–259. 205. Lauer MS. Exercise electrocardiogram testing and prognosis. Novel markers and predictive instruments. Cardiol Clin. 2001;19:401–414. 206. Lauer MS. Lipid-lowering drugs in acute coronary syndromes. Biomed Pharmacother. 2001;55:413. 207. Lauer MS. Uses of error: more chefs. Lancet. 2001;358:1641. 208. Lauer MS. Focused review: heart rate responses in stress testing, clinical implications. ACC Curr J Rev. 2001;10:16–19. 209. Lauer MS. Medical therapy for coronary artery disease works, even (especially) in the real world. Am J Med. 2001;110:497–498. 210. Lauer MS, Fontanarosa PB. Updated guidelines for cholesterol management. JAMA. 2001;285:2508–2509.
  • 68.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 68 211. Lauer MS, Snader CE. Using exercise testing to prognosticate patients with heart failure. Which parameter should we measure? Cardiol Clin. 2001;19:573–581. 212. Lin SS, Lauer MS, Asher CR, Cosgrove DM, Blackstone E, Thomas JD, Garcia MJ. Prediction of coronary artery disease in patients undergoing operations for mitral valve degeneration. J Thorac Cardiovasc Surg. 2001;121:894–901. 213. Marwick TH, Case C, Sawada S, Rimmerman C, Brenneman P, Kovacs R, Short L, Lauer M. Prediction of mortality using dobutamine echocardiography. J Am Coll Cardiol. 2001;37:754–760. 214. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–2209. 215. Pashkow F, Lauer MS, Harvey SA. Diagnosis of coronary artery disease. In: Roitman JL, herridge M, editors. American College of Sports Medicine resource manual for guidelines for exercise testing and prescription. New York: Lippincott, Williams and Wilkins; 2001. p. 246–253. 216. Peterson JG, Lauer MS. Using aspirin and ACE inhibitors in combination: why the hullabaloo? Cleve Clin J Med. 2001;68:569–574. 217. Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, Blackstone EH, Harrington RA, Califf RM, Lauer MS. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 2001;87:532–536. 218. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation. 2001;104:1911–1916. 219. Campbell L, Snader CE, Lauer MS. Relationship between exercise hypertension and perfusion defects. Cardiol Rev. 2000;17:24–27. 220. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med. 2000;132:552–555. 221. Dresing TJ, Blackstone EH, Pashkow FJ, Snader CE, Marwick TH, Lauer MS. Usefulness of impaired chronotropic response to exercise as a predictor of mortality, independent of the severity of coronary artery disease. Am J Cardiol. 2000;86:602–609.
  • 69.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 69 222. Lauer MS. Commentary on use of daclizumab for preventing acute rejection in non- sensitized patients receiving first transplants. Evidence-based Cardiovasc Med. 2000;4. 223. Lauer MS. Role of stress testing and cardiac imaging in patients who have undergone previous coronary revascularization. Cardiol Rev. 2000;8:158–165. 224. Lauer MS. Primary angioplasty--time is of the essence. JAMA. 2000;283:2988–2989. 225. Lauer MS. Role of stress testing and cardiac imaging after myocardial revascularization. Cardiol Rev. 2000;8:158–165. 226. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA. 2000;284:1392–1398. 227. Pasquet A, Lauer MS, Williams MJ, Secknus MA, Lytle B, Marwick TH. Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction. Impact of pre-operative myocardial function, perfusion, and metabolism. Eur Hear J. 2000;21:125–136. 228. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000;109:371–377. 229. Shaw LJ, Hachamovitch R, Heller G V, Marwick TH, Travin MI, Iskandrian AE, Kesler K, Lauer MS, Hendel R, Borges-Neto S, Lewin HC, Berman DS, Miller D. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group. Am J Cardiol. 2000;86:1–7. 230. Srivastava R, Blackstone EH, Lauer MS. Association of smoking with abnormal exercise heart rate responses and long-term prognosis in a healthy, population-based cohort. Am J Med. 2000;109:20–26. 231. Campbell L, Marwick TH, Pashkow FJ, Snader CE, Lauer MS. Usefulness of an exaggerated systolic blood pressure response to exercise in predicting myocardial perfusion defects in known or suspected coronary artery disease. Am J Cardiol. 1999;84:1304–1310. 232. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351– 1357. 233. Lauer M. Making sense of blood pressure medication. Health News (Rochester). 1999;5:3. 234. Lauer MS. Resuscitating the exercise stress test. Cleve Clin J Med. 1999;66:278–282.
  • 70.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 70 235. Lauer MS. Chronotropic incompetence: new insights. In: Pashkow F, Defoe WA, editors. Clinical cardiac rehabilitation: a cardiologist’s guide, 2nd edition. Baltimore: Williams and Wilkins; 1999. 236. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol. 1999;34:618–620. 237. Lauer MS, Cole C, Krumholz HM. Exercise electrocardiography with right precordial leads. N Engl J Med. 1999;341:208; author reply 209. 238. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. 1999;281:524–529. 239. Lauer MS, Larson MG, Evans JC, Levy D. Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. Am Hear J. 1999;137:903–909. 240. Marwick TH, Shaw LJ, Lauer MS, Kesler K, Hachamovitch R, Heller G V, Travin MI, Borges-Neto S, Berman DS, Miller DD. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. Am J Med. 1999;106:172–178. 241. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33:750–758. 242. McHam SA, Marwick TH, Pashkow FJ, Lauer MS. Delayed systolic blood pressure recovery after graded exercise: an independent correlate of angiographic coronary disease. J Am Coll Cardiol. 1999;34:754–759. 243. Pasquet A, Armstrong G, Beachler L, Lauer MS, Marwick TH. Use of segmental tissue Doppler velocity to quantitate exercise echocardiography. J Am Soc Echocardiogr. 1999;12:901–912. 244. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K, Young JB, Lauer MS. Ventilatory and heart rate responses to exercise  : better predictors of heart failure mortality than peak oxygen consumption. Circulation. 1999;100:2411–2417. 245. Schweikert RA, Pashkow FJ, Snader CE, Marwick TH, Lauer MS. Association of exercise-induced ventricular ectopic activity with thallium myocardial perfusion and angiographic coronary artery disease in stable, low-risk populations. Am J Cardiol. 1999;83:530–534.
  • 71.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 71 246. Shaw LJ, Heller G V, Travin MI, Lauer M, Marwick T, Hachamovitch R, Berman DS, Miller DD. Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. Economics of Noninvasive Diagnosis (END) Study Group. J Nucl Cardiol. 1999;6:559–569. 247. Singh JP, Larson MG, Manolio TA, O’Donnell CJ, Lauer M, Evans JC, Levy D. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Circulation. 1999;99:1831–1836. 248. Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller G V, Iskandrian AE, Kesler KL, Travin MI, Lewin HC, Hendel RC, Borges-Neto S, Miller DD. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study G. J Am Coll Cardiol. 1999;33:661–669. 249. Lauer MS. Noninvasive risk stratification after myocardial infarction: which test is best? Am Hear J. 1998;136:565–569. 250. Folz-Murphy N, Partin M, Williams L, Harris CM, Lauer MS. Physician use of an ambulatory medical record system: matching form and function. Proc AMIA Symp. 1998;260–264. 251. Grady TA, Chiu AC, Snader CE, Marwick TH, Thomas JD, Pashkow FJ, Lauer MS. Prognostic significance of exercise-induced left bundle-branch block. JAMA. 1998;279:153–156. 252. James KB, Rodkey S, McCarthy PM, Thomas JD, Blackburn G, Sapp S, Vargo R, Lauer MS, Young JB. Exercise performance and chronotropic response in heart failure patients with implantable left ventricular assist devices. Am J Cardiol. 1998;81:1230–1232. 253. Lauer MS, Fortin D. Databases in cardiology. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998. p. 1083–1106. 254. Lauer MS, Lytle B, Pashkow F, Snader CE, Marwick TH. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery- bypass grafting. Lancet. 1998;351:615–622. 255. Lauer MS, Mehta R, Pashkow FJ, Okin PM, Lee K, Marwick TH. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol. 1998;32:1280–1286. 256. Lin SS, Lauer MS, Marwick TH. Risk stratification of patients with medically treated unstable angina using exercise echocardiography. Am J Cardiol. 1998;82:720–724.
  • 72.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 72 257. Marwick TH, Lauer MS, Lobo A, Nally J, Braun W. Use of dobutamine echocardiography for cardiac risk stratification of patients with chronic renal failure. J Intern Med. 1998;244:155–161. 258. Pilote L, Pashkow F, Thomas JD, Snader CE, Harvey SA, Marwick TH, Lauer MS. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol. 1998;81:219–224. 259. Secknus MA, Niedermaier ON, Lauer MS, Marwick TH. Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography. Am J Cardiol. 1998;81:1318–1322. 260. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, Topol EJ. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366– 1370. 261. Taragin MI, Lauer M, Savir M, Sivan E, Siesel D, Aufgang B. HCFA documentation guidelines and the need for discrete data: a golden opportunity for applied health informatics. Proc AMIA Symp. 1998;653–656. 262. Asher CR, Chung MK, Eagle KA, Lauer MS. Atrial fibrillation following cardiac surgery. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. Philadelphia: Lippincott-Raven; 1997. p. 183–204. 263. Ballal RS, Secknus MA, Mehta R, Kapadia S, Lauer MS, Marwick TH. Cardiac outcomes in coronary patients with submaximum dobutamine stress echocardiography. Am J Cardiol. 1997;80:725–729. 264. Heupler S, Lauer M, Williams MJ, Shan K, Marwick TH. Increased left ventricular cavity size, not wall thickness, potentiates myocardial ischemia. Am Hear J. 1997;133:691–697. 265. Lauer MS, Pashkow FJ, Larson MG, Levy D. Association of cigarette smoking with chronotropic incompetence and prognosis in the Framingham Heart Study. Circulation. 1997;96:897–903. 266. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Age and referral to coronary angiography after an abnormal treadmill thallium test. Am Hear J. 1997;133:139–146. 267. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Sex and diagnostic evaluation of possible coronary artery disease after exercise treadmill testing at one academic teaching center. Am Hear J. 1997;134:807–813.
  • 73.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 73 268. Marwick TH, Mehta R, Arheart K, Lauer MS. Use of exercise echocardiography for prognostic evaluation of patients with known or suspected coronary artery disease. J Am Coll Cardiol. 1997;30:83–90. 269. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol. 1997;80:865–870. 270. Popovic AD, Thomas JD, Neskovic AN, Cosgrove 3rd DM, Stewart WJ, Lauer MS. Time-related trends in the preoperative evaluation of patients with valvular stenosis. Am J Cardiol. 1997;80:1464–1468. 271. Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. J Am Coll Cardiol. 1997;30:641–648. 272. Eagle KA, Lauer MS. Preoperative evaluation before noncardiac vascular surgery. Cleve Clin J Med. 1996;63:325–330. 273. Lauer MS. The diagnosis of coronary artery disease in the setting of left ventricular hypertrophy. In: Marwick TH, editor. Cardiac stress testing and imaging. New York: Churchill Livingston; 1996. p. 189–202. 274. Lauer MS. The enlarged heart: risk factor with a paradox. Heartline. 1996;26:4–5. 275. Lauer MS. Implications of exercise hypertension. Cardiol Rev. 1996;13:35–39. 276. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation. 1996;93:1520–1526. 277. Lauer MS, Pashkow FJ, Snader CE, Harvey SA, Thomas JD, Marwick TH. Gender and referral for coronary angiography after treadmill thallium testing. Am J Cardiol. 1996;78:278–283. 278. Levy D, Lauer MS. Left ventricular hypertrophy: echocardiographic assessment and prognostic ijmplications. In: Sutton MSJ, Oldershaw PJ, Kotler MN, editors. Textbook of echocardiography and doppler in adults and children. Cambridge: Blackwell Science; 1996. p. 342–352. 279. Okin PM, Lauer MS, Kligfield P. Chronotropic response to exercise. Improved performance of ST-segment depression criteria after adjustment for heart rate reserve. Circulation. 1996;94:3226–3231.
  • 74.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 74 280. Smedira NG, Zikri M, Thomas JD, Lauer MS, Kelleman JJ, McCarthy PM. Blunt traumatic rupture of a mitral papillary muscle head. Ann Thorac Surg. 1996;61:1526– 1528. 281. Williams B, Isaacson JH, Lauer MS. An 81-year-old woman with dyspnea on exertion. Cleve Clin J Med. 1996;63:209–212. 282. Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;27:132–139. 283. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995;25:1155–1160. 284. Lauer MS, Eagle KA. Atrial fibrillation following cardiac surgery. In: Podrid PJ, Kowey P, editors. Cardiac arrhythmia: mechanisms, diagnosis, and management. Baltimore: Williams and Wilkins; 1995. 285. Brener SJ, Pashkow FJ, Harvey SA, Marwick TH, Thomas JD, Lauer MS. Chronotropic response to exercise predicts angiographic severity in patients with suspected or stable coronary artery disease. Am J Cardiol. 1995;76:1228–1232. 286. Lauer MS. The epidemiology of heart disease: what we have learned from 40 years of research. Heartline. 1995;25:4–5. 287. Lauer MS. Left ventricular hypertrophy and cardiovascular prognosis. Cleve Clin J Med. 1995;62:169–175. 288. Lauer MS, Larson MG, Levy D. Gender-specific reference M-mode values in adults: population-derived values with consideration of the impact of height. J Am Coll Cardiol. 1995;26:1039–1046. 289. Lauer MS, Okin PM, Anderson KM, Levy D. Impact of echocardiographic left ventricular mass on mechanistic implications of exercise testing parameters. Am J Cardiol. 1995;76:952–956. 290. Lauer MS, Pashkow FJ, Harvey SA, Marwick TH, Thomas JD. Angiographic and prognostic implications of an exaggerated exercise systolic blood pressure response and rest systolic blood pressure in adults undergoing evaluation for suspected coronary artery disease. J Am Coll Cardiol. 1995;26:1630–1636. 291. Marwick TH, Shan K, Go RT, MacIntyre WJ, Lauer MS. Use of positron emission tomography for prediction of perioperative and late cardiac events before vascular surgery. Am Hear J. 1995;130:1196–1202.
  • 75.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 75 292. Lauer MS, Anderson KM, Larson MG, Levy D. A new method for indexing left ventricular mass for differences in body size. Am J Cardiol. 1994;74:487–491. 293. Coles NA, Lauer MS, Field TS, Connolly M, Eagle KA. Cardiac emergencies at a major international airport: a prospective observational study. Am Hear J. 1992;124:257–260. 294. Galderisi M, Lauer MS, Levy D. Echocardiographic determinants of clinical outcome in subjects with coronary artery disease (the Framingham Heart Study). Am J Cardiol. 1992;70:971–976. 295. Krumholz HM, Douglas PS, Lauer MS, Pasternak RC. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med. 1992;116:785–790. 296. Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992;19:130–134. 297. Lauer MS, Eagle KA. Atrial fibrillation following cardiac surgery. In: Falk RH, Podrid PJ, editors. Atrial fibrillation: mechanisms and management. New York: Raven Press; 1992. p. 127–144. 298. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180–1184. 299. Lauer MS, Levy D. Left ventricular hypertrophy: risk, clinical correlates, and therapeutic implications. Focus Hypertens. 1992;3:5–10. 300. Lauer MS, Levy D, Anderson KM, Plehn JF. Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. Ann Intern Med. 1992;116:203–210. 301. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA. 1991;266:231–236. 302. Lauer MS, Anderson KM, Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1991;18:1287–1294. 303. Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis. 1989;31:367–378.
  • 76.
    Michael S. Lauer,MD, FACC, FAHA Curriculum Vitae Page 76 304. Miller KJ, Lauer MS, Caloccia W. Interactions of molecules with nucleic acids. XII. A theoretical model for the interaction of a fragment of bleomycin with DNA. Biopolymers. 1985;24:913–934. 305. Miller KJ, Lauer MS, Archer S. Interaction of molecules with nucleic acids. V. Thioxanthenones into DNA. Int J Quantum Chem. 1980;18:11–34.